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Abstract 
Modifying scaffolds with regulatory signals has been shown to enhance the scaffold's biomimetic 
properties (hydrophilicity, degradation, and biocompatibility) resulting in improved regeneration. However, 
most polymers available for scaffolding lack chemical functionality in the backbone, limiting our ability to 
modify scaffolds through the conjugation of regulatory signals (growth factors, biomolecules, and peptides). 
Therefore, synthesizing polymers that can be fabricated into scaffolds with biomimetic physical architecture 
(porous, interconnected, and nanofibrous) and can be easily conjugated with these molecules through the 
polymers chemical functionality would result in enhanced regeneration conditions.  
Poly(spirolactic-co-lactic acid) (PSLA), a derivative of poly(L-lactic acid) (PLLA), is an attractive 
candidate for scaffolding in tissue engineering due to its tailorable functionality and PLLA-like properties. 
However, traditional polymerization methods have resulted in low molecular weight PSLA copolymers 
(<30 kDa) unsuitable for tissue engineering (< 150 kDa). To mitigate these effects and develop lactone 
polymers containing high molecular weight (HMW) suitable for scaffolding in the laboratory, we developed 
a method of using cold polymerization (-80 ºC) and triazabicyclodecene organocatalyst in solution 
polymerization. In this manner, we can mitigate the viscosity and water effects that plague traditional 
polymerizations, thereby producing polymers suitable for scaffolding (<  350 kDa).  
To demonstrate the utility of the PSLA copolymer for tissue engineering, small diameter (< 6 mm 
ID) biomimetic tubular scaffolds were developed for in situ implantation in female rat models. Through the 
PSLA’s highly reactive norbornene ring, an anticoagulant molecule (heparin) was conjugated into the 
backbone to mitigate the effects of thrombosis. Thus, by modulating the amount of heparin, we were able to 
increase the biocompatibility as well as tune the hydrophilicity and degradation rate. The viability of the 
 xiv 
scaffolds modified with heparin was tested in vivo by implanting the scaffolds as replacement vessels (1 
cm) in the descending aorta below the renal arteries. The patency and viability were confirmed through 
dynamic ultrasound and histological analysis of the explanted tissue, demonstrating excellent tissue 
reconstruction with a laminar cellular arrangement and no sign of hyperplasia, aneurysm, or thrombosis. 
Furthermore, we achieved complete endothelization of the vessel lumen and enhanced extracellular matrix 
decomposition (collagen & elastin). Through the use of PSLA, we developed a biocompatible vascular graft 
that can mitigate thrombosis and generate small-diameter blood vessels in animal models.  
To improve current post-modification methods, we have developed a copolymer derived from L-
lactide, poly(exomethylene-co-lactic acid) (PELA), with click-chemistry reactivity under physiological 
conditions in the absence of catalyst, heat, or organic solvents and without producing toxic byproducts. The 
copolymer itself (exomethylene lactide segment) can be rapidly (seconds) conjugated with amine-
containing molecules, forming a stable and enzymatically cleavable amide bond. The polymer can be 
processed into biomimetic tissue engineering scaffolds with excellent mechanical properties. Taking 
advantage of the facile conjugation method, we were able to demonstrate that we can tune properties such as 
wettability, degradation rate, and biocompatibility. Finally, we demonstrate biocompatible and enhanced 
cell penetration into the PELA scaffolds through the use of in vitro and in vivo (subcutaneous implantation) 
assessment. 
This original work provides insightful molecular design and development strategies that can be 
readily adapted by researchers in tissue engineering and regenerative medicine research due to the 
simplicity, cost-effectiveness, and effectiveness. 
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Chapter 1. Biodegradable Polymers for Biomedical Applications Scaffolds in Tissue Engineering 
1.1 Tissue Engineering Scaffolds 
1.1.1 Tissue engineering for tissue regeneration  
Tissue engineering is exciting interdisciplinary approach to supply tissue and organs after 
injury or disease 1-6. The goal of tissue engineering is to restore, maintain, and improve tissue 
function after critical loss of tissue 2, 7-9. Through the combination of material science and 
engineering and life sciences novel approaches are developed to address the need of vital tissues 
that at times can prevent death. At the core of tissue engineering, polymers fashioned into tissue 
engineering scaffolds are an invaluable tool to provide support for tissue regeneration 10-14. 
Scaffolds don’t only provide a supporting environment in which cells are able to occupy but can 
also be involved in promoting cellular processes and response 2, 10-15. Specifically, scaffolds are 
able to guide cell growth, promote natural extracellular matrix formation, which can lead to 
formation of functional tissues and organs 4, 16-18. In the absence of such scaffolds, where the 
body is unable to regenerate itself after disease or injury the body can experience i) scar tissue 
formation leading to loss of function ii) improper repair and regeneration iii) and extreme cases 
death18. Therefore, depending on the tissue that is injured or diseased it is crucial to identify 
means in which to optimize regeneration. Beyond providing structural support scaffolds that 
have experienced the best success also include support for cell attachment, proliferation, and 
differentiation 11, 16, 19-21. Therefore, scaffolds play an equal part in combination with regulatory 
 2 
signals and cells that lead to the best tissue formation possible. This thought has led to the 
development of the tissue engineering triad, a scheme to illustrate how biomaterials can be 
utilized in combination with cells and regulatory signals for tissue engineering [Figure 1.1] 22-24.  
When discussing the favorable scaffold properties, it is important to mention that 
scaffolds derive their characteristics from the polymers that they are fabricated from 2, 15, 25-27. 
The polymers inherit properties – hydrophobicity, biocompatibility, mechanical properties – will 
directly translate into the retention/degradation rate, biocompatibility, and mechanical properties 
exhibited by the scaffolds. For this reason, polymers for tissue engineering will be discussed in 
depth in a later section. The work presented in this document will focus on the development of 
biodegradable polymers to fabricate the best scaffolds possible, therefore it is imperative that we 
define what basic criteria scaffolds should exhibit i) biocompatible ii) biodegradable iii) three-
 
Figure 1.1 Tissue engineering triad depicting the interplay of cells, regulatory signals, and 
biomaterials in tissue engineering. 
Tissue Engineering
Cells Regulatory 
Signals
Biomaterials
Growth Factors, Adhesion 
Peptides, Biomolecules
Cell lines, Progenitor 
Cells, Primary Cells
Synthetic & Natural
Polymers, Ceramics
Promotes regulatory 
signal attachment & delivery 
Induces cell differentiation 
And mature tissue formation 
Cell support and attachment, 
proliferation, and matrix deposition  
 3 
dimensional structure iv) mechanical integrity to support handling and regeneration 3, 4, 11, 16. 
Particularly, biodegradation is important as tissue engineering scaffolds should be remodeled to 
produce tissue similar to the natural tissue found 28-31. Another important factor that has been 
shown to improve tissue formation is the geometry that scaffolds are fabricated in order be match 
the tissue need 12, 21, 32-36. Scaffolds can be fabricated through various process and methods. 
Currently, the most favorable approaches utilize molds, electrospinning, or templates (porogen). 
Through these methods scaffolds can be fabricated in an array of shapes such as disk, tubular, 
and sphere to name a few34-38. What is important to note is that with current approaches we are 
able to fabricate scaffolds for specific tissue applications which have made a tremendous 
difference in the resulting tissue. This has been of particular importance in vascular tissue 
engineering as we are able to fabricate specific inner and outer diameter tubular scaffolds that fit 
the vasculature which is being replaced.  
1.1.2 Imparting biomimetic properties through physical architecture 
To this point, we have discussed the basic requirements of tissue engineering scaffolds; 
however, since they were first utilized, scaffolds have been optimized to contain biomimetic 
features 17, 39, 40. These biomimetic features are defined as the development of facets of the 
natural environment in which cells find themselves and can range from topography, the inclusion 
of regulatory signals, mechanical properties, matching degradation to cell proliferation, and 
tissue formation, among others 41-48. It has been demonstrated that as scaffolds most closely 
mimic the natural environment in which cells occupy the regenerated tissue more closely 
resembles the natural tissue. Therefore, it has become the material scientist's goal and objective 
to replicate both the macro and microenvironment.  
 4 
In an attempt to accomplish this goal, much effort has been devoted to imparting 
biomimetic cues through the physical architecture of the scaffold. The use of porous and 
interconnected scaffolds has been of particular interest since they allow excellent mass flow, as 
well as cellular penetration and migration; therefore, the scaffold provides for faster remodeling 
and improved tissue formation3, 12, 38, 49-51. It has been shown that scaffolds fabricated with these 
features prevent sieving of the cells on the top layer when seeded and can lead to faster 
reconstruction in vitro and in vivo. The formation of this architecture can be achieved through 
the use of a porogen, such as salt or sugar that is slightly annealed 12, 14, 52-57. When removed by 
washing away, a template of the spheres is left behind, providing the porous and interconnected 
structure. Additionally, techniques such as thermally-induced phase separation (TIPS) in 
combination with polymers such as PLLA have been extensively studied since they produce 
nanofibrous morphology that mimics the native extracellular matrix (ECM) environment both in 
size of fiber and mechanical forces exuded on the cell 4, 27, 33, 38, 49, 55, 56, 58-61. This technique is 
particularly useful due to the ease and reproducibility, and it requires only to dissolve the 
polymer in a hot solvent solution such as tetrahydrofuran (THF) and quickly cool it down with 
best results at – 80 ºC 14, 51, 55, 62. As the solution cools, the solvent quickly leaves, creating a 
polymer-rich area with fibers and pores that closely mimic the ECM proteins collagen and 
elastin. When combined, TIPS and porogen leaching, we can produce a biomimetic scaffold that 
is nanofibrous, porous, and interconnected that is conducive to an array of tissue engineering 
applications such as bone, vascular, cartilage, and muscle regeneration 4, 27, 33, 38, 40, 42, 49, 50, 58, 59, 
63-68. 
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1.1.3 Polyesters for tissue engineering 
Polyesters make up the primary bulk of degradable polymers utilized for tissue 
engineering 15, 69-72. The mode of degradation is through biological and hydrolytic cleavable of 
the ester bond as it reverts to the starting materials. Their primary advantage is that they typically 
comprise natural molecules found in the body, and therefore when they are introduced as a 
biomaterial in the body and degrade, they do so without any adverse effects 26, 73. Additionally, 
polyesters can be tailored in molecular weight, degradation rate (hydrophobicity), and 
composition, which will be discussed in this section to highlight the positive attributes of 
polyesters and demonstrate why they have been utilized broadly in tissue engineering 70, 74. 
Polyester are fabricated from the condensation reaction between a carboxylic acid and a 
hydroxyl group traditionally under heat [Figure 1.2A] 69, 75-79. Although, the polycondensation 
reaction seems simple enough, as they only require the addition of starting material under a heat 
source. In reality, synthesizing polyesters that can be used for tissue engineering is difficult and 
require precise control of polymerization conditions. The primary obstacle to overcome in 
polycondensation reactions is the removal of water in the reaction vessel 80. As the reaction 
proceeds, water molecules are produced from the condensation reaction that can terminate the 
reaction. Additionally, polycondensation reactions are carried out in a bulk reaction and therefore 
experience viscosity issues preventing the continued chain growth addition, further amplifying 
the accumulation of water molecules by trapping them in the viscous glob. When produced in the 
industrial level, these issues can be adequately addressed through powerful reactors that can 
continuously stir the viscous polymer and vacuums to remove the water.  
This has resulted in various polyesters that are commercially available with a varying 
composition (homo, copolymers, block polymers, linear, star), molecular weight, hydrophobicity 
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such as fast degrading polyesters (more hydrophilic) to slow degrading polyesters (less 
hydrophilic) 15, 74, 79. The range of hydrophobicity can vary significantly with polyesters, which 
translates into a varying retention time both in vitro to in vivo. This time can differ from 
degradation as early as three weeks in (poly(glycolic acid) (PGA) and poly(glyceral-co-sebacate) 
(PGS) to delayed degradation of 3 years with polymers such as poly(caprolactone) (PCL) 47, 81-87. 
Another method to effects retention and degradation rate is to modulate the polymer's molecular 
weight. Through the use of higher molecular weight, we can directly affect the degradation rate 
and mechanical properties of the resulting biomaterial. Lastly, polyester can be tailored by 
including various compositions such as adding segments of slow degrading polymers with fast 
degrading polymers or changing the geometry of the polymers from linear to star-shaped 
polymers 8, 25, 81, 88-90. Changes that can affect the resulting biomaterials properties and retention 
time. 
 
 
Figure 1.2 Polyester condensation and dissociation. 
A) Ester condensation reaction between carboxylic acid and hydroxyl under heat leads to 
the release of water B) Hydrolytic cleavage of ester bonds results into dissociation back to 
carboxylic acids and hydroxyl group. 
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1.1.4 Lactones for tissue engineering 
Of all the polyesters available and currently used as biomaterials for tissue engineering, 
lactones derived polymers are the gold standard. Particularly of all the lactones, PGA, PLLA, 
and PCL are the most widely utilized for scaffold fabrication for tissue engineering 26, 91, 92. This 
is due to their ease of synthesis through ring-opening polymerization in a bulk reaction, 
properties (hydrophobicity, mechanical, degradation rate) can be easily tailored, and their 
biocompatibility [Figure 1.3]15, 69, 70, 79.  Similarly, to the polycondensation described in the 
previous chapter, lactones are polymerized through the use of heat that provides the energy and 
drives the reaction. However, the ring-structure is stable in the absence of water, base/acid, and 
catalyst; therefore, a tin catalyst is utilized to coordinate the ring-opening by cleaving the ester 
bond [Figure 1.3] 93, 94. Once the ring is cleaved, the polycondensation can proceed, as 
previously discussed in section 1.1.2. The reaction is rapid and can grow polymers efficiently in 
the laboratory using basic systems (without the use of expensive reactors or vacuums) to mid-
range molecular weight (MW) (50-60 k Da) and HMW polymers in industrial settings (>100 k 
DA). Like the polyesters described in the previous section, lactone polyesters degrade through 
hydrolytic cleavage. Most importantly, it has been noted that these polymers experience bulk 
degradation – meaning we get equal degradation of the biomaterial fabricated from these lactone 
polymers 95, 96. 
What makes these polymers and why they have remained the gold standard for several 
decades is their versatility, tunability, and defined properties. Each of the polymers has a range 
of degradation that has been thoroughly investigated, and predictions on retention rates can be 
carefully determined. Traditionally, we have seen degradation times of 1-3 months for PGA, 6-
12 months for PLLA, and 2-3 years for PCL15, 69, 70, 79. These retention times can be extrapolated 
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to both in vitro and in vivo studies. Additionally, the retention time is directly related to the 
hydrophobicity of the resulting polymer. In the case of between PGA and PLLA, the defining 
difference is a single methyl group that projects out from the backbone in PLLA and results in 
          
 
Figure 1.3 Synthesis of lactone monomers to produce biodegradable polymers. 
A) Ring-Opening polymerization of L-lactide to produce poly(L-lactic acid) utilizing tin 
catalyst B) Ring-Opening polymerization of glycolide to produce poly(glycolic acid) 
utilizing tin catalyst C) Ring-Opening polymerization of e-caprolactone to produce 
poly(caprolactone) utilizing tin catalyst D) Ring-Opening polymerization of L-lactide and 
glycolide to produce poly(L-lactic-co-glycolic acid) utilizing tin catalyst. 
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increased hydrophobicity and retention rate. In the case of PCL, this polymers repeat unit 
contains 6 methylene groups that increase the hydrophobicity resulting in prolonged time 
retention times and increased hydrophobicity. The physical structure of the polymer repeat unit 
also gives us an indication of the polymers varying levels of crystallinity, with PGA being highly 
crystalline, PLLA semi-crystalline, and PCL containing a very low crystalline structure. The 
latter polymer also exhibits a low Tg at around - 60 ºC and demonstrates elastic properties, which 
expands the uses of the lactone polymers93.  
Although all three polymers have been extensively utilized as biomaterials for tissue 
engineering due to their unique properties – fast degradation, elasticity, etc, PLLA has been 
shown to provide the most beneficial biomimetic properties of the three when fabricated into 
tissue engineering scaffolds 36, 49, 56, 58, 65. This is due to how it can be processed to produce 
nanofibers that mimic the natural extracellular matrix proteins such as collagen and elastin. 
Additionally, PLLA has an average retention rate (6-12 m) that, for most applications, becomes 
beneficial as it provides structural support by not degrading fast like PGA, but it also does not a 
linger beyond when it's needed as seen with PCL28, 69, 97. Furthermore, PLLA can be fabricated 
into tissue engineering scaffolds with less toxic and cost-effective solvents compared to PGA, 
which requires the use of highly fluorinated solvents 47, 85. Likewise, PLLA can be processed into 
tissue engineering constructs more broadly than PCL. This is due to PCLs elastic properties that 
make it difficult to yield biomimetic physical architecture 62, 83, 98. Therefore, the preferred 
method to fabricate into biomimetic fibrous architecture is through the use of electrospinning62, 
99. Limiting its utility and substantiating the broader use of PLLA for tissue engineering scaffold. 
 10 
1.1.5 Functionalization of polymers leads to post fabrication 
In the previous section, we highlight encouraging aspects that have made PLLA one of 
the most highly used polymers in tissue engineering scaffolding – can be fabricated into 
biomimetic physical architecture, tailorable (mechanical properties, hydrophobicity, and 
retention), biocompatible 38, 100. However, as we try and fabricate scaffolds with enhanced 
biomimetic features, it is useful to conjugate regulatory signals (growth factors, peptides, 
biomolecules) that elicit response cellular response – whether it is differentiation, proliferation, 
or enhanced tissue formation 101-103. However, since scaffolds derive their properties from the 
polymers in which they are fabricated from (hydrophobicity, retention, biocompatibility), and 
many polymers such as the lactone-based polymers lack chemical functionality in the polymer 
backbone it is problematic to conjugate these signals unto the polymer under normal 
circumstances.  
Chemical functionality or backbone functionality is being defined in this work as the 
presence of chemical groups that quickly and efficiently permit the modification of the polymer 
or resulting tissue engineering construct by chemical attachment of the desired regulatory signal. 
Meaning that the molecule introduced is not only fouling the surface by entanglement, 
hydrophilic, ionic, or Van Der Waals interactions, but a chemical bond has formed between the 
two molecules. Specifically, we highlight the preference of polymers and resulting biomaterials 
that contain the primary (traditional) chemical groups such as amines (NH2), double bonds 
(C=C), thiols (SH), or carboxylic acids (COOH) that are more reactive and yielding a greater 
conjugation efficiency over hydroxyl groups 64, 101, 104, 105. Furthermore, there is an array of newer 
and more efficient chemical groups, such as click-chemistry tools, which will be discussed in the 
following section. Nonetheless, to efficiently modify the polyesters, such chemical groups are a 
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necessity to conjugate the desired molecules. Unfortunately, like PLLA, many of the polyesters 
that are favorable in tissue engineering scaffolding lack these groups and can be considered 
“chemically inert” as we can’t easily chemically conjugate regulatory signals. We do 
acknowledge that, especially when using polyesters, carboxylic acids are present; however, they 
are the least reactive of the groups mentioned, and the MWs of the polymers utilized 
dramatically reduces the density of these groups in the fabricated scaffold. Therefore, 
conjugation of desired molecules is diminished based on the amount of COOH present and their 
low reactivity.  
A facile method to introduce these chemical groups into the polymer would be to initiate 
the reaction with an initiator containing the desired chemical group [Figure 1.4] 106, 107. The 
polycondensation reaction can occur in the same fashion as described in the previous section, 
except that the resulting polymer will now contain one of the favorable chemical groups [Figure 
1.4]. However, as mentioned in the earlier sections, polycondensation reactions in the laboratory 
without specialized equipment are challenging to control when producing polymers for tissue 
engineering scaffolds (> 100 k Da). In our experience, creating polyester in this manner only 
produces medium weight polymers due to the accumulation of water and high viscosity issues. 
Without achieving these high molecular weights (HMWs), the tissue engineering scaffolds will 
suffer from low mechanical properties resulting in a fragile scaffold that breaks apart when 
handling. A facile method to solve this would be to blend a HMW polymer with the lower 
molecular weight (LMW) end-functionalized polymer. However, this can lead to deleterious 
effects on the scaffold from poor mechanical properties that lead to fragile scaffolds to scaffolds 
with little to none favorable biomimetic nanofibrous architecture65. Of note, is that 
commercially, HMW polymers that have been end-functionalized are not readily available. 
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Likewise, custom orders are costly and unattainable for most groups wishing to conduct basic 
                   
 
Figure 1.4 Synthesis of end-functionalized PLLA.  
Bulk polymerization of PLLA and end functionalized PLLA via tin catalyst and initiator 
A) synthesis of HEMAPLLA using hydroxyethyl methacrylate to initiate the 
polymerization resulting in acrylate functional group for post modification B) synthesis of 
Amine-PLLA using propanol amine to initiate the polymerization resulting in amine 
functional group for post modification. 
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research. Additionally, as mentioned previously, as the polymer grows in MW, the density of the 
functional groups available becomes less, which can affect the conjugation efficiency and the 
effect the regulatory signals have on the cells. 
Therefore, the polyesters that would produce the best outcome are those in which all the 
polymers utilized are equal and made out of HMW polymers, contain chemical functionalization, 
and can provide favorable nanofibrous architecture 65. Ideally, the polymers produced would 
have a higher degree of functionalization beyond a single point of conjugation. Various 
polyesters, such as poly(spiro-co-lactic acid) (PSLA), can fit these criteria. However, current 
polymerization methods have failed to produce these polymers with MWs required for tissue 
engineering purposes. For this reason, novel synthesis methods that can produce HMW 
polyesters such as PSLA could provide new tools in tissue engineering scaffolding by providing 
polymers with tailorable backbone functionality density that can be quickly and conjugated with 
regulatory signals. Development of the method of synthesizing HMW polymers easily, rapidly, 
and a cost-effective manner and developing tissue engineering scaffolds is the focus of Chapter 2 
and Chapter 3 and will be discussed in detail in those chapters. 
1.2 Click-Chemistry for scaffold optimization 
1.2.1 Click chemistry 
Traditionally click-chemistry is defined as the ring formation between an azide and 
alkyne. This cycloaddition follows the described 3+2, addition of azide (3) to alkyne (2), with the 
reaction being coordinated by copper [Figure 1.5A]108-112. This is made possible by the active 
Cu(I) that can coordinate the electron exchange between the alkyne and the azide effectively 
yielding a cycloaddition very rapidly and with a high yield111. This work was first introduced by 
the German chemist Huisgen in 1963 at the University of Munich, since then certain parameters 
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have been set for click-chemistry reactions 1) rapid 2) high yield 3) stereospecific 4) nontoxic by 
product 5) broad solvent to include aqueous environments 113, 114. Although, these parameters set 
a bar for click-chemistry reactions, since it was first discovered by Huisgen there has been a 
large expansion of reactions that fall under click reactions that push some of these parameters 115-
121. Therefore, it can be said that the method is ever expanding allowing for a variety of 
chemistries to be highlighted under the click-chemistry umbrella.  
1.2.2 Copper-free click chemistry 
For all the perceived benefits of the copper catalyzed click reaction, this proved 
problematic when carrying out in biological systems due to toxicity of the catalyst as it can 
interfere with cellular processes 122-124. Therefore Click-chemistry did not shine again until 2001 
when Karl Sharpless rediscovered the work and expanded the use of click reactions by 
highlighting the use of cyclooctynes in the reactions 113, 125. Through the use of these highly ring-
strained rings the reaction can be carried out in the absence of the copper-catalyst. This is made 
possible by the use of the ring-strain to drive the reaction 108, 113, 125 [Figure 1.5 B-C]. Most 
importantly, this reaction became wide known and useful across many disciplines as it could be 
carried out in an aqueous environment at various temperatures without being pH dependent. 
Specifically, in the field of polymer science and biomaterials researchers have made this click 
reaction the gold standard, following on the footsteps of Carolyn Bertozzi in 2007, as it allows 
for facile, high yield conjugation of biomolecules in a biorthogonal fashion at physiological 
conditions 126.  
1.2.3 Hydrazone and Oxime click-chemistry  
Since Sharpless work in 2001 and Bertozzi bringing click-chemistry in vivo copper free 
click chemistry has expanded to additional substrates beyond azides and alkynes. In this section 
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we will discuss two click-reactions,  hydrazone and oxime click-chemistry, that highlight the 
need to rethink the stringent notion of an orthogonal reaction when addressing click reactions 114. 
In the case of these reactions a ketone or aldehyde and a hydrazide (amine bound to amine) or 
aminooxy (amine bound to oxygen) come together to form an imine adducts [Figure 1.5 D-E]. 
In these reactions the heteroatom-bound amine becomes more nucleophilic which promotes the 
attack of the carbonyl carbon causing the water to be expelled and a bond formation between the 
carbonyl carbon and the hydrazide/aminooxy agent127-131. Although these reactions naturally 
occur in biological systems the imine is usually transient and easily dissociates. Additionally, 
these reactions are thermodynamically unfavorable and require low pH to proceed efficiently 127-
131. Nevertheless, these click-chemistry reactions have been utilized for various tissue 
engineering and biomedical applications such as hydrogels, biosensors, drug delivery systems 90, 
132-137 However due to their limited selectivity for aldehydes and ketones that are naturally 
present this has limited their used in vivo, nevertheless these reactions are labeled as semi-
biorthogonal and classified as click-chemistry 114. Thereby broadening our interpretation of 
click-chemistry reactions and can be applied to the work in chapter 4. Where in this case we have 
weaker nucleophilic amine but a much more reactive ketone driving the click-chemistry reaction 
by ring-strain. 
1.2.4 Thiol-ene click chemistry 
The conjugation of alkenes to thiols is another class non biorthogonal click-chemistry 
reaction that has been widely explored [Figure 1.5F] 104, 138-143. These reactions fulfill the 
requirements set forth by Sharpless and coworkers – producing high yielding coupling – that is 
widely utilized in tissue engineering to post-modify biomaterials with cysteine containing 
molecules 144-148. The reaction is catalyzed by base or UV light with a photo initiator that 
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proceeds rapidly to conjugate the molecules together. Most importantly, this is one of the less 
                
 
Figure 1.5 Modes of click-chemistry reported in the literature. 
 
A) Copper catalyzed click-chemistry as reported by Huisgen and coworkers B - C) 
Demonstration of copper-free click chemistry via ring strain provided by the 
cyclooctyne and DBCO as described by Sharpless  D – E) Expanding the notion of 
click-chemstry to form imine bonds through the use of hydrazine and oxime groups 
with aldehydes or ketones. 
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cost-effective system which when coupled with the efficiency and ease makes it popular among 
biomaterial scientist 138. In the work described in chapter 2 we focused on this method due to its 
ease and low-cost of the thiol reactive groups which can be conjugated to biomolecules. 
1.3 Vascular tissue engineering for cardiovascular disease 
1.3.1 Cardiovascular disease a global pandemic 
Cardiovascular diseases (CVDs) has become the leading cause of death in the U.S. and 
internationally accounting for over for 17.7 million deaths, almost a third of all global deaths, in 
2015149. As this figure is predicted to increase to over 23 million deaths by 2030, CVD has 
become a pandemic that will continue to be a key health issue for the foreseeable future149, 150. In 
addition to CVD’s impact on human health and life, the monetary cost of CVD has been 
estimated to be around $530 billion in direct and indirect costs150. Of all the deaths caused by 
CVD, over 50 percent have been attributed to vascular damage induced by accumulation of 
vascular plaque, which leads to blocked and hardening vessels that deteriorate over time and may 
cause lesions151. This is known as atherosclerosis, when plaque builds up in the arteries, made up 
of fat, cholesterol, and calcium leads to narrowing in the blood vessel. As the cholesterol and 
other molecules accumulate the disease progresses to stenosis which is a much more serious 
condition that requires surgical intervention. If left untreated the accumulation leads to hardened 
walls and lesion calcification forming a necrotic core that weakens the vasculature, plaque 
rupture that exposes the accumulated materials to blood causing thrombus formation, as well as 
the walls becoming leading to vasculature to rupture 149, 152-157.  
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1.3.2 Current therapeutics for cardiovascular disease 
Currently, early treatments for vascular disease include changes in diet, exercise, and 
pharmacological therapy such as from statins. Statins are a type of drugs which target cholesterol 
in the vasculature and reduce the amount of lipids produced in the liver in an attempt to reduce 
the amount accumulated 56, 158, 159. However, as the severity of the disease progresses surgical 
intervention is often necessary. Most commonly these cases require replacement of the damaged 
vessel9, 160, 161. Due to the lack of readily available grafts, physicians are forced to utilize 
inefficient replacements. As of now, autologous blood vessels derived from the saphenous vein 
have served as the gold standard in these treatments1, 37, 162-168. However, this is not ideal for most 
patients because harvested autologous vessels often do not embody the same properties as the 
vessels, they replace4-6. Additionally, for patients who have exhausted the number of useful 
vessels that may be harvested or who suffer from widespread atherosclerotic vascular disease 
which has damaged suitable vessels, this treatment is simply not an option. In these cases, 
allografts from cadavers and xenografts from pigs have been widely used as replacement vessels, 
but they have been shown to elicit an undesirable immune response in some patients and there 
are not enough allografts available to treat everyone who needs one85, 169, 170.  
1.3.3 Synthetic materials as vascular grafts 
The shortage of grafts available and the issues of immune response with currently 
available treatments has led to the development of synthetic materials that may be used to create 
grafts that can meet the clinical demands for the replacement of blood vessels165, 167, 168. While 
synthetic grafts made from Dacron® or Teflon® have made a major impact on helping mitigate 
the effects of vascular disease and loss of life due to shortage of suitable replacements, these 
grafts also suffer from several limitations: thrombosis has been observed in small diameter (<6 
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mm) grafts, limiting their use to large arterial blood vessels 169, 171-174. Additionally, these grafts 
are made from bioinert polymers that are not biodegradable which prevents cellular migration, 
proliferation and remodeling, thereby the implanted material becomes susceptible to wear and 
tear over time and cannot be regenerated as the body might regenerate a vessel with minor 
injury172-175.  
1.3.4 Tissue engineering scaffolds as vascular engineer grafts 
Due to these limitations with synthetic grafts, tissue engineering is a promising approach 
to address these problems and to create a vascular graft that is biocompatible, biodegradable, and 
promotes mature native tissue formation 17, 57, 160, 165, 167, 169, 176-179. Currently, small diameter 
tissue engineered scaffolds used as vascular grafts have been successful in meeting the 
mechanical properties necessary for surgical implantation and physiological conditions in rat 
models 4, 177, 180-182. Additionally, much work has gone into identifying ideal scaffold morphology 
and architecture, such as creating nanofibrous and porous scaffolds which optimize cell 
infiltration and proliferation49, 161, determining the effect of the supportive structure on vascular 
muscle reconstruction182, 183, and the conjugation of biological molecules to improve the patency 
of implanted scaffolds,20, 184, 185. However, these parameters still require further work and 
methods to implement and optimize more than one of these are absent in the literature. This has 
led to limits in cellular infiltration and proliferation and has had deleterious effects in small 
diameter blood vessels, yielding poor cell-scaffold interactions, cellular migration, extracellular 
deposition and scaffold remodeling, and thrombus and aneurism formation1, 162, 163, 186. Therefore, 
it is essential to optimize the scaffold design before tissue engineering reaches its full potential as 
an alternative for vascular grafts.  
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1.3.5 Acellular scaffolds as “in situ” vascular grafts 
The last decade has seen the development of highly efficient biomimetic acellular 
scaffolds that can serve as vascular grafts. More recently, researchers have sought to avoid time 
consuming in vitro bioreactor-assisted vascular reconstruction and take advantage of the body’s 
capability to regenerate using in situ implementations of tissue engineered scaffolds 164, 166, 167, 179, 
187. 
The goal for in situ vascular tissue engineering is to create a functional blood vessel that 
is regenerated by the body through a cell-free off-the-shelf scaffold that is biodegradable, 
biocompatible, and tailored for patient-specific application. In doing, the method of in situ cell-
free vascular tissue engineering demonstrates a promising method to address the critical need for 
readily available vascular grafts caused by the ongoing shortage by shortening the time necessary 
to produce a graft8,15 The use of cultured cells to create small-diameter TEBV for cardiac and 
peripheral revascularization procedures is not suitable for most clinical applications due to the 
immediacy in which the vessel is commonly needed; therefore cell-free tissue engineered 
vascular grafts allow for elimination of the time required for cell culture/harvest and immediate 
implantation 166, 167. Since the first polymer scaffold was fabricated for blood tissue engineering, 
numerous platforms have been developed using three main fabrication methods - molds, 
templets, and electrospinninng49, 160, 177, 188 1, 163, 186, 189. This has led to synthesis of sheets that are 
rolled or sutured together, single layer tubular scaffolds, or bilayered tubular scaffolds to 
promote rapid host vascular cell invasion as well as scaffold-supported vascular reconstruction 
after implantation into animal models49, 177. Through these methods suitable scaffolds have been 
developed repeatedly that are able to evenly match the physical characteristic in diameter and 
length of the replacement vessel. 
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1.3.6 Polymers used in scaffold fabrication for tissue engineering 
There has been a large variance in the polymers utilized for development of vascular 
tissue engineered scaffolds. Both slow degrading polymers, such as polycaprolactone (PCL), and 
faster degrading polymers, such as poly(urethane), poly(glycolic acid), and poly(glycerol 
sebacate) have been used in scaffold designs 62, 99, 160, 190. Polycaprolactone is a polymer 
frequently used in the fabrication of mono-layer scaffolds since it is easily incorporated into 
tubular scaffolds via electrospinning and provides excellent mechanical properties98, 190, 191. 
However, it degrades very slowly (1.5 to 3 years) and development of calcification within the 
formed tissue has been observed in long term studies192. These observations were confirmed by 
Sugiura, T. and coworkers who assessed long-term studies of a bilayered scaffold containing a 
layer of slow degrading PCL and a layer of PLCL, a faster degrading copolymer, and then 
compared the level of calcification within the layers. From this work, we can conclude that the 
issue of calcification could be avoided if faster-degrading materials are used97. Fast degrading 
polymers such as PGS and PGA have also been utilized in scaffold fabrication and have been 
shown to provide rapid degradation of the scaffolds leading to faster infiltration, proliferation 
and matrix production5. However, rapid degradation has also led to formation of aneurysms and 
also results in the need for a slower degrading polymer to provide structural support160, 177, 178. 
For this reason, slow-degrading polymers such as PCL still prove to be useful due to their 
elasticity and continue to be used to improve the durability of tissue engineered scaffolds.  
1.3.7 Optimization of vascular tissue engineered scaffolds 
 In order to increase the compatibility of the tissue engineered scaffolds, much effort has 
been devoted to imparting biomimetic cues through the physical architecture of the scaffold as 
well as incorporating biomolecules. The use of porous and interconnected scaffolds has been of 
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particular interest since they allow excellent mass flow, as well as cellular penetration and 
migration from the points of anastomosis 49, 160, 177. Techniques such as TIPS and electrospinning 
have been extensively studied since they produce nanofibrous morphology that mimics the native 
extracellular matrix environment both in size of fiber and mechanical forces exuded on the cell9, 
49, 68, 177, 188, 193. Previously, Ma and coworkers developed large diameter nanofibrous scaffolds 
fabricated from a sugar leaching template and TIPS from PLLA that showed superior cellular 
attachment, proliferation, and migration49. Additionally, the nanofibrous architecture of the 
scaffold was shown to be conducive for mature vascular tissue formation through the 
differentiation of cardiovascular progenitor cells into smooth muscle cells with contractile 
phenotype both in vitro and in subcutaneous implantation in mouse models 50, 54, 161, 194.  
Recently, in an attempt to increase the biomimetic nature of the tissue engineered 
scaffolds regulatory signals, biological motifs, and anticoagulant molecules have been introduced 
unto the vascular engineering scaffolds to enhance the microenvironment and biocompatibility 
181, 185, 191. Specifically, heparin has a desirable molecule to be added as it has antithrombogenic 
properties and enhances the scaffolds biocompatibility 181, 184, 191, 195. The prefer method to 
introduce the heparin unto the scaffold is through conjugation directly unto the polymer. 
However, due to the chemical structure of the polymers most widely utilized, there is no 
backbone chemical functionality and the only points of attachment are at the ends of the 
polymers. Therefore, very little heparin can be attached to the scaffold160, 170, 181, 184, 191, 195. To work 
around the low chemical functionality, researchers have taken to dipping the scaffold in a 
heparin solution in an attempt to foul the surface. However, due to heparin’s hydrophilic nature 
and high solubility, retention of heparin is minimal after scaffold implantation and therefore 
many systems experience thrombosis issues177, 192, 196-198  
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1.4 Introduction and thesis outline  
This dissertation will be used to advance the development of polymers used in the 
fabrication of biomimetic scaffolds for tissue engineering and regenerative medicine. Polyesters 
such as those synthesized from lactones, poly(caprolactone) (PCL), poly(L-lactic acid) (PLLA), 
and poly(glycolic acid) (PGA), are currently the gold standard used for scaffolding material. Due 
to their favorable properties such as processability, degradability, and biocompatibility (FDA 
approved).  However, these polymers lack functionality in the backbone, and therefore platforms 
fabricated from them are limited in the manner in which they can be conjugated with regulatory 
signals (growth factors, biomolecules, peptides). For this reason, polymers with increased 
functionality that can incorporate these signals post-fabrication would be beneficial in enhancing 
the microenvironment. Currently, there is a lack of such polymers which are suitable for 
scaffolding due to the polymerization efficiency (MW which can be attained), how they can be 
processed, and biocompatibility. In this work, two novel polymers are explored as possible 
biomaterials for the fabrication of tissue engineering scaffolds. These polymers are 
poly(spirolactide-co-lactic acid) PSLA, a polymer with tunable functionality in the polymer 
backbone that demonstrates properties similar to PLLA, and poly(exomethylene-co-lactic acid) a 
novel copolymer with click-chemistry like reactivity with amine-containing molecules. These 
polymers were used to develop three-dimensional scaffolds, and we demonstrate how the 
functionality of the polymers is beneficial in enhancing the scaffolds biomimetic properties.  
1.4.1 HMW Polymerization of PLLA and PSLA using extreme temperature 
Chapter 2 will provide essential background on polyesters used in tissue engineering, 
specifically focusing on PLLA, which is the most commonly used polymer due to it’s retention 
time and the unique architecture that can be formed via processing techniques (smooth, 
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nanofibrous, textured surface). We describe methods of synthesis and modification to add 
functionality to the platforms developed from PLLA. We describe different properties that are 
required of polymers to be used to create scaffolds with biomimetic physical properties as well 
as scaffold design and previous models used in vasculature engineering and bone formation.  
1.4.2 Tubular scaffold from PLLA/PSLA for vascular engineering 
In chapter 3, we will describe a novel method to synthesize high molecular weight 
PLLA through cold temperature-induced polymerization. Here we describe how the cold 
temperature can be used to polymerize HMW PLLA using organocatalyst DBN (1,5-
Diazabicyclo[4.3.0]non-5-ene) and TBD (1,5,7-Triazabicyclo[4.4.0]dec-5-ene) with living 
polymerization like properties and MW > 300 k Da. We implemented this cold technique to 
synthesize the copolymer PSLA, which previously has only been shown at low MW < 30 K Da 
(size not suitable for scaffold fabrication) and demonstrated for the first time an HMW PSLA 
copolymer with a MW > 300 k Da. This copolymer displayed PLLA like characteristics with the 
added benefit of tunable backbone functionality (controlled by modulating the feed ratio of L-
lactide and spirolactide used) was fabricated into biomimetic scaffolds with porous, 
interconnected, and nanofibrous architecture.  
1.4.3 PELA polymer with click-chemistry like reactivity 
Chapter 4 focuses on using the HMW PSLA copolymer to develop biomimetic tubular 
scaffolds that are porous, interconnected, and nanofibrous for in situ implantation in rat models. 
Due to the tailorable backbone functionality of the PSLA copolymer, we can conjugate heparin 
unto the scaffolds and modulate the microenvironment. In doing so, we can control the 
hydrophilicity, degradation, with anti-thrombogenic properties. The scaffolds developed where 
implanted in situ in rat models (> 45) and observed post-operative for up to 3 months. We 
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determined the scaffolds to be patent with zero thrombi leading to death, no aneurysm formation, 
and fully remodeled mature vascular tissue. Thereby demonstrating the utility of HMW PSLA in 
the development of biomimetic scaffolds that can be modified to enhance the microenvironment 
and alter the physical properties. 
1.4.4 PELA polymer with click-chemistry like reactivity 
Chapter 5 delves into the novel synthesis of the PELA copolymer with click-chemistry 
like reactivity. In this chapter, we explored the facile and rapid method of modification that leads 
to a peptide bond formed between the amine-containing molecule and the tissue-engineered 
platformed developed. The conjugation can occur in water, buffer, or media, as well as polar 
protic (methanol & ethanol) and polar aprotic solvents (dimethyl sulfoxide). Thereby making it 
possible to broadly modify the copolymer and platform fabricated with a variety of regulatory 
signals such as protein, peptides, or small hydrophobic molecules. The copolymer was used to 
develop a three-dimensional nanofibrous scaffold that is porous and interconnected via thermally 
induced phase separation (TIPS) and sugar leaching method. These scaffolds were shown to 
contain the same “click-chemistry” like reactivity towards amine-containing molecules and can 
promote bone formation.  
1.4.5 Summary of Work and Proposed Future Work 
Chapter 6 will summarize our findings, detailing how the surface modification of tissue 
engineering scaffolds enhances the biomimetic properties and allow us to tailor the material for a 
specific purpose. These favorable properties attained and modifications made possible through 
the development of two highly reactive polymers never before used for tissue engineering. 
Lastly, Chapter 7 will detail future directions which these polymers are currently being applied 
in tissue engineering purposes as well as provide possible new research avenue 
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Chapter 2. Facile and Rapid Cold Synthesis of High Molecular Weight Biodegradable Polymers 
R. Navarro, P.X. Ma., “Biodegradable polymers and nanofibrous scaffold thereof,” U.S. Patent 
Application No. 63/014,484, Filed April 2020. Patent Pending 
 
R. Navarro*, A. Adiwidjaja, P.X. Ma., “Facile and rapid cold synthesis by guanidine 
organocatalyst leads to HMW PLLA and PSLA.” In Process. 
2.1 Introduction  
2.1.1 Synthesis of lactones into biodegradable polymers for biomedical applications  
Biodegradable polymers are widely used in biomedical applications, such as tissue 
engineering scaffolds, drug-releasing micro-/nano-particles, and implants. Traditionally, lactones 
such as L-lactide are cheaply and easily polymerized via ring-opening polymerization (ROP) 
through the use of a tin catalyst such as stannous octoate in a reaction vessel that has been purged 
and heated (120 – 150 °C) 67, 94, 199. The reaction quickly proceeds in a step-growth fashion 
producing water molecules as the condensation reaction occurs between adjoining lactic acid 
molecules. As the polymer grows, the viscosity of the growing polymer increases until you reach 
a point in which no more stirring is possible. Thereby limiting the interactions between chains 
and preventing continued growth. Likewise, the water molecules released will become entrapped 
in the viscous polymer and can either quench the reaction or hydrolytically cleave the polymers 
formed, resulting in polymers with a small molecular weight. In our experience, polymers 
produced in this fashion only reach an average of 50 k Da due to the viscosity and water issues 
mentioned. 
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2.1.2 The need for high molecular weight polymers in tissue engineering 
Yet, for many applications, a reasonably high molecular weight (HMW) is often 
necessary for such polymers to be processed into the desired biomimetic physical forms or/and to 
possess the desired mechanical and nanofibrous properties. Such fibers are unique in that they 
mimic the fibrillar structure of natural extracellular proteins such as collagen and elastin and 
have been shown to facilitate cell attachment, proliferation, differentiation, and tissue 
regeneration. To develop scaffolds with this preferred nanofibrous architecture, PLLA should 
contain HMW due to the increased crystallinity observed and the resulting mechanical 
properties. Unfortunately, synthesizing HMW polymers (such as above 100 k Da) often requires 
high temperature, extended reaction periods, and specialized reaction vessels that are costly. 
Thereby limiting the access to HMW PLLA for scaffolding purposes and forcing researchers to 
outsource production to external vendors, at considerable cost and time. 
2.1.3 Synthesis of functional polymers for scaffold fabrication with enhanced biomimetic 
properties 
Beyond imparting tissue engineering scaffolds with biomimetic architecture such as 
porous, interconnected, and nanofibrous architecture, considerable effort has been expended to 
introduce regulatory signals into the scaffold. The preferred method of introducing these signals 
is to conjugate them directly into the scaffold and thereby prevent the diffusion and washing 
away of the regulatory signals that can be costly and limited in quantity. To prevent this, the 
polymers used should contain the preferred functional groups NH2, SH, or alkene. These groups 
allow for a wide range of flexibility in post-modification, and the coupling reactions have a high 
level of efficiency. However, lactone polymers such as PLLA lack any of these functional 
groups, and therefore we are limited to the degree in which we can impart biomimetic properties.  
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2.1.4 Guanidine organocatalyst used to induce ring-opening polymerization  
Previously, catalyst derived from guanidine has been shown to polymerize lactides with a 
very narrow polydispersity (PDI) in a facile and cost-effective manner leading to medium size 
polymers (50 - 70 k Da) 92, 93, 200, 201. The catalyst which include 1,5,7 Triazabicyclo [4.4.0]dec-5-
ene (TBD), 7-Methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (MTBD), 1,5-Diazabicyclo[4.3.0]non-
5-ene (DBN), and 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) are strong basic organo-catalyst 
which coordinate the ring-opening and esterification through an amidine base. Unlike tin-based 
ROP reactions, which are traditionally performed as bulk polymerizations, the reactions 
performed in solution reduces viscosity problems. The solution polymerization is usually carried 
out in DCM at room temperature producing polymers with narrow distribution but with varying 
kinetics based on the catalyst used. Typically, TBD is reported as a fast-acting catalyst that is 
able to quickly consume > 99 % of the monomers and produce polymers within 5 min. MTBD, 
DBU, and DBN have been reported as less efficient (90 - 98 %) and slower compared to TBD 92, 
200. However, the efficiency changes between lactones polymerized and therefore warrant further 
investigation. The organocatalyst works by initiating the ring opening polymerization and 
simultaneously coordinating the esterification with a hydroxyl group [Figure 2.1]. Unlike in 
traditional polymerization where heat can help drive this process (esterification) and causes a 
more random esterification of monomer to monomer, monomer to polymer, and/ or polymer to 
polymer the TBD catalyst can produce the esterification in the absence of heat. Therefore, in the 
absence of the TBD catalyst (i.e. catalyst degrades), we expect the lactone ring will not be 
cleaved and the esterification (polymer growth to also not occur). 
In this work, we surprisingly discovered a facile, rapid, and low-cost method to 
polymerize HMW polymers from lactones and other cyclic monomers by utilizing extremely low 
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temperatures and guanidine derived catalysts. Further investigating the extreme cold   
polymerization while changing the following conditions: solvent utilized, solvent concentration, 
catalyst concentration, and using/ not using an initiator. The latter having the effect of allowing 
us to control the molecular weight of the resulting polymers and producing polymers with 
defined MWs. Applying the most favorable conditions discovered, we can extend this technique 
to synthesize HMW PLLA, and polymerizing other lactone-based polymers, as well as the 
synthesizes of HMW PSLA for the first time. Furthermore, we showed the utility of the cold 
polymerization to produce HMW copolymers such as poly(lactic-co-spirolactic acid) (PSLA) 
that can be processed into desired physical forms such as nanosized fibers, which could not be 
 
 
Figure 2.1 TBD catalyst mechanism of polymerization. 
Ring opening of L-lactide by TBD catalyst and polymerization with hydroxyl group (step 4) 
coordinated by the organocatylist. Step 6 yields the catalyst and growing molecule. 
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achieved before using current polymerization methods. Most importantly, in this work, we 
demonstrate that compared to the conventional polymerization conditions, the extreme cold 
polymerization does not require large equipment investment and can yield HMW polymers, 
including functionalized specialty polymers with low costs.   
2.2 Materials and methods 
2.2.1 Materials 
L-lactide was purchased from Altasorb® and recrystallized two times in ethyl acetate 
before use. Glycolide (recrystallized in ethyl acetate), 2-hydroxyethyl methacrylate (HEMA), 3-
chloropropanol, propargyl alcohol, benzyl alcohol, anhydrous acetone (AT), anhydrous 
tetrahydrofuran (THF), anhydrous dichloromethane (DCM), and anhydrous ethyl acetate (EA) 
were purchased from Sigma. The catalysts methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene (MTBD), 
5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-
Diazabicyclo[4.3.0]non-5-ene (DBN) were purchased from Sigma and stored under an inert 
environment. 
2.2.2 General procedure for ring-opening polymerization using cold polymerization and TBD 
organocatalyst 
In a reaction flask L-lactide was purged three times via a standard vacuum/nitrogen gas 
treatment before dissolving in anhydrous DCM. The flask was cooled to -80 °C for 1 h and then 
injected with catalyst dissolved in DCM. The reaction was monitored via gel permeation 
chromatography and the polymer formed was precipitated in ethyl ether, re-dissolved in DCM, 
then precipitated in ethyl ether and stored under vacuum for two days before use. All reactions 
performed in subsequent experiments were performed with an n = 3. 
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2.2.3 General procedure for the ring-opening polymerization with a change in concentration 
In a reaction flask L-lactide was added and purged three times via a standard 
vacuum/nitrogen gas treatment before dissolving in anhydrous DCM. The reaction was dissolved 
at 5, 10,15, and 20% w/v concentrations. The flask was cooled to -80 °C for 1 h and was then 
injected with 0.01 % mol initiator followed by 0.5 % mol of catalyst dissolved in DCM. The 
reaction was monitored via gel permeation over a week at designated times. 
2.2.4 General procedure for the ring-opening polymerization change in catalyst concentration 
In a reaction flask L-lactide was added and purged three times via a standard 
vacuum/nitrogen gas treatment before dissolving in anhydrous DCM. The reaction was dissolved 
at 5, 10, 15, and 20% w/v concentrations. The flask was cooled to -80 °C for 1 h and was then 
injected with either 0.05 %, 0.1. %, 1.0 %, and 2.5% mol catalyst dissolved in DCM. The 
reaction was monitored via gel permeation over a week at designated times. 
2.2.5 General procedure for the ring-opening polymerization with benzyl alcohol initiator  
In a reaction flask L-lactide was added and purged three times via a standard 
vacuum/nitrogen gas treatment before dissolving in anhydrous DCM at 5% w/v. The reactions 
were then injected with initiator (benzyl alcohol) dissolved in DCM and added to the L-lactide to 
synthesize polymers of 10k, 25k, 50k, and100k molecular weight. The flask was cooled to -80 
°C for 1 h and was then injected with 0.5% catalyst dissolved in DCM. The reaction was 
monitored via gel permeation chromatography and the polymer formed was precipitated in ethyl 
ether, re-dissolved in DCM, then precipitated in ethyl ether and stored under vacuum.  
2.2.6 General procedure for the ring-opening polymerization in diverse solvents used  
 
 32 
In a reaction flask L-lactide was added and purged three times via a standard 
vacuum/nitrogen gas treatment before dissolving in anhydrous solvents. The reactions were 
dissolved at a concentration of 5 % and 10 % w/v in anhydrous DCM, THF, AC, and EA. The 
flask was cooled to -80 °C for 1 h and was then injected with 0.5 % mol of catalyst dissolved in 
the respective solvent. The reaction was monitored via gel permeation over a week at designated 
times. 
2.2.7 General procedure for the ring-opening polymerization of PLGA 
In a reaction flask L-lactide and glycolide were added in a 1:1 ratio and purged three 
times via a standard vacuum/nitrogen gas treatment before dissolving in anhydrous DCM at 5% 
w/v. The flasks were cooled to -80 °C for 1 h and were then injected with 0.5% catalyst 
dissolved in DCM. The reaction was monitored via gel permeation chromatography and the 
polymer formed was precipitated in ethyl ether, re-dissolved in DCM, then precipitated in ethyl 
ether and stored under vacuum.  
2.2.8 General procedure for the ring-opening polymerization of PCL 
In a reaction flask ε-caprolactone was added and purged three times via a standard 
vacuum/nitrogen gas treatment before dissolving in anhydrous DCM at 5% w/v. The flask was 
cooled to -80 °C for 1 h and was then injected with 0.5% catalyst dissolved in DCM. The 
reaction was monitored via gel permeation chromatography and the polymer formed was 
precipitated in ethyl ether, re-dissolved in DCM and precipitated in ethyl ether and stored under 
vacuum. 
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2.2.9 Spiro[6-methyl-1,4-dioxane-2,5-dione-3,2’-bicyclo[2.2.1]hept[5]ene] synthesis 
L-Lactide was modified based on a method reported by Hillmyer et. al.202. Briefly, L-
Lactide was combined with NBS (1.1 eq.) in benzene (20 % w/v) and heated to reflux. Benzoyl 
peroxide dissolved in benzene was added dropwise and the reaction was monitored by thin layer 
chromatography (TLC) until completion. The reaction was vacuum filtrated and condensed and 
the resulting solid was dissolved in DCM, washed in sodium thiosulfate solution, and 
concentrated. The solid was recrystallized from ethyl acetate and hexane twice to yield white 
crystals, (3S, 6S)-3-Bromo-3,6-dimethyl-1,4-dioxane-2,5-dione (bromo-lactide) (1). The white 
crystals were dissolved in DCM in a flask under nitrogen and cooled in an ice bath. TEA (1.1 eq) 
was added in dropwise and allowed to react for 1 h at 0° C and 1 h at 25° C. The reaction was 
washed with 1M HCl three times and condensed. The crystals were further purified by liquid 
chromatography on silica gel and recrystallization in ethyl acetate to yield white crystals, (6S)-3-
Methylene-6-methyl-1,4-dioxane-2,5-dione (methylene lactide) (2). To freshly distilled 
cyclopentadiene (2.2 eq.) 2 was added (1 eq.) and refluxed overnight in benzene under argon. 
The reaction was condensed and purified by liquid chromatography in 50/50 hexane:DCM (rf = 
0.31) followed by recrystallization in ethyl acetate to yield white crystals, Spiro[6-methyl-1,4-
dioxane-2,5-dione-3,2’-bicyclo[2.2.1]hept[5]ene] (spiro-lactide) (3). 
2.2.10 General procedure for the ring-opening polymerization of PSLA 
In a reaction flask L-lactide and spirolactide were added in a 1:0, 1:1,1:2,1:3,1:5, 
1:10,1:20 mol ratio and purged three times via a standard vacuum/nitrogen gas treatment before 
dissolving in anhydrous DCM at 5% w/v. The flasks were cooled to -80 °C for 1 h and then 
injected with 0.5% catalyst dissolved in DCM. The reaction was monitored via gel permeation 
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chromatography and the polymer formed was precipitated in ethyl ether, re-dissolved in DCM, 
then precipitated in ethyl ether and stored under vacuum.  
2.2.11 Nanofibrous Film Fabricated from PSLA Polymer using TIPS 
A two-dimensional film with a thickness of 200 μm with nanofibrous architecture was 
fabricated using thermal induced phase separation (TIPS). TIPS was carried out according to 
procedures developed by Ma et. al.4, 33, 61, 203. Briefly, a 10 % w/v polymer solution consisting of 
PSLA was dissolved in THF by heating to 60 °C and casting onto a glass surface. The solution 
was then quickly cooled to - 80 °C and maintained at this temperature for 48 h in order to allow 
for phase separation. The films were brought to room temperature by placing them in an ice bath 
and allowing the bath to reach RT before removing the film. The films were dried and stored 
under vacuum until ready for use.  
2.2.12 Nanofibrous scaffold fabricated from PSLA polymer using TIPS  
The porous, interconnected and nanofibrous scaffolds are fabricated using a sugar 
leaching method and TIPS as previously reported by Ma et. al. 20, 61, 68, 204, 205. Briefly, the sugar 
template spheres are fabricated through an emulsion method and sieved to collect spheres 
ranging between 250 to 425 µm. The sugar is deposited in cylindrical molds and is heat treated 
to achieve the desired interconnected structure and then vacuum dried. A solution of PELA or 
PLLA was dissolved in THF to a concentration of 15% and 10% respectively and heated to 60 
°C. The solution was then added to the dry sugar template and treated to reduced pressure to 
force the polymer solution into the template. TIPS was then induced at -80 °C for two days 
followed by submerging in excess hexane overnight to remove residual THF and maintain the 
scaffolds free of moisture. The scaffolds were then submerged overnight in DDH2O to leach 
away the sugar template and the scaffolds cut to the desired diameter and width. 
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2.2.13 Fibrous Mesh Fabricated from PSLA Polymer Through Electrospinning  
In a 20 mL vial PCL (MW 60-80 k), L-lactide (viscosity of 1.6 dl/g), and PSLA (MW 50, 
100, and 300 k) were each dissolved in a mixture of 90:10 chloroform and methanol and allowed 
to stir for 24 h. The viscous solutions were then electrospun (15 kV, 10 cm, 2 mL/h) onto a flat 
surface covered in aluminum foil for 5 min to create a fibrous mesh. The mesh was then placed 
in hexane for 24 h to remove unevaporated solvent and stored under vacuum until use.  
2.2.14 Nanofibrous scaffold and mesh modified via thiol-ene click chemistry 
Scaffolds were modified through UV-light induced thiol-ene click-chemistry with the 
desired molecules to be conjugated. Briefly, thiol containing molecule and 
tetramethylethylenediamine (TEMED) were dissolved in DDH2O. The UV-initiator, Irgacure 
2959, was dissolved in 100 μL of dimethyl sulfoxide (DMSO) and added to the solution. The 
scaffolds were quickly soaked in ethanol then added to the PEG/Heparin solution prior to being 
exposed UV-light. The scaffolds were then washed in methanol and DDH2O to remove excess 
TEMED and Irgacure 2959 before being lyophilized. The scaffolds were then sterilized with 
ethylene oxide (Anproline Gas Sterilizer) and stored at -20 °C. 
2.2.15 General techniques and strategies 
Nuclear magnetic resonance characterization:  All monomers (L-lactide, exomethylene 
lactide and spirolactide) and polymers formed were characterized via 500 MHz 1H and 13C 
(Varian Inova 500) by dissolving in CDCl3. 
Ultraviolet–visible spectroscopy: All monomers and polymers formed were characterized 
by first dissolving in DCM and using a quartz cuvette to obtain spectrum from 200 - 700 nm (up 
to 350 shown) (Hitachi U-2910). 
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Fourier-transform infrared spectroscopy: Monomers, polymers, and modified tubular 
scaffolds were characterized by directly placing the sample on the diamond crystal sample holder 
to obtain the spectrum from 600 – 4000 nm (Thermo-Nicolet IS-50). 
Scanning electron microscopy (SEM) observation: Empty scaffolds were sputter-coated 
with gold for 150 seconds and observed under a scanning electronic microscope (JEOL JSM-
7800FLV).  
Gel permeation chromatography: Polymers formed were dissolved in anhydrous 
tetrahydrofuran and the molecular weight of the polymers were determined by comparing to 
polystyrene standards (Shimadzu GPC).  
 
        
 
Figure 2.2 Synthesis of lactone monomers through the use of TBD organocatalyst.  
 
Through the use of extreme cold temperature lactones such as PLLA, PLGA, and PCL. 
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2.3 Results 
2.3.1 Cold polymerization of HMW PLLA using TBD organocatalyst 
PLLA polymer was successfully synthesized using extreme temperature (-80 °C) and 
TBD organocatalyst. We were excited by the speed, efficiency, and reproducibility of results 
achieved with synthesis of PLLA with TBD as an organocatalyst via a solution polymerization. 
The polymerization occurred rapidly and efficiently with most of the monomer consumed in 15 
min. The polymer also grew to ~ 80% of its maxed MW within 1 h of polymerization [Figure 
2.2]  
2.3.2 Effects of low temperature on the molecular weight of polymerized PLLA  
To demonstrate the effects that the extreme temperature has on the polymerization 
efficiency, the polymerization was conducted at RT, 0 °C, - 20 °C, and - 80 °C monitoring the 
                            
Figure 2.3 Growth of polymer Mw based on change in temperature.  
 
Observation in change in molecular weight after 24 h due to the change in temperature. 
Polymerizations where observed at RT, -4 °C, -20 °C and -80 °C.  
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reaction over 7 days at predetermined times (24h reported). As previously described, we 
observed high efficiency in the consumption of L-Lactide monomer and synthesis of PLLA. The 
Mw of PLLA observed at -80 °C after 15 min exceeded over 90 k Da Mw compared to 
approximately 20 k Da, 30 k Da, and 50 K Da Mw for the reactions at RT, 0, and - 20 °C, 
respectively. We continued to observe the change in Mw reporting a change of approximately 20 
% increase at 24 h and no change by day 7, reaching a Mw of ~ 110 k Da and a PDI of 1.3. This 
is a 57 % increase in Mw over the - 20 °C reaction and 440 % increase when compared to the 
reaction at room temperature. This observation shows a clear correlation between the reaction 
temperature and the growth of the polymer [Figure 2.3].  
2.3.3 TBD catalyzed polymerization of PLLA in diverse solvents  
In the literature PLLA synthesis using the organocatalyst TBD has utilized DCM as the 
solvent of choice92, 200. This solvent was shown to perform the reaction at a fast rate while 
maintaining the polymer solubilized as it grew in molecular weight. Previously, our experiments 
in this study utilized this solvent due to its extremely low melting point (MP) (- 96.7 °C). 
Additionally, the solvent demonstrated extremely high solvation for PLLA at the extreme 
reaction temperature (- 80 °C). In order to investigate if DCM was the optimal solvent for this 
reaction at this temperature, we chose 4 additional solvents with low MPs in which PLLA was 
soluble: acetone (-95 °C), THF (-108.4 °C), ethyl ether (-116.3 °C), and toluene (-95 °C). All the 
solvents maintained the L-Lactide in solution before the polymerization and allowed for the 
polymerization of PLLA using TBD. However, as the polymer grew in MW in these 4 solvents 
the solubility at these extreme temperatures caused the polymer to precipitate in 3 out of the 4 
solvents (Acetone, Toluene, Ethyl Acetate) resulting in low molecular weight polymers. In this 
study, we noticed that acetone polymerized the smallest PLLA polymers with a range between 
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10 – 15 k Da, followed by Toluene ~ 15 k da, ethyl acetate 30 – 45 k Da, and THF 50 – 70 k Da. 
Of these solvents, we postulated that THF would be able to match the molecular weight achieved 
using DCM since we did not observe precipitated polymer. However, we postulate that at these 
temperatures the solubility affected the polymer growth based on the results seen in the 
additional solvents. With this information going forward we utilized DCM as the solvent to 
conduct all polymerizations.  
2.3.4 Effects of the solution concentration (w/v %) on polymerization MW 
The effects of polymerization concentration at 5 %, 10 %, 15 %, and 20 % where tested 
with a catalyst concentration at 1 % and excluding an initiator. To our knowledge we are the only 
group to report the polymerization of PLLA using the TBD organocatalyst without the use of an 
 
Figure 2.4 Growth of polymer Mw based on change in polymerization concentration. 
 
Effects of polymerization concentration of molecular weight of PLLA polymer after 24 h at 5, 
10, 15, 20 % weight by volume conducted at extreme cold temperature of - 80 °C in DCM.  
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initiator. We discovered that under these conditions we are able to achieve molecular weights 
exceeding > 170 K Da Mw with a PDI of 1.9 for the reaction with 5% w/v. The polymers 
collected showed a clear trend of increasing Mw as the concentration of the reaction went from 
20% to 5% with an “R” value of 0.987. Additionally, all other reactions reached a minimum of > 
130 k Da with a PDI ~ of 1.9 after 24 h. It is important to note that we attempted to polymerize 
the reaction at 1% weight by volume however, at this concentration the reaction produced 
polymers of ~ 50 k Da. Therefore, there seems to be a minimal threshold for the concentration of 
the reaction. The optimal concentration among those investigated is 5 % w/v [Figure 2.4]. 
2.3.5 Effects of TBD catalyst concentration on polymerization 
After evaluating the effects that the solvent concentration is able to impart on the Mw of 
the polymer, we investigated the effects that catalyst concentration plays on the reaction using 
the parameters of 5% & 10% w/v, -80 °C, no initiator, 24 h reaction time,  and TBD 
concentrations of 5%, 2.5%, 1%, .5%, .1% mol of lactide. We theorized that changing the 
Table 2.1 Growth of polymer Mw based on change in TBD concentration. 
 
    
Polymerization parameters of -80 °C, no initiator. Mw measured by GPC. 
% W/V TBD mol % Time (h) Mw (g/mol) PDI
5 0.1 0.25 254712 2.4
5 0.1 24 357642 2.28
5 5 0.25 16299 3.5
5 5 24 23959 2.09
10 0.1 0.25 173057 2.94
10 0.1 24 221532 2.2
10 5 0.25 11426 2.78
10 5 24 33918 5.54
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concentration of organocatalyst would have the most effect on polymerization. This is due in part 
to the work described by Goodman et. al. and our experience working with the fast-acting 
catalyst 92. We theorized that the catalyst would create more active centers at higher 
concentrations leading to smaller polymer molecular weights. We were able to achieve a high 
Mw by lowering the catalyst concentration from 5% to 0.1% mol of L-lactide, (29,000 (PDI 2.09) 
and 357,000 (PDI 2.28) g/mol, respectively). Likewise, by comparing the Mw achieved at 0.1% 
mol catalyst concentrations to the Mw achieved in solvent concentrations of 5 and 10 % w/v 
(357,000 (PDI 2.28) and 221,000 (PDI 2.20) g/mol, respectively) we can confirm that decreasing 
the concentration of the reaction provides the highest molecular weight possible [Table 2.1 and 
      
 
Figure 2.5 Growth of polymer Mw with change in catalyst mol % and W/V %. 
 
As the catalyst concentration was lowered to 0.1% percent the polymer molecular weight 
increased both at 5, 10, 20 % w/v reactions after 24h.  
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Figure 2.5]. Additionally, we attempted to polymerize the reaction using 0.01 % mol of the  
organocatalyst however, at 5% w/v, we only achieved molecular weights of ~ 87,700 g/ mol after 
24 h. Likewise, when polymerizing the reaction at 10 % w/v at 0.01 % TBD we observed that the 
polymer Mw was approximately equal to that achieved by using 0.5% TBD, ~120 k Da. 
Therefore, there appears to be a minimum amount catalyst concentration needed to polymerize 
the largest polymers possible and the optimal TBD concentration among those studied is 0.1 %. 
2.3.6 Controlled polymerization using initiator to synthesize polymers with defined Mw  
While synthesis of HMW PLLA is beneficial for scaffold fabrication, we were also 
interested in showing that our system could be utilized to create defined polymers. For this 
reason, we investigated if we could use benzyl alcohol to synthesize polymers with a defined 
number of repeat units [Table 2.2]. We were able to demonstrate that this cold polymerization 
method can not only be used to synthesize HMW PLLA with Mw > 300 k Da, but can also be 
used to synthesize polymers with defined Mw, approximately the theoretical value up to 140 k 
Da. Although we achieved high molecular weight PLLA, when we attempted to polymerize 
PLLA with a L-lactide to initiator mol ratio of > 1000:1, respectively, we were not able to 
replicate the molecular weight of > 300 k Da. In most cases our polymerizations stalled around ~ 
180 k Da with PDIs close of 1.8 – 2.5.  
 
Table 2.2 Controlled growth of PLLA using anhydrous benzyl alcohol as initiator. 
 
 
Polymerization parameters -80 °C, with initiator. Mw measured by GPC. 
% 
W/V
TBD 
mol % Time (h)
[I]/L-
lactide
Mw, theo
(g/mol)
Mw, GPC 
(g/mol) PDI
5 0.1 24 70 10089 9940 1.16
5 0.1 24 175 25223 24200 1.22
5 0.1 24 350 50446 62002 1.38
5 0.1 24 700 100891 98403 1.41
5 0.1 24 1000 144130 142935 1.55
5 0.1 24 1500 216195 186200 1.72
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2.3.7 Cold polymerization of general lactone polymers: PLGA, PCL using TBD organocatalyst  
In order to demonstrate the versatility of our cold polymerization method we synthesized 
PLGA, PCL, and PGA utilizing our established method with minor modification when 
polymerizing PGA. What we discovered was that when polymerizing PLGA the reaction 
occurred extremely fast and polymerized high Mw polymers of approximately 101 k Da PDI 1.8. 
NMR determined the ratio of glycolide to L-lactide varied with an average of 43:57. The 
synthesis of PCL using the cold polymerization method in combination with the TBD catalyst 
produced polymers with a range of Mw 30 – 60 k Da. Although not considered high molecular 
weight this is higher than previously reported values for the synthesis of PCL using TBD 
organocatalyst206.  
2.3.8 Synthesis of HMW PSLA polymer with controlled ratio of spirolatide to L-lactide  
Previously, Hillmeyer et. al described the synthesis of PSLA with varying ratios of L-
lactide to spirolactide demonstrating Mn of < 35 k Da for all permeations 200. To demonstrate the 
range of polymerization methods for lactones and derivatives we polymerized the permeations of 
spirolactide and L-lactide without the use of an initiator under our predetermined conditions 
[Figure 2.6]. We determined that our method can be used to create HMW PSLA polymers with a 
Mw  > 300 k Da (~ 10 times previously published) [Table 2.3]. We did observe a trend of lower 
 
 
Figure 2.6 Synthesis scheme of PSLA polymerization with TBD.  
 
PLSA with controlled feed ratio between spirolactide and L-lactide to synthesize PSLA with 
tailorable degree of functional norbornene groups in the polymer backbone. 
 
 
N
N
N
H
 44 
molecular weight at the higher ratios of spirolactide to L-lactide (1:0, 1:1, 1:2, and 1:3). 
However, all permeations achieved HMW with values near or > 100 k Da. We postulate, that the 
reactivity and self-polymerization efficiency of spirolactide impedes the reaction leading to 
lower MW polymers. After evaluating the co-polymerization via NMR, we were able to 
determine that the formed polymers closely matched the theoretical ratio values. Additionally, it 
is important to note that this is the first time the polymer has been reported with such a HMW, 
allowing us to utilize the polymer for fabrication of nanofibrous scaffolds fibrous meshes. 
2.3.9 HMW PSLA Fabricated into Biomimetic Scaffolds and Electrospinning  
To demonstrate the utility of the PSLA polymer we fabricated fibers through two 
different means, TIPS and electrospinning. We first began by showing that PSLA polymer could 
indeed form fibers at a high molecular weight. By creating a 10% w/v polymer solution in THF 
with the PSLA ratios we induced TIPS between glass slides and characterized the resulting films 
via SEM. We observed that although all the polymers were of proper MW those with ratios 
below 1:5 did not form the nanofiber morphology. Therefore, we focused on the PSLA1:5 to 
fabricate three-dimensional scaffolds and the electrospun fibers. Using the PSLA1:5 we fabricated 
disk-shaped 3D scaffolds with porous and interconnected morphology. Most, importantly we 
Table 2.3 Growth of PSLA polymer Mw based on change in TBD concentration. 
 
 
 
Polymerization parameters of -80 °C, with no initiator, and a controlled ratio between 
spirolactide and L-lactide. Mw measured by GPC. 
% W/V TBD mol % Time (h) Monomer Ratio (Spiro:L-Lactide)
Repeat Ratiotheo
(spiro:L-lactide)
Actual Ratiotheo
(spiro:L-lactide) Mw, GPC (g/mol) PDI
5 0.1 24 1 : 0 1 : 1 1 : 1 98200 1.31
5 0.1 24 1 : 1 1 : 3 1 : 4 151052 1.4
5 0.1 24 1 : 2 1 : 5 1 : 6 174599 1.38
5 0.1 24 1 : 3 1 : 7 1 : 8 180010 1.41
5 0.1 24 1 : 5 1 : 11 1 : 13 336629 1.58
5 0.1 24 1 : 10 1 : 21 1 : 21 318230 1.70
5 0.1 24 1 : 20 1 : 41 1 : 41 263940 1.81
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were able to visualize that the scaffolds retained the favorable nanofibrous morphology [Figure 
2.7]. We then explored the PSLA1:5 polymer for its potential to be electrospun and create a fibers 
mesh. Through this method we were able to demonstrate that indeed the PSLA1:5 polymer can be 
formed into a fibrous mesh that has the potential to serve for numerous tissue engineering 
purposes. Above all, we are able to demonstrate that we are able to synthesize HMW PSLA 
polymers via cold polymerization with the TBD organocatalyst to fully explore the potential of 
this attractive polymer. 
 
 
Figure 2.7 Fiber formation from PSLA 1: 5 mol ratio 300 k Da Mw. 
 
A) Gross image of 3D scaffold fabricated through TIPS and Sugar Leaching B) Magnified 
image of scaffold demonstrating interconnectivity and porosity via (SEM) C) Gross image 
of tubular scaffold fabricated via electrospinning D) Magnified image of PSLA fibers 
formed via electrospinning using SEM. 
 
A
B
PLLA PDLLA
1:4 Spyro:Lactide 300kDa 10% w/v 1:4 S iro:L ti 0 kDa 10% w/v  
A
C
B
D
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2.3.10 Cold polymerization of PLLA and PSLA with alternative guanidine catalysts  
Additionally, we tested the cold polymerization method using a varity of guanidine 
derived catalysts to demonstrate the efficiency of cold polymerization. Here we utilized DBN , 
MTBD, and DBU in a similar manner to polymerize PLLA. All three catalyst have been 
previously shown to effectively catalyze the polymerization of PLLA at room temperature and 
higher temperature ( up to 80oC). However, none of these catalyst has been previously shown to 
catalyze the polymerization of PLLA under such extreme low temperatures ( -80oC). 
Surprisingly we discovered that utilizing these catalysts the polymerization occurred in the same 
manner producing high molecular weight polymers with two of the 3 catalysts (DBN and 
MTBD). Of these DBN demonstrated superior properties of catalysing polymerization of HMW 
PLLA with very narrow PDI similar to living polymerization. For this reason, we utilized DBN 
to catalyse the polymerization of PSLA and showed that it too can polymerize HMW PSLA but 
with improved PDI [Table 2.4]. 
Table 2.4 Polymerization of PLLA and PSLA using DBN, MTBD, DBU. 
   
 
Polymerization parameters of -80 °C, with no initiator, and a controlled ratio between 
spirolactide and L-lactide. Mw measured by GPC. 
 
Polymer
Synthesized Catalyst % W/V TBD mol % Time (h) Mw, GPC (g/mol) PDI
PLLA DBN 5 0.5 24 250911 1.08
PLLA DBN 10 0.5 24 144000 1.05
PLLA MTBD 5 0.5 24 152358 1.23
PLLA MTBD 10 0.5 24 125464 1.33
PLLA DBU 5 0.5 24 60195 1.05
PLLA DBU 10 0.5 24 22327 1.06
PSLA1:5 DBN 5 0.5 24 220828 1.58
PSLA1:5 DBN 10 0.5 24 122925 1.64
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2.4 Discussion  
Researchers working to develop biomaterials for biomedical applications such as tissue 
engineering scaffolds are interested in synthesizing HMW polymers cheaply and with ease. 
Currently, acquiring HMW polymers requires purchasing from manufacturers that utilize 
expensive systems raising the cost of the final product. Additionally, HMW polymers from 
lactones such as PLLA that can form the favorable biomimetic nanofibrous architecture that 
contains functionality (NH2, SH, or Alkene) are not commercially available. Therefore, a cheap 
and facile method to synthesize HMW PLLA polymers and derivatives with desired functionality 
with equipment readily available to most labs has been the focus in this work.  
Traditionally, PLLA synthesis involves the ROP of L-lactide catalyzed by the tin catalyst 
stannous octoate67, 199. In an academic laboratory, the reaction is typically carried out in small 
scales using reaction vessels that severely limit the growth of the polymer. This is because the 
polymerization is carried out in a bulk reaction, and as the PLLA increases in MW, it becomes 
viscous; when the polymer reaches ~ 10-15 k Da, the polymer becomes too viscous to stir 
continuously. Therefore, the interactions within the polymer chains become limited and the 
polymer throttles. Additionally, the polymer releases water that can become entrapped in the 
viscous polymer and cause hydrolytic cleavage of the growing chains. In our experience, 
laboratory polymerization of PLLA rarely produces polymers in molecular weight larger than 50 
k Da. Furthermore, the reactions are time-consuming and utilize toxic metal catalysts. In 
industry, these issues are remedied by using large reactors with powerful rotors and vacuums to 
remove the water released, thereby producing polymers with high molecular weight. However, 
these polymers are not tailorable (i.e., able to be end-functionalized), the cost is prohibitively 
expensive, and the lead time is several weeks.  
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For these reasons, our facile and rapid method of developing high molecular weight 
PLLA is an attractive method when compared to the traditional synthesis stated above. This 
method uses no heat, uses small amounts of an organocatalyst, and can, be performed at low 
concentrations (% w/v) to facilitate the growth of the polymer. As we have shown in the study, 
in this method, PLLA is rapidly polymerized with an organocatalyst reducing the toxicity over 
the tin catalyst. Most importantly, this method is facile, cheap, and scalable as we have produced 
batches of 5 g, which serve most laboratories’ immediate needs. The reaction requires limited 
space and can be performed with the equipment readily available in most labs, thereby making 
this method accessible to most researchers. 
In our experience, we achieved the same conversion and polymer molecular weight as 
those reported in the literature. Initially, when the reaction was performed at room temperature, a 
green/yellow tint was observed, leading us to believe there was a possible degradation of the 
catalyst due to the release of nitrogen. When the reaction was performed at 4°C, we noted the 
disappearance of the green/yellow tint, higher efficiency of the monomers consumed, and an 
increase in molecular weight of the polymer. These observations led us to believe that 
temperature played a role in stabilizing the reaction and increasing the molecular weight. 
Therefore, we began by focusing on the general procedures reported in the literature (15 % w/v, 
1 % organocatalyst, and the use of benzyl alcohol as an initiator) to synthesize HMW PLLA and 
explored the effects that temperature would have on the polymer weight. Importantly, the PDI of 
the reaction demonstrated near living polymerization results similar to those reported using atom 
transfer radical polymerization (ATRP), or reversible addition fragmentation chain transfer 
(RAFT) when the polymer was below 100 k Da. 
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This extreme cold temperature was chosen because - 20 °C and - 80 °C freezers are 
commonly available and because the temperatures are far from the melting temperature of DCM. 
This ensured that the reaction would not solidify due to the temperature used in our method. 
After determining the optimal polymerization condition for the reaction with the TBD 
organocatalyst to be -80 °C, various parameters were investigated to determine the effect on the 
polymer growth. To accomplish this, we focused on three primary parameters: concentration of 
polymerization (w/v %), the concentration of organocatalyst used, and addition of benzyl alcohol 
as an initiator where we saw clear trends as we optimized the parameters.  
Of interest and note was that we did not require an initiator to initiate the polymerization. 
To our knowledge, the use of TBD organocatalyst to polymerize lactone polymers has used an 
initiator to induce the polymerization. Here we report that when we utilized an initiator, we saw 
smaller polymers than when we did not include an initiator. We hypothesize that this is due to 
the fast-acting TBD catalyst activating numerous reactive centers at once in addition to those 
provided by the initiator concentration, the chains with the initiator can only grow in one 
direction as opposed to in a bifunctional manner with no initiator, and purity and dryness of the 
initiator; thereby limiting how large the chains can grow. Although we have reached a molecular 
weight limitation utilizing an initiator, we believe that this system is still superior over tin 
catalyzed ROP reactions, which can only polymerize PLLA in the 40-50 k Da range under 
standard laboratory conditions. In contrast, this this novel TBD catalyzed cold polymerization 
reaction can achieve defined polymers up to ~ 140 k Da. 
Polymers synthesized from lactones such as PLLA have been the gold standard in 
biomedical applications such as tissue engineering in the fabrication of scaffolds and implants 
due to their favorable properties that include biodegradability, biocompatibility, and the ease of 
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processing17, 18. PLLA has been widely utilized for the development of scaffolds suitable for 
various tissue regeneration, such as blood vessels, cartilage, bone, and dental pulp9, 18, 38, 54, 161, 
207. The utility and advantage of PLLA have been amplified by imparting biomimetic properties 
onto the scaffolds through the development of nanofibrous architecture4, 68. This feature is 
feasible when the polymer reaches a certain high molecular weight and is processed through a 
method known as thermal-induced phase separation (TIPS)55, 68. When combining a porogen 
made from sugar and the TIPS technique, a HMW PLLA can be processed into a porous, 
interconnected, and nanofibrous scaffold to improve cell attachment, proliferation, and 
differentiation for a wide range of tissues59, 194, 207. This is due to the unique fiber morphology 
that mimics the extracellular matrix (ECM) collagen and provides similar physical and 
mechanical properties in which cells naturally occupy40, 102, 208. 
In an attempt to optimize and improve the biomimetic properties of tissue engineering 
scaffolds, researchers made considerable effort introducing growth factors, biomolecules, and 
peptides that will enhance the microenvironment2, 17, 56, 209. Adding these signals by conjugating 
them to the polymers can prevent them from being washed away. However, PLLA and most 
other polymers used for tissue engineering scaffolds lack functionality in the backbone. For this 
reason, poly(spirolactide-co-lactide) (PSLA) synthesized from L-lactide and spirolactide, a 
derivative of L-lactide with a norbornene ring substituting a methyl group, with a high degree of 
backbone functionality that can be post-modified via thiol-ene click chemistry is of interest for 
tissue engineering scaffolding. The tailorable of norbornene rings in the polymer produced can 
be easily modified via thiol-ene and tetrazine click chemistry and most importantly at PSLA1:5 
and higher ratios we are able to fabricate the favorable nanofibrous architecture. Previously, 
PSLA has never reached a molecular weight higher than 30 k Da, which is not suitable for the 
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fabrication of tissue engineering scaffolds. In this work, we were able to demonstrate the broad 
nature of the extreme cold polymerization to synthesize HMW PSLA copolymers suitable for 
tissue engineering. 
2.5  Conclusion  
In this work, we have developed a facile and rapid method of synthesizing HMW 
polymers in an economical and reproducible manner. Cold temperature polymerization can be 
used to provide HMW for multiple applications. We demonstrate how this method can be 
utilized to polymerize PLLA and the functional polymer PSLA for tissue engineering platforms. 
Never before has PSLA been synthesized with a high molecular weight. In this work, the HMW 
PSLA polymer was shown that it too could be fabricated with biomimetic porous, 
interconnected, and nanofibrous architecture and be easily post-modified to enhance the 
biomimetics. For these reasons, we believe that this polymerization method will change how 
polymer scientists will synthesize PLLA and PSLA, allowing for a higher degree of specification 
and thereby expanding their use in tissue engineering.
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Chapter 3. Biomimetic Tubular Scaffold with Tunable Conjugation of Heparin and Modulated 
Degradation for Rapid in situ Regeneration of a Small Diameter Neoartery 
R. Navarro#, L. Jiang#, O. Yang, P. Qiu, L. Zhiyong, B Yang, Y. E. Chen, P.X. Ma, 
“Biomimetic tubular scaffold with tunable conjugation of heparin and modulated degradation for 
rapid in situ regeneration of a small diameter neoartery.” #Both authors contributed equally to 
this work. Under Review in Journal of Biomaterials. 
3.1 Introduction 
3.1.1 Cardiovascular disease and the need for vascular grafts 
Cardiovascular disease (CVD) remains a severe burden on global healthcare, accounting 
for 17.7 million deaths, almost a third of all global deaths, in 2015 149. As this figure is predicted 
to increase to over 23 million deaths by 2030, CVD has become a pandemic that will continue to 
be a health issue for the foreseeable future149, 150. In addition to CVD’s impact on human health 
and life, the monetary cost of CVD has been estimated to be around $530 billion in direct and 
indirect costs 150. Of all the deaths caused by CVD, over 50 percent have been attributed to 
vascular damage induced by accumulation of vascular plaque, which leads to blocked and 
hardening vessels that deteriorate over time and may cause lesions. For these reasons, much 
effort has been put forth to develop suitable replacement vessels from allografts, xenografts, and 
synthetic grafts. However, these sources do not satisfy the demand for replacement vessels, 
particularly small diameter vessels (< 6 mm ID)164, 171, 193. This is due to limited supply of 
available allografts, biocompatibility issues with xenografts, and thrombosis issues associated 
with synthetic grafts smaller than 6 mm in diameter. Therefore, scientists have turned to tissue 
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engineering as a means to produce suitable substitutes particularly for small diameter vessels167, 
168, 210.  
3.1.2 Tissue engineered vascular grafts  
While synthetic grafts have served as off the shelf replacement for blood vessels, these 
grafts suffer from several limitations: thrombosis has been observed in small diameter (<6 mm) 
grafts, thereby limiting their use to large arterial blood vessels; these grafts are made from 
nondegradable polymers which prevent generation of natural tissue; and the implanted material 
becomes susceptible to wear and tear over time 169, 171. Tissue engineering has been seen as a 
promising way to address these limitations and create a vascular graft that is biocompatible, 
biodegradable, and promotes mature native tissue formation. Recently, biomimetic scaffolds that 
are porous, interconnected and contain nanofibrous architecture have been synthesized 38, 50, 54, 
161. These poly(lactic acid) (PLLA) scaffolds have been shown to develop mature vascular tissue 
in vitro and when implanted subcutaneously. This is due to the enhanced biomimetic nature of 
the scaffold which allowed for enhanced penetration of vascular smooth muscle cells (VSMCs) 
into the construct promoting the desired VSMC contractile phenotype 54, 161, 194. The nanofibrous 
architecture is able to mimic the natural extracellular protein in physical properties 27, 65, 68.  
3.1.3 Concerns with tissue engineering scaffolds  
Despite these advances, much work is still needed for tissue engineering scaffolds to 
regenerate viable vascular replacements. For example, PLLA is hydrophobic itself and may not 
provide the ideal surface for cell interactions. The degradation rate of PLLA is slow and may not 
optimally match the vessel regeneration. In addition, PLLA may not have the desired anti-
thrombogenic properties 86, 93, 98, 177, 196, 211. Researchers have attempted to incorporate heparin 
onto scaffolds, but due to the little chemical functionality of the polymers used to fabricate the 
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scaffolds, very little to no conjugation of heparin is possible, which requires the formation of 
covalent or physical covalent bonds through the surface chemical groups  160, 170, 181, 184, 191, 195. In 
addition, it is not just important that we can tailor the scaffolds with biological motifs or 
regulatory signals, but the polymers themselves must allow us to process them into biomimetic 
architecture in order to retain the favorable architecture. This requires the use of HMW polymers 
as described in Chapter 1. Therefore, making many polymers unsuitable for tissue engineering 
when compared to HMW PLLA, which has been previously shown to be conducive for vascular 
tissue engineering. In this work, we developed a high molecular weight poly(spirolactic-co-lactic 
acid) (PSLA), which provides the high chemical functionality in the backbone to achieve the 
desired density of heparin conjugation that would prevent thrombosis when implanted in situ and 
the MW necessary for biomimetic scaffold fabrication. In addition, the high level of functionality 
allowed us to demonstrate how to tailor the degradation, mechanical properties, and the surface 
hydrophilicity. We investigated the ability of these biologically activated scaffolds for blood 
vessel replacement in rat models and demonstrated their ability to promote vascular tissue 
regeneration in vivo.  
3.2 Materials and methods 
3.2.1 Materials 
L-lactide was graciously donated by Altasorb® and recrystallized in ethyl acetate before 
use. Poly(L-lactic acid) (PLLA, Resomer L207S) with an inherent viscosity of 1.6 dl/g was 
purchased from Boehringer Ingelheim (Ingelheim, Germany). Heparin was purchased from 
Fisher Scientific and modified with L-cysteine. Polyethylene glycol modified at one end with 
thiol (PEG-SH) of a MW of 10 kDa was purchased from Layson Bio. Polycaprolactone 70-80 k 
Da (PCL), N-Bromosuccinimide (NBS), triethylamine (TEA), Luperox® A98 benzoyl peroxide, 
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benzene, mineral oil, Span 80®, ethyl acetate, hexane, benzyl alcohol, magnesium sulfate 
(MgSO4), sodium thiosulfate, triazabicyclodecene (TBD), L-cysteine, fructose, tetrahydrofuran 
(THF) and dichloromethane (DCM) were purchased from Sigma-Aldrich Company (USA) and 
used as received. 
3.2.2 Spiro[6-methyl-1,4-dioxane-2,5-dione-3,2’-bicyclo[2.2.1]hept[5]ene] synthesis  
PSLA was synthesized following [Figure 3.1].  L-Lactide was modified based on a 
method previously reported 202. Briefly, L-Lactide was combined with NBS (1.1 eq.) in benzene 
(20 % w/v) and heated to reflux. Benzoyl peroxide dissolved in benzene was added dropwise and 
the reaction was monitored by thin layer chromatography (TLC) until completion. The reaction 
was vacuum filtrated and condensed and the resulting solid was dissolved in DCM, washed in 
sodium thiosulfate solution, and concentrated. The solid was recrystallized from ethyl acetate 
and hexane twice to yield white crystals, (3S, 6S)-3-Bromo-3,6-dimethyl-1,4-dioxane-2,5-dione 
(bromo-lactide) (1). The white crystals were dissolved in DCM in a flask under nitrogen and 
cooled in an ice bath. TEA (1.1 eq) was added in dropwise and allowed to react for 1 h at 0° C 
and 1 h at 25° C. The reaction was washed with 1M HCl three times and condensed. The crystals 
were further purified by liquid chromatography on silica gel and recrystallization in ethyl acetate 
to yield white crystals, (6S)-3-Methylene-6-methyl-1,4-dioxane-2,5-dione (methylene lactide) 
(2). To freshly distilled cyclopentadiene (2.2 eq.) 2 was added (1 eq.) and refluxed overnight in 
benzene under argon. The reaction was condensed and purified by liquid chromatography in 
50/50 hexane:DCM (rf = 0.31) followed by recrystallization in ethyl acetate to yield white 
crystals, Spiro[6-methyl-1,4-dioxane-2,5-dione-3,2’-bicyclo[2.2.1]hept[5]ene] (spiro-lactide) (3). 
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3.2.3 General procedure for the ring-opening polymerization 
In a reaction flask spirolactide was added in a 1:3 ratio with L-lactide and purged three 
times via a standard vacuum/nitrogen gas treatment before dissolving in anhydrous DCM at 5% 
w/v. The flask was cooled to - 80 °C for 1 h and was then injected with 0.5 % mol TBD catalyst 
dissolved in DCM. The reaction was allowed to react for 24h and the polymer formed was 
precipitated in ethyl ether, re-dissolved in DCM and precipitated in ethyl ether and stored under 
              
 
Figure 3.1 Synthesis route of PLLA-based copolymer poly(spirolactide-co-lactic acid). 
 
A) Addition of bromine from NBS followed by the elimination of the bromine using TEA 
to produce exomethylene lactide (1) B) Diels-Alder addition of freshly distilled 
cyclopentadiene to exomethylene lactide yielding spirolactide C) Polymerization of PSLA 
from L- lactide and spirolactide. 
 
1. NBS
2. Reflux
1. Et3N
1. Reflux
1. TBD
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vacuum. The copolymer produced is referred to in the remainder of this work as poly(spirolactic-
co-lactic acid) (PSLA).  
3.2.4 Monomer, polymer and scaffold characterization 
Nuclear magnetic resonance characterization:  All monomers (L-lactide, exomethylene 
lactide and spirolactide) and polymers formed were characterized via 500 MHz 1H and 13C 
(Varian Inova 500) by dissolving in CDCl3. 
Ultraviolet–visible spectroscopy: All monomers and polymers formed were characterized 
by first dissolving in DCM and using a quartz cuvette to obtain spectrum from 200 - 700 nm (up 
to 350 shown) (Hitachi U-2910). 
Fourier-transform infrared spectroscopy: Monomers, polymers, and modified tubular 
scaffolds were characterized by directly placing the sample on the diamond crystal sample holder 
to obtain the spectrum from 600 – 4000 nm (Thermo-Nicolet IS-50). 
Scanning electron microscopy (SEM) observation: Empty scaffolds were sputter-coated 
with gold for 150 seconds and observed under a scanning electronic microscope (JEOL JSM-
7800FLV).  
Gel permeation chromatography: Polymers formed were dissolved in anhydrous 
tetrahydrofuran and the molecular weight of the polymers were determined by comparing to 
polystyrene standards (Shimadzu GPC). 
3.2.5 Bilayer nanofibrous tubular scaffold fabrication 
A tubular scaffold with favorable nanofibrous architecture and tunable physical 
properties, such as pore size, interconnectivity, internal diameter, and wall thickness was 
fabricated using a method incorporating a sugar template and thermally induced phase separation 
(TIPS).  
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Molds for the tubular scaffold were fabricated in a facile, economic, and reproducible 
method by using aluminum foil cut to 5 cm wide strips. The aluminum foil was wrapped around 
a metal rod with the desired external diameter (1.85 mm) and the sugar spheres were then 
deposited inside the aluminum mold while submerged in hexane to prevent moisture from 
agglomerating the sugar spheres. The sugar template spheres were fabricated through an 
emulsion method developed by Ma et. al17, 64. The sugar spheres were separated using sieves to 
recover spheres ranging from 60 – 150 µm in diameter. A mandrel with the desired internal 
diameter (1.0 mm) was placed in the center and the sugar spheres annealed to the desired 
interconnectivity by placing in a 37 °C incubator for 7 minutes followed by vacuum drying the 
scaffold. 
TIPS was carried out according to procedures developed by Ma et al61, 68. The aluminum 
foil was removed, and the sugar template was dipped into a 10 % w/v polymer solution 
consisting of 50 % PLLA (inherent viscosity of 1.6 dl/g) and 50 % PSLA dissolved in THF, and 
then quickly cooled to - 80 °C in order to allow for phase separation. The scaffolds where 
maintained at this temperature for 24 h. PCL dissolved in trifluoroethanol (TFE) was then 
electrospun immediately after brushing with a mixture of 90:10 Hexane to THF (15 kV, 10 cm, 2 
mL/h, w/rotation). This mixture created a tacky surface in which the electrospun PCL fibers 
could anneal to. The scaffolds were then placed in hexane for 24 h to remove excess THF and 
TFE and were subsequently placed in DDH2O to remove the sugar spheres. After the sugar is 
completely washed away, the mandrel was easily removed, and the scaffold was cut to the 
desired length.  
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3.2.6 Surface modification with anticoagulant molecules   
Tubular scaffolds were modified through UV-light induced thiol-ene click-chemistry 
with the desired molecules to be conjugated. Briefly, methoxy-PEG-SH 2k (50 mg), heparin 
modified with L-cysteine (100 mg), and tetramethylethylenediamine (TEMED) were dissolved 
in DDH2O. The UV-initiator, Irgacure 2959, was dissolved in 100 μL of dimethyl sulfoxide 
(DMSO) and added to the solution. The scaffolds were quickly soaked in ethanol then added to 
the PEG/Heparin solution prior to being exposed UV-light. The scaffolds were then washed in 
methanol and DDH2O to remove excess TEMED and Irgacure 2959 before being lyophilized. 
The scaffolds were then sterilized with ethylene oxide (Anproline Gas Sterilizer) and stored at -
20 °C.  
3.2.7 Contact angle measurements of thin-films  
Thin-films were fabricated through TIPS process of a 10% polymer solution on a silicon 
surface to determine the wetness and change of hydrophilicity due to the conjugation of heparin. 
Films from both PSLA/PLLA blend and PLLA were fabricated, and a subfraction of each type 
were further modified with increasing concentration of heparin to produce films with the 
following permeations: PLLA no heparin, PLLA w/ Heparin (50 mg), PSLA, PSLA with 
increasing heparin concentration 10 mg, 50 mg, and 100 mg and a PEG575 gel as a positive 
control, n = 3 each and a standard error of ± 2°. The films were attached to a glass side using 
double sided tape and the advancing contact angle of a drop of water was measured utilizing 
Rame-Hart 200-F1 contact angle goniometer.  
3.2.8  “In vitro” degradation  
Flat three-dimensional scaffolds were fabricated in a Teflon® mold utilizing the sugar 
template previously discussed to determine the degradation rate of the interior loose layer in the 
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tubular scaffolds with or without being modified with heparin 38, 161. Scaffolds from the 
PSLA/PLLA blend and PLLA were fabricated using this method and cut into a 2 mm thick disk. 
As a control, PLLA scaffolds were included with and without heparin conjugated as well as 
PSLA/PLLA blend scaffolds with and without heparin conjugated, n = 5. The scaffolds were 
placed in a pre-weighed 20 mL vial and then weighed to determine the mass of the scaffold at 
day 0. To each 20 mL vial containing a scaffold, 10 mL of 1 M PBS pH 7.4 was added and 
incubated at 37 °C. The PBS was removed at predetermined times, the scaffolds were 
lyophilized, and the mass was taken and recorded. The scaffolds were then submerged in fresh 
PBS and incubated at 37 °C. Images were taken at day 0 and day 35 to track the change in mass 
loss and degradation.  
3.2.9 In situ implantation of tubular scaffold as a replacement for descending aorta in rat  
A scaffold 10 mm in length and 1 mm in inner diameter were in situ implanted into 
Sprague Dawley (SD) rats, 2 - 4 month-old, weighing 200 - 400 g (Charles River Laboratories, 
Boston, MA) as abdominal aorta interposition grafts to evaluate the viability and effectiveness of 
the tubular scaffolds and to determine the remodeling in vivo. All procedures were approved by 
the Institutional Animal Care and Use Committee at The University of Michigan. After 
anesthesia with Ketamine (80mg/kg) and Xylazine (8mg/kg), heparin was administered 150 
units/kg intravenously through the tail vein. The animal was placed in the supine position on a 
warming pad (37℃) and a midline laparotomy was performed. The infrarenal aorta was 
dissected and clamped using two microclamps. The vascular scaffold was implanted in an end-
to-end interrupted anastomotic pattern using 9-0 prolene sutures under a microscope. The 
abdomen was then closed in multiple layers. Lovenox was given 100 units/kg twice a day 
subcutaneously for anticoagulation.    
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3.2.10 Doppler and ultrasound visualization and analysis of in situ graft 
At a predetermined time of 1, 2, and 3 months after implantation, animals were examined 
using a Vevo 770® Micro-ultrasound System (Visual- Sonics, Toronto, Canada) equipped with 
the RMV-704 scanhead (spatial resolution 40 mm) to determine graft patency and blood flow. 
The diameter of the graft at the midpoint was measured from both transverse and longitudinal 
axis ultrasound images. Grafts were explanted at 1 w, 2 w, 1, 2, and 3 months post-operatively.  
3.2.11 Histological observation of remodeled tissue engineered blood vessels (TEBVs) 
The TEBVs were washed with PBS prior to being fixed with 3.7% formaldehyde in PBS 
and left overnight to react. Subsequently they were dehydrated through the use of ethanol, 
embedded in paraffin, and sectioned at a thickness of 5 mm. Sections were deparaffinized, 
rehydrated with a graded series of ethanol, and stained with H-E, Masson's trichrome, and 
Verhoeff-Van Gieson method. 
3.3 Results 
3.3.1 Synthesis of spirolactide and poly(spirolactide-co-lactictide)  
A high molecular weight co-polymer derived from L-lactide that is biodegradable and 
can be easily modified via thio-lene click chemistry leading to tunable properties was 
successfully synthesized [Figure 3.2]. L-Lactide was used as the starting material in the 
synthesis of spirolactide and then copolymerized in a 1:3 ratio between spirolactide to L-lactide. 
The resulting polymer, poly(spirolactide-co-lactictide), had a molecular weight of Mw = 179 kg 
mol-1 PDI of 1.6 (measured by GPC). The monomers and polymer were thoroughly characterized 
using NMR, UV-VIS, and FTIR to demonstrate that we have successfully synthesized them 
[Figure 3.2 D - G] and compared with previous published results to confirm our findings 200, 202. 
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This PSLA was blended with PLLA at a 50:50 ratio (w/v %) and used in the fabrication of the 
tubular scaffolds, referred as PLLA/PSLA.   
3.3.2 Nanofibrous tubular scaffold fabrication  
A tubular scaffold was fabricated using the 50/50 PLLA/PSLA blend via thermally 
induced phase separation (TIPS) and porogen leaching methods [Figure 3.3 A - C]. With this 
chosen polymer blend and utilizing our previously developed sugar leeching and TIPS 
 
 
Figure 3.2 Characterization of PSLA and precursor monomers. 
 
A) Addition of bromine from NBS followed by the elimination of the bromine using TEA to 
produce exomethylene lactide (1) B) Diels-Alder addition of freshly distilled cyclopentadiene 
to exomethylene lactide yielding spirolactide C) Polymerization of PSLA from L- Lactide 
and Spirolactide D - H) FTIR characterization depicting stretches of key functional groups L-
lactide, exomethylene lactide, spirolactide, and PSLA to compare absorption peaks and trends 
H)  UV – Vis absorbance of monomers, PLLA, and PSLA to compare absorption peaks and 
trends. 
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techniques, we developed a highly porous and interconnected tubular scaffold that retained the 
favorable nanofibrous architecture (pore size of 60-150 µm; interconnectivity of ~30 µm), 
similar to those of PLLA. Most significantly, the tubular scaffolds could now be easily modified 
with anticoagulant molecules. 
3.3.3 Conjugation of anticoagulant molecules on tubular scaffold 
The above tubular scaffolds were modified with anticoagulant molecules (heparin and 
PEG) via thiol-ene click chemistry between the norbornene ring on the PSLA and a thiol group 
[Figure 3.4 A]. Characterization of this conjugation via FTIR demonstrated that the click 
 
 
Figure 3.3 Fabrication of a tubular scaffold that can be easily post-modified. 
 
A) Fabrication method for sugar template annealed on mandrel for the fabrication of porous 
and interconnected network B) Overview and SEM characterization of PSLA/PLLA loose 
layer that is highly porous, interconnected, and nanofibrous C) Visualization of PCL dense 
layer that is electrospun to provide enhanced mechanical support.   
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reaction between the thiol and the norbornene ring was successful because of the presence of the 
thiol-ene clicked peak at 800 nm and the absence of the double bond peak at around 1630 nm 
[Figure 3.4 B]. The scaffolds were visualized by SEM to demonstrate preservation of the 
favorable biomimetic physical properties after the surface modification (unobstructed lumen, 
porous and interconnected, and nanofibrous architecture) [Figure 3.4 C]. The conjugation was 
visualized through confocal microscopy by the conjugation of SH-PEG-FITC onto the 
PLLA/PSLA scaffolds and comparing these results to PLLA scaffolds treated in the same 
manner [Figure 3.4 D]. Compared to the control scaffold fabricated from pure PLLA, the 
scaffold comprised of the advanced functional polymer blend were highly modified with the 
fluorescent polymer (SH-PEG-FITC) and elucidated by confocal microscopy.  
3.3.4 Thin-film contact angle measurement 
Heparin conjugated films showed increased wettability with contact angles ranging from 
25 – 40° as compared to the unmodified PLLA (100°) and PLLA/PSLA blend (110°) films. This 
indicates the highly hydrophilic property of the heparin conjugated materials. Both films with 50 
mg heparin and with 100 mg heparin were able to absorb the water droplet after 3 and 1 min 
respectively [Figure 3.4 E].   
3.3.5 Scaffold “in vitro” degradation 
Three dimensional scaffolds were fabricated and conjugated with heparin to determine 
the mass loss of the porous layer. Four groups were made: two containing unmodified 
PLLA/PSLA blend and PLLA and two containing conjugated heparin. The fabricated scaffolds 
were incubated in PBS at 37°C and loss of mass was observed over time. Visually, the 
PLLA/PSLA group conjugated with heparin began to fall apart at day 10, with all scaffolds 
breaking apart into large and small pieces by day 28. In comparison, the PLLA group remained  
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Figure 3.4 Post-modification via thiol-ene click chemistry and characterization.  
A) Post-Modification scheme of PSLA polymer with heparin via thiol-ene click chemistry B) 
FTIR demonstrating pre and post-medication changes in spectrum stretching C) SEM 
visualization of tubular scaffold post modification D) Confocal Image of PLLA and PSLA 
modified with FITC-PEG-SH E) Change of Hydrophilicity observation, quantification, and 
comparison of PLLA, PSLA unmodified, and PSLA films with increasing concentration of 
heparin. 
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intact and only a small amount of scaffold was lost after 35 d [Figure 3.5 A - B]. This was also 
observed by quantifying mass loss during this time: the PLLA scaffold lost only ~ 15 % of its 
initial mass, the PLLA/PSLA with no heparin and the PLLA scaffold with heparin lost ~ 20-25 
%, and the PLLA/PSLA scaffold with conjugated heparin lost ~ 52 % of the total mass. The 
nanoarchitecture observed at day 0 and at day 35 showed that the nanofibers and overall 
             
 
Figure 3.5 Degradation and mass loss of PLLA/PSLA scaffolds after heparin conjugation. 
 
A) visualization of PSLA scaffold conjugated with heparin began disintegrate at week 3 with 
all other groups intact at end of experiment while PLLA scaffolds show minimal degradation 
B) quantification of scaffold mass loss over time due to heparin conjugation on PLLA/PSLA 
scaffolds compared to PLLA and PLLA/PSLA scaffolds with no heparin conjugated C) SEM 
characterization of scaffold degradation at day 35. 
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morphology had changed considerably in the heparin modified PLLA/PSLA blend but did not 
change significantly in the other groups [Figure 3.5 C].   
3.3.6  Implantation “In situ” of tubular scaffolds in rat models 
Engineered scaffolds of ~ 10 mm in length were implanted in situ into female rats of 
approximately 200 – 400 g to assess the ability of the tubular scaffolds to serve as vascular grafts 
and form tissue engineered blood vessels [Figure 3.6 A]. The scaffolds were implanted using 
standard surgical technique and practices. The rats were sacrificed at predetermined times of 1w, 
2w, 1m, and 3m. All rats survived to time of sacrifice with no signs of bleeding, rupture, or 
mechanical failure of the vessel [Figure 3.6 B]. Most importantly, there was no discoloration of 
the vessel, darkening of surrounding tissue, and fascia had grown around the regenerated vessels 
signifying an absence of either necrosis or trigger of an immune response. Additionally, the 
tissue excised at three months looked similar to that of the natural vasculature [Figure 3.6 C - 
E]. After implantation, the scaffolds were observed for blood flow obstruction internal diameter 
changes, wall size changes, and any arising thrombosis issues via laser Doppler ultrasound and 
ultrasound imaging [Figure 3.6 F - G]. Through these means, we determined that blood flowed 
unobstructed, the wall size and internal diameter remained nearly identical.  Additionally, the 
loose layer began to degrade at 2 weeks and remodeling began within 1 month as observed by a 
slight increase in diameter of the in situ implanted graft [Figure 3.6 H]. Likewise, we were able 
to determine that the in situ implanted scaffolds did not form aneurysms or hyperplasia.  
3.3.7 Characterization and assessment of explanted tissue engineered vessels  
The porous and interconnected scaffolds were infiltrated by native cells after as little as 
one week, resulting in the degradation of the polymer and the remodeling of the inner layer. 
After one month of in situ implantation, the interior of the scaffold had mostly degraded, been  
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replaced with native cells forming complex tissue configuration [Figure 3.7]. Hematoxylin and 
eosin staining (H&E) of the vascular graft at 1 w, 2 w, 1 mo, and 3 mo demonstrated the 
effectiveness of the scaffold design to promote cellular infiltration, migration and proliferation. 
Through these images proliferating and migrating cells were observed within the scaffold and 
               
 
Figure 3.6 Scaffold evaluation post-implantation in situ. 
 
A – B) Operative images for the implanted scaffolds (A: immediately after implant; B: 3 
months post-operation). C – E) Morphologies of nanofibrous vascular scaffolds before rat 
abdominal aortic interpositional implant (C), 3 months post-operation (D) and native rat 
abdominal aorta (E). F – G) Ultrasound images of the implanted scaffold 3 months post-
operation. H) Comparison of native aorta vs TEBVs over 3-month period. 
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tissue was formed with cells orientated in a laminar fashion, similar to natural vasculature. The 
deposition of collagen and elastin in the newly formed tissue at 1 and 3 months was illustrated 
using Masson’s Trichrome and Verhoeff-Van Gieson staining methods [Figure 3.8]. The 
staining demonstrated that a high quantity of collagen was deposited after one month and a high 
quantity of elastin was deposited after three months, with both ECM proteins approaching native 
 
 
Figure 3.7 Comparison of vascular muscular reconstruction at anastomosis and middle sites of 
implanted scaffolds by H&E staining. 
 
(A, B): 10x and 40x magnification from anastomosis site of scaffold at 1 week’s post-
operation. (C, D): 10x and 40x magnification from middle site of scaffold at 1 week’s post-
operation. (E, F): 10x and 40x magnification from anastomosis site of scaffold at 2 weeks’ 
post-operation. (G, H): 10x and 40x magnification from middle site of scaffold at 2 weeks’ 
post-operation. (I, J): 10x and 40x magnification from anastomosis site of scaffold at 1 month’s 
post-operation. (K, L): 10x and 40x magnification from middle site of scaffold at 1 month’s 
post-operation. (M, N): 10x and 40x magnification from anastomosis site of scaffold at 3 
months’ post-operation. (O, P): 10x and 40x magnification from middle site of scaffold at 1 
week’s post-operation. (Q, R): 10x and 40x magnification from rat’s native aorta. (Scale bar: 
For A, C, E, G, I, K, M, O, Q=400um; For B, D, F, H, J, L, N, P, R=40um). 
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tissue levels. Immunofluorescence staining was utilized to illustrate SM22, a marker protein 
secreted by smooth muscle cells, showing cells occupying the remodeled scaffold to be smooth 
muscle cells. This indicates that smooth muscle cells have infiltrated the scaffold and regenerated 
the rat aorta at 1 mo and 3 mo post-op [Figure 3.9]. Endothelization of the vascular graft is 
important for long-term viability and for the formation of mature tissue. Immunohistochemistry 
 
 
Figure 3.8 Comparison of vascular extracellular matrix reconstruction of implanted scaffolds 
after 1 and 3 months implantation.  
 
(A, B): 10x and 40x magnification from rat’s native aorta by Masson trichrome staining. (E, 
F): 10x and 40x magnification from implanted scaffold at 1 month’s post-op by Masson 
trichrome staining. (I, J): 10x and 40x magnification from implanted scaffold at 3 months’ 
post-op by Masson trichrome staining. (C, D): 10x and 40x magnification from rat’s native 
aorta by Verhoeff Van Gieson staining. (G, H): 10x and 40x magnification from implanted 
scaffold at 1 month’s post-op by Verhoeff Van Gieson staining. (K, L): 10x and 40x 
magnification from implanted scaffold at 3 months’ post-op by Verhoeff Van Gieson 
staining. (Scale bar: for A, C, E, G, J, K=400um; For B, D, F, H, J, L=40um). 
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was done using von Willebrand factor (vWf) to demonstrate the effectiveness of the scaffold’s 
ability for endothelization, with incomplete endothelization at 2 weeks and complete 
endothelization at one and three months [Figure 3.10].  
 
 
Figure 3.9 Immunofluorescence of smooth muscle cell marker SM22 indicates smooth 
muscle cells infiltration and reconstruction in rat aorta, 1 mo post-op and 3 mo post-op in 
scaffolds.  
 
A) flourescence of SM22 in rat’s native aorta D) DAPI shows nuclei in rat’s native aorta 
G) Merged of flourescence and DAPI in rat’s native aorta B) Flourencesce of SM22 in 
implanted scaffold at 1 mo post-op E) DAPI shows nuclei in implanted scaffold at 1 mo 
post-op H) Merged image of flourencesce and DAPI in implanted scaffold at 1 mo post-op 
C) Flourecense of SM22 in implanted scaffold at 3 mo post-op F) DAPI shows nuclei in 
implanted scaffold at 3 mo post-op I) merged of fluorescence and DAPI in implanted 
scaffold at 3 mo post-op. (Scale bar= 40um). 
 
H
merged
Rat aorta 1 month post-op
Lumen Lumen
DAPI
Lumen
A
Lumen
B
3 months post-op
Lumen
C
Lumen
D
Lumen
E
Lumen
F
G
Lumen
I
SM22
 72 
 
3.4 Discussion 
The goal of this study was to create a functional blood vessel that is regenerated by the 
body through a cell-free off-the-shelf tubular scaffold that is biocompatible, anticoagulant, and 
with tailorable degradation rate. Current methods that entail the use of cultured cells to create 
small-diameter TEBVs for cardiac and peripheral revascularization procedures are not suitable 
for most clinical applications due to the immediacy when the vessel is commonly needed. Cell-
free tissue engineering vascular grafts, like the one described in this study, allow for the 
elimination of the prohibitive lead-time required for cell culture and enable immediate 
implantation 167, 212. 
Considerable effort has been devoted to imparting biomimetic properties through the 
physical architecture of the scaffold. Techniques such as TIPS and electrospinning produce 
nanofibrous morphology that mimics the native extracellular matrix environment both in size of 
the fiber, and mechanical forces exuded on the cell38, 68, 177, 193, 213-215. Previously, our lab 
developed large-diameter scaffolds fabricated from a sugar leaching template and TIPS from 
 
 
Figure 3.10 Immunohistochemistry of endothelial marker vWF of implanted scaffolds 
indicate endothelial cells reconstruction. 
 
(A): Rat’s native aorta; (B): 2 weeks’ post-op; (C): 1 month’s post-op; (D): 3 months’ post-
op. (Scale bar= 40um). 
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PLLA that showed superior cellular attachment, proliferation, and migration38. Additionally, the 
nanofibrous architecture of the scaffold was shown to be conducive in mature vascular tissue 
formation through the differentiation of cardiovascular progenitor cells into smooth muscle cells 
with contractile phenotype both in vitro and in subcutaneous implantation mouse models 50, 54, 
161. Because of these desirable attributes, these methods for scaffold production were used as a 
starting point to build upon in this study. We scaled the previously developed tubular scaffold to 
fit a rat model and included a PCL layer to withstand hemodynamic stresses and suturing. 
There has been a large variety of polymers utilized to fabricate tissue engineering 
scaffolds. Both slow degrading polymers, such as polycaprolactone (PCL), and faster degrading 
polymers, such as poly(urethane), poly(glycolic acid), and poly(glycerol sebacate) have been 
used in scaffold designs37, 160, 177, 178, 196. Rapidly degrading and slow degrading tissue 
engineering scaffolds have been shown to have distinct advantages and disadvantages. While 
slow degrading polymers have been shown to improve the durability of tissue engineering 
scaffolds, they often lead to calcification within formed tissue due to their long degradation 
times86, 190, 197. Similarly, rapidly degrading polymers have been shown to provide faster cell 
migration, proliferation, and matrix production, but suffer from the formation of aneurysms and 
lack of structural support 37, 177, 178, 196. 
In this study we took advantage of the beneficial properties of both slow and rapidly 
degrading polymers to create a bilayered scaffold with a porous inner layer fabricated from 
PLLA/PSLA blend, a highly functional material that can be easily modified via thiol-ene click 
chemistry. Three dimensional porous and interconnected scaffolds with the nanofibrous 
architecture were fabricated and were easily post-modified.  
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In this work we also demonstrated that PLLA/PSLA blend can be modified with 
hydrophilic polymers or macromolecules, such as heparin, to modulate the scaffold 
hydrophilicity. Typically, PLLA has a degradation time of 6-12 months in vitro. However, the 
PLLA/PSLA blend demonstrated a mass retention of ~ 50 % at 1 month when modified with 
heparin (100 mg). Not surprisingly, this shows that the increased hydrophilicity also increased 
degradation rate. In addition, heparin is anticoagulant helping to decrease risk of thrombus 
formation. Furthermore, heparin has been shown to facilitate cell adhesion 170, 181, 191, 195.  
In previous studies, heparin has been introduced by dipping the scaffold in a solution of 
heparin. With that method retention of heparin is minimal after scaffold implantation as it is 
washed away due to heparin’s hydrophilic nature and high solubility. As previously mentioned, 
PLLA and most polymers used to fabricate tubular scaffolds lack functionality in the backbone. 
The only points of attachment on those polymers are at the ends of the polymers due to their 
chemical structure, therefore very little heparin can be attached onto the scaffold216. We 
demonstrated that PLLA alone cannot be conjugated with heparin and PSLA-containing scaffold 
can be stably conjugated with heparin. Through the use of the PLLA/PSLA blend we were able 
to create a scaffold that not only contains the favorable physical attributes but can also be 
tailored with varying degrees of heparin to tailor surface hydrophilicity and optimize degradation 
rate.  
The scaffolds were then implanted in situ and demonstrated biocompatibility 3 months 
post-op. Integration into the surrounding in situ environment was favorable. Excellent cellular 
migration was observed within the scaffold likely facilitated by the highly porous and 
interconnected architecture. The scaffolds were rapidly remodeled with most of the PLLA/PSLA 
inner layer degraded within a month.  
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Collagen and elastin play key roles in vascular tissue matrix and function. In native 
arteries, collagen mainly contributes arterial tensile strength, while elastin provides elasticity and 
compliance193, 216. Historically, elastin production during in situ vascular tissue engineering has 
been a major challenge193, 217. Excitingly, larger amounts of collagen and elastin were secreted 
with native-like structure in the engineered blood vessels in this study. The regenerated blood 
vessels functioned well in the rat models.  
3.5 Conclusions 
We have developed a new polymer system that allows the design of rapid and facile 
fabrication of tissue engineering scaffolds with tunable compositions and functionalities. By 
conjugating varying amounts of heparin, we were able to achieve broad ranges of hydrophilicity, 
degradation rate, and anti-thrombogenicity. The new PLLA/PSLA system also allows the 
fabrication of scaffolds with porous and nanofibrous features that are advantageous for cell 
migration, attachment, proliferation and smooth muscle regeneration. By combining the 
advantageous physical structures with the chemical functionalities, a superior bilayer scaffold 
was developed to achieve endothelization of blood vessels reconstructed with native-like 
collagen-rich and elastin-rich ECM. Importantly, after the degradation of the scaffold, the neo 
vessel achieved 3-month patency in a rat blood vessel replacement mode.
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Chapter 4. Fabrication of Biomimetic Scaffolds from Poly(Exomethylene-co-Lactic Acid) for Facile 
and Click-Chemistry Functionalization for Tissue Engineering 
R. Navarro, K. Rambhia, R. Kannan, W.B. Swanson, Z. Zhang, A. Adiwidjaja, J. Rieland, P.X. 
Ma., “Fabrication of biomimetic scaffolds from Poly(exomethylene-co-lactic acid) for facile and 
click-chemistry functionalization for tissue engineering” In Preparation. 
4.1 Introduction 
4.1.1 Biomimetic scaffolds for tissue engineering  
Developing advanced biomimetic scaffolds for tissue and regenerative engineering has 
been an engineering challenge and goal for material scientists for the last 30 years 2, 17, 49, 64, 68, 205. 
Scaffolds that closely mimic the microenvironment of the extracellular matrix (ECM) are 
deemed to have biomimetic properties. These scaffolds have shown the best results advantages in 
tissue engineering, producing tissue that often more closely resembles that of the native 
construct17, 65, 209, 218. This has been accomplished by imparting biomimetic properties to 
scaffolds, such as forming nanofibers, creating porous and interconnected architecture, matching 
mechanical properties, as well as incorporating biomolecules, growth factors (GFs), and minerals 
64, 188, 204, 209, 218, 219. As a result, scaffolds that include one or more of these biomimetic features 
allow for enhanced cell attachment, proliferation, and even facilitate stem cell differentiation 107, 
204, 209, 219. 
Of particular interest and importance is the nanofibrous and porous architecture typically 
seen in the ECM. Ma et. al. and others have previously demonstrated the impact of developing 
scaffolds with similar nanofibrous architecture, as seen in the native ECM 20, 38, 51, 61, 65, 68, 219-221. 
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A range of configurations (tubular, three-dimensional disks, and spongy microspheres) that 
contain this particular architecture have been engineered, and subsequently utilized for tissue 
engineering, including cardiovascular 38, 54, 160, 161 , bone 204, 209, 217, cartilage 107, 220, 222, and dental 
59, 60, 207, 223, 224 tissue regeneration. The nanofibrous and porous biomimetic architectures was 
shown to advantageously enhance regeneration and therefore should be a key feature to be 
included when developing novel polymeric tissue engineering scaffolds. 
4.1.2 Modification of scaffolds for tissue engineering 
Polymers frequently used for scaffold fabrication lack chemical functionality in the 
backbone, therefore means for further functionalization to enhance the microenvironment are 
limited. To circumvent the lack of functionality, scaffolds can be fabricated by blending 
polymers that bear chemical motifs that permit further modificaiton together  as well as 
subjecting the fabricated scaffold to aminolysis or plasma treatment, 64, 91, 105, 107, 225. Aminolysis 
utilizes a relatively strong base to catalyze the attack on the carbon of the carbonyl with an amine 
containing molecule resulting in an amide or peptide bond. Plasma treatment uses electrons in 
the air directed at the scaffold surface to break bonds on the surface of a film or scaffold. When 
performed in the presence of O2 or N2, there are radicals formed can react with the gas present 
and yield hydroxyls, carboxylic acids, and amines which can be used for further 
functionalization. However, the plasma treatment only alters the surface as it does not penetrate 
deeply, the radicals are short-lived, and both plasma treatment and aminolysis can affect 
nanofiber morphology, as well as affect the mechanical properties of the scaffold. Polymers that 
contain acrylates, amines, or other functional groups have been blended to yield scaffolds that 
can be post modified. However, due to a lack of commercially available functional HMW 
polymers such as PLLA or facile and low-cost methods to synthesize these polymers. 
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Biomaterial scientists have to utilize low molecular weight polymers, which can disrupt the 
biomimetic nanofibrous architecture, as well as affect the mechanical properties 107. Therefore, 
considerable effort has been expended in developing novel chemistries that can address this. 
4.1.3 Click-chemistry in tissue engineering 
Click-chemistry is a technique that has been used to improve the quantitative yield of the 
conjugation of the desired molecule to biomaterials (Huisgen et. al. in 1967, Sharpless et. al. in 
2001). It is a facile method of conjugating substrates through the use of a primary alkyne and 
azide group coordinated by a copper catalyst. The reaction is highly selective with efficient 
yields and can be carried out at physiological conditions. Copper-free click chemistry is a 
modified method with the same specificity, yield efficiency, and capability of being performed 
under physiological conditions, but without the use of the copper catalyst. This process is 
possible due to the ring strain of the cyclooctyne driving the addition of the nucleophilic azide to 
form a 5-membered ring. In addition to these two methods of click-chemistry, the field has 
expanded to include epoxides that use ring strain and hydrazone and oxime. The latter involves 
nucleophilic addition by attacking a carbonyl carbon. Hence, click-chemistry is a technique that 
continues to evolve in the ability to produce new reactions that can occur at physiological 
conditions (37 ºC, aqueous environment, 7.4 pH) and are more inclusive of biological molecules 
while preserving their structure and function. 
4.1.4 A novel “click-chemistry like” approach in tissue engineering 
Introducing a high density of functional groups with click-chemistry reactivity in the 
scaffold is one of the approaches to impart additional biomimetic cues. It would be ideal to have 
a scaffold that can be conjugated under physiological conditions if needed with high conjugation 
efficiency and bioactivity, as seen in click-chemistry. Here we hypothesized that a copolymer 
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synthesized from L-lactic acid with segments containing a pendent lactic acid ring structure 
(formed from Exomethylene lactide (EML)) that is highly reactive, specific, tailorable that can 
be processed into tissue engineering constructs could provide a cost-effective and facile 
alternative to currently surface modification techniques and strategies. Click-chemistry like 
reactivity can address the problem by rapidly conjugating regulatory signals without denaturing 
sensitive proteins or growth factors in a high yield quantitative manner. Exomethylene lactide, 
derived from L-lactide, is a low-cost monomer that can provide the similar conjugation 
parameters as click-chemistry tools at a fraction of the cost when polymerized. The copolymer 
can be processed into biomimetic scaffolds with the favorable physical morphology but can also 
be facilely modified in a click-chemistry fashion with amine containing molecules.  
To achieve this, we developed and synthesized a novel copolymer using HEMA-PLLA 
(HPLLA) and exomethylene lactide (EML) through a free radical polymerization. The unique 
conformation of EML when polymerized, creates a flat ring structure tightly packed together 
(separated by one methylene group), which induces neighbor dipole-dipole interaction leading to 
ring strain that can be disrupted when in contact with an amine containing molecule 226. This 
causes immediate cleavage of the ring producing an amide bond between the carboxylic acid of 
the EML pendent and that of the amine-containing molecule to conjugated. Therefore, the novel 
biomimetic tissue engineering scaffolds fabricated contain a high degree of functional groups 
that are readily available for conjugation with available amines in biomolecules and regulatory 
signals that contain free amines such as peptides, hormone, and proteins. The scaffolds studied 
were efficiently and expediently modified and showed excellent cell viability indicating that this 
system can be used to impart biomimetic motifs for various tissue engineering applications 
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without the need for catalyst, heat, toxic chemicals or experienced material scientist as they 
effectively conjugated rapidly in facile in a click chemistry fashion. 
4.2  Materials and methods 
4.2.1 Materials 
L-Lactide was graciously donated by Altasorb® and recrystallized in ethyl acetate before 
use. Poly(L-lactic acid) (PLLA, Resomer L207S) with an inherent viscosity of 1.6 dl/g was 
purchased from Boehringer Ingelheim (Ingelheim, Germany). NH2-PEG-Methoxy 2kDa & 
5kDa, 4-arm PEG-NH2 10kDa, COOH-PEG-NH2 was purchased from Layson Bio. N-
Bromosuccinimide (NBS), Triethylamine (TEA), fluorescein isothiocyanate (FITC), Luperox® 
A98 Benzoyl Peroxide, Azobisisobutyronitrile (AIBN) (recrystallized in methanol before use), 
aminehexanol, Hydroxyethylmethacrylate (HEMA), L-Cysteine, Benzene, Mineral oil, Span 
80®, ethyl acetate, hexane, N-Boc-Serinol, Magnesium Sulfate (MgSO4), Sodium Thiosulfate, 
Fructose, tetrahydrofuran (THF) and dichloromethane (DCM) were purchased from Sigma-
Aldrich Company (USA). All reagents were used as received unless otherwise noted.  
4.2.2 Preparation of (6S)-3-Methylene-6-methyl-1,4-dioxane-2,5-dione (EML) and general 
procedure for the polymerization of poly(Exomethylene Lactide). 
L-Lactide was modified and polymerized as previously reported by Hillmyer et. al 202. 
Briefly, L-Lactide was combined with NBS (1.1 eq.) in benzene (20 % w/v) and heated to reflux. 
Benzoyl peroxide dissolved in benzene was added dropwise and the reaction was monitored by 
thin layer chromatography (TLC) until completion. The reaction was vacuum filtrated and 
condensed and the resulting solid was dissolved in DCM, washed in sodium thiosulfate solution, 
and concentrated. The solid was recrystallized from ethyl acetate and hexane twice to yield white 
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crystals, (3S, 6S)-3-Bromo-3,6-dimethyl-1,4-dioxane-2,5-dione (bromo-lactide). The white 
crystals were dissolved in DCM in a flask under nitrogen and cooled in an ice bath. TEA (1.1 eq) 
was added in dropwise and allowed to react for 1 h at 0° C and 1 h at 25 °C. The reaction was 
washed with 1M HCl three times and condensed. The crystals were further purified by liquid 
chromatography on silica gel and recrystallization in ethyl acetate to yield white crystals, (6S)-3-
Methylene-6-methyl-1,4-dioxane-2,5-dione (exomethylene lactide) (EML). Exomethylene 
Lactide was polymerized using 1 mol % AIBN in dioxane under inert environment at 70° C. 
After polymerization was complete, the polymer was precipitated in methanol, filtered, and dried 
under vacuum. 
4.2.3 Synthesis of HEMA-PLLA 
HEMA-PLLA was synthesized through ring-opening polymerization (ROP) as previously 
described by Zhang et al 107. Briefly, HEMA was used as the polymerization initiator with L-
Lactide and the ROP catalyzed by stannous octoate in degassed environment at 150 °C to 
produce a polymer (Mw = 65 k Da, measured by GPC).  
4.2.4 Synthesis of 2-Methylene-1,3-dioxepane (MDO) 
MDO was synthesized according to the previously described method by Bailey et. al. 227, 
228. Briefly, chloroacetaldehyde dimethyl acetal and butanediol were reacted in a 1:1 ratio with 
Dowex® 50WX2 until all the methanol is distilled and collected and 2-Chloromethyl-1,3-
Dioxapane is formed. The reaction was vacuum filtrated to remove the 50WX2 distilled under 
vacuum to isolate and then dissolved in THF and reacted with 2 mol ratio of potassium tert-
butoxide in an ice bath and catalyzed with aliquot® 336 overnight. The reaction was 
concentrated, dissolved in ethyl ether, and purified by filtration using aluminum oxide. MDO 
was concentrated and isolated by vacuum distillation and stored at -20 °C.    
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4.2.5 Synthesis of poly(exomethylene-co-Lactic acid) (PELA)  
PELA was polymerized at various ratios of HPLLA to EML 10:1, 25:1, 50:1, 75:1, and 
100:1 by adding HPLLA and EML at the desired ratios and 0.5 mol ratio of MDO (relation to 
EML and HPLLA) into a reaction vessel which was then purged via vacuum with N2 three times 
to reduce the oxygen concentration. Anhydrous Dioxane was then added to bring the 
concentration to 20 % w/v followed by the addition of 1% mol AIBN dissolved in anhydrous 
Dioxane. The reaction was then heated to 70 °C and stirred for 3 d. The reaction was removed 
from the heat and allowed to reach room temp before precipitating in cold methanol. The 
polymer was filtered and dried under vacuum for 2 d before use. 
4.2.6 Conjugation efficiency of PELA polymer with various amine containing molecules 
The PELA polymers with varying ratios of HPLLA to EML was conjugated with various 
amine containing molecules to serve as models to test if it still functioned in the same manner of 
conjugation when synthesized as a copolymer. This was done by dissolving the PELA polymers 
in DCM and mixing with solutions of NH2-PEG-Methoxy (Aq. & DCM), aminehexanol (Aq), 
and L-Cysteine (Aq). The two faces were then separated (aminehexanol & L-Cysteine) before 
precipitating in methanol, filtered, and dried under vacuum. The conjugation was characterized 
via FTIR and NMR. 
4.2.7 General procedure for the fabrication of thin-films 
Nanofibrous thin-films were fabricated by using the thermally induced phase separation 
(TIPS) procedure. Briefly, PELA or PLLA was dissolved to a concentration of 12.5 (PELA) or 
10 % (PLLA) w/v in THF and heated to 60 °C. The solution was cast on a flat silicon wafer and 
covered with a glass plate, phase separation was allowed to take place at -80 °C for 48 h. The 
films were slowly warmed to room temperature by immersing in an ice bath until all the ice 
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melted, then stored flat to dry. Thickness was measured to be approximately 200um using digital 
calipers and morphology was observed via SEM. 
4.2.8 Microporous and interconnected nanofibrous scaffold fabrication  
The porous, interconnected and nanofibrous scaffolds are fabricated using a sugar 
leaching method and TIPS as previously reported by Ma et. al. 20, 61, 68, 204, 205. Briefly, the sugar 
template spheres are fabricated through an emulsion method and sieved to collect spheres 
ranging between 250 to 425 µm. The sugar is deposited in cylindrical molds and is heat treated 
to achieve the desired interconnected structure and then vacuum dried. A solution of PELA or 
PLLA was dissolved in THF to a concentration of 15% and 10% respectively and heated to 60 
°C. The solution was then added to the dry sugar template and treated to reduced pressure to 
force the polymer solution into the template. TIPS was then induced at -80 °C for two days 
followed by submerging in excess hexane overnight to remove residual THF and maintain the 
scaffolds free of moisture. The scaffolds were then submerged overnight in DDH2O to leach 
away the sugar template and the scaffolds cut to the desired diameter and width. 
4.2.9 General procedure for modification of PELA thin-films and scaffolds  
To visually demonstrate the conjugation potential of our PELA thin-films and three-
dimensional scaffolds, NH2-PEG-FITC was conjugated and observed via confocal imaging. 
FITC-PEG-NH2 was synthesized according to Liu et al 229. Briefly, 4-arm PEG-NH2 (0.000025 
mol, 250mg) was dissolved in 500uL 0.5M carbonate-bicarbonate buffer. FITC (0.00005 mol, 
16.6mg) was dissolved in a minimum amount of acetone (approx. 50uL) and added to the PEG-
amine solution, it was then left to spin in the dark for 24 hours on ice. The resulting solution was 
dialyzed for 72 h in 1000 mL DDH2O, changed every 24 hours, and lyophilized. Using the 
lyophilized FITC-PEG-NH2, a 10mg/mL solution was made in millipore water and protected 
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from light. Thin films or scaffolds were soaked for 24 h and dipped one at a time in 1mL of 
FITC-PEG-amine solution in the dark for 1 min, then washed extensively in 1000 mL of 
millipore water before being left to dry in the dark. 
4.2.10 Visualization after modification with FITC-conjugated molecules through confocal 
Microscopy  
To visualize the distribution of PELA conjugation sites, FITC-PEG-NH2 was conjugated 
as described. Thin films and scaffolds were examined using confocal laser scanning microscopy 
(Nikon Eclipse C1). All the parameters for laser intensity and gain were adjusted until 
fluorescent signals cannot be seen from the control group and were kept constant within a sample 
group. 
4.2.11 Change of surface hydrophilicity determined via contact angle  
PELA thin-films containing 5 & 25 mg of PEG conjugated unto the surface and 
unconjugated PELA and PLLA samples where used. Contact angle measurements were taken 
with a Rame-Hart 200-F1 contact angle goniometer. DI water was used as probe liquid. 
Advancing contact angle was obtained by measuring the angle while the water was slowly added 
to the surface from a ∼10 μL droplet in contact with the sample and a micrometer syringe. Three 
measurements were performed per sample, and the standard error is ±2°.  
4.2.12 Mass loss quantification in vitro  
Three-dimensional scaffolds made from PELA and PLLA, prepared as previously 
described (diameter 12.0 mm, height 2.0 mm), were conjugated with increasing NH2-PEG 5k 
Da: 0 mg, 1 mg, 10 mg, 25 mg, 100 mg were immersed in phosphate buffer solution (10 mL, 0.1 
M, pH 7.4) in a pre-weighed 20 mL vial. The PLLA scaffolds were only introduced to a 100 mg 
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PEG solution or 0 mg PEG solution. The samples were kept at 37 °C with a shaking speed of 25 
rpm. The buffer solution was renewed at predetermined times and the sample was lyophilized 
and the mass taken. Morphology change was examined visually and using SEM. 
4.2.13 Quantification of thin-film and scaffold modification with amine containing molecule  
In order to quantify the attachment of amine containing molecules once fabricated into 
thin-films (8 mm diameter) with a small molecular weight amine containing molecule. The films 
and scaffolds were dipped into a 0.1 mg/mL solution of dopamine, the solution was then 
lyophilized and reconstituted in 1 mL of DDH2O and the UV-Vis absorption was taken using a 
quartz cuvette (Hitachi U-2910) for Dopamin. The concentration was determined by comparing 
to a concentration curve ranging from 0.1 mg to 0.0005 mg with an absorption peak at 280 nm. 
The concentration of amine-PEG5k conjugated unto three dimensional scaffolds (2mm thick and 
17 mm diameter) by dissolving 50 mg in 5 mL of DDH2O in a pre-weighed 20 mL vial. The 
scaffolds where placed in the solution for 2 min in a shaker to allow the conjugation to occur. 
The scaffolds were removed and washed in 5 mL of DDH2O for 30 min. The solutions were then 
combined in the pre-weighed 20 mL, frozen, and lyophilized. The 20 mL vial was then weighed 
to determine the unconjugated mass of NH2-PEG5k.  
4.2.14 Polymeric nanospheres fabricated and attachment on surface PELA thin-films and 
scaffolds 
NH2PLLA and NH2PEGPLLA were synthesized as previously described by Ju et. al. 230. 
These polymers and PLLA were utilized to fabricate polymeric nanospheres using a double 
emulsion method (water/oil/water) as previously described by Wei et. al. 204. The microspheres 
were loaded with PEG-Rhodamine B and were characterized by SEM. The nanospheres were 
attached on the surface of PELA and PLLA thin-films and scaffolds in both methanol and 
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aqueous environment. The attachment of the nanospheres was characterized by SEM and 
confocal imagery.  
4.2.15 General characterization of monomers and polymers 
Nuclear magnetic resonance characterization. 1H and 13C spectra of macromonomers 
and copolymers were recorded with an Inova 500 NMR instrument operating at 500 MHz at 
room temperature. Deuterated chloroform (CDCl3) was used as the solvent. Spectral analysis is 
carried out in VnmrJ (Version 4.2, Agilent) and MestReNova (Version 12.0.0-200080, Metrelab 
Research) 
Ultraviolet–visible spectroscopy. All monomers and polymers formed were characterized 
by first dissolving in DCM and using a quartz cuvette to obtain spectrum from 200 - 700 nm (up 
to 350 shown) (Hitachi U-2910). 
Fourier-transform infrared spectroscopy. Monomers, polymers, thin-films, and scaffolds 
were characterized by directly placing the sample on the diamond crystal sample holder to obtain 
the spectrum from 600 – 4000 nm (Thermo-Nicolet IS-50). 
Scanning electron microscopy (SEM) observation. The surface morphology of thin films 
and three-dimensional scaffolds were examined using SEM (JEOL JSM-7800FLV) with an 
accelerating voltage of 15 kV. Prior to observation the samples were coated with gold for 150 s 
using a sputter coater (Desk II, Denton Vacuum Inc.). 
Gel permeation chromatography. Polymers formed were dissolved in anhydrous 
tetrahydrofuran and the size of the polymer were determined comparing to polystyrene standards 
(Shimadzu GPC). 
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4.2.16 Cell culture and osteogenic differentiation 
Human iPSC-MSCs were obtained from the Bo Yang lab. Cells were maintained in 
iPSC-MSC growth media (I-media) containing α-MEM, 20% FBS, 1% Penicillin-Streptomycin, 
and supplemented with L-glutamine (2 mM), non-essential amino acids (NEAA), 2-
mercaptoethanol (1 mM), and FGF-2 (1 ng/mL). These cells were proliferated on 0.1% gelatin 
coated T75 flasks under normal cell culture conditions (5% CO2 and 37°C). Media was changed 
every 48-72 hours. 24 hours after seeding, growth medium was replaced with osteogenic 
medium, consisting of high glucose DMEM with 10% FBS, 1% Penicillin-Streptomycin, and 
supplemented with ascorbic acid (50 μg/ml), β glycerophosphate (10 mM), and dexamethasone 
(100 nM). 
4.2.17 Scaffold sterilization and cell seeding  
Scaffolds were vacuum sterilized in 70% ethanol in 48-well suspension cell culture plates 
at 20-25 in Hg for 30 mins. Then scaffolds were washed three times in 1X PBS and two times in 
growth medium (10% α-MEM, 10% FBS, 1% Penicillin-Streptomycin) for 30 mins/wash on a 
shaker (5% CO2 and 37°C). For some studies scaffolds were soaked in FBS or 1 μg/mL BMP-2 
in place of the third PBS wash. Human iPSC-MSCs were seeded at 5×105 in 12 μL per scaffold 
and incubated with 1x PBS in surrounding wells for 2 hours. I-media was added after 2 hours 
and cells maintained or differentiated as described earlier. 
4.2.18 Proliferation assay  
Cell proliferation was measured by a colorimetric method using a 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-sulfonphenyl)-2H-tetrazolium (MTS 
tetrazolium) compound (Cell-Titer 96 Aqueous One Solution Cell Proliferation Assay; Promega, 
Madison, WI). The cells were cultured at 5×103/well in a 96-well plate using I-media. Then 200 
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µL of 10% MTS reagent in I-media was added to per well and incubated for 2 hours in normal 
culture conditions. The incubated solution was transferred to a new 96-well plate and absorbance 
at 490nm was measured by a 96-well spectrophotometer on days 1-5. 
4.2.19 Confocal imaging of cells on PELA scaffolds  
After 3 days of in vitro culture, human iPSC-MSCs on PLLA and PELA scaffolds were 
washed in 1x PBS, 100X Triton X, and 1X PBS again. Cells were then stained with Phalloidin 
(Alexa Fluor™ 555) (Invitrogen) and counterstained with 4′,6-diamidino-2-phenylindole 
(DAPI). Human iPSC-MSC seeded scaffolds were examined using Confocal Laser Scanning 
Microscopy (CLSM) (Nikon Eclipse C1). 
4.2.20 Calcium quantification  
Cells were washed 3 times with distilled water and incubated in 500 μL of 0.5N 
hydrochloric acid (HCl) overnight on a shaker at 4°C to extract calcium. HCl supernatant was 
stored at -20°C prior to sample analysis. Calcium quantification was determined with Pointe 
Scientific Calcium Liquid Reagents according to the manufacturer’s manual. Absorbance was 
measured at 570 nm. A calcium standard was used to calculate the calcium content in each 
sample.  
4.2.21 RNA extraction and qRT-PCR  
Total RNA was extracted using TRIzol. A cDNA library was created with SuperScriptII 
Reverse transcription reagents (Applied Biosystems) and real time qPCR was performed using 
TaqMan Universal PCR Master Mix (Applied Biosystems). qRT-PCR was performed using 
primers for Runx2 (Hs01047973_m1) and GAPDH (Hs02786624_g1). GAPDH was used to 
normalize gene expression as an internal standard.  
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4.2.22 Subcutaneous implantation  
Male 6~8-week-old C57BL/6 mice (Charles River Laboratories International, Inc., 
Wilmington, MA) were used for the subcutaneous implantation of PLLA and PELA scaffold 
study. Surgery was performed under general inhalation anesthesia with isoflurane as previously 
described 229. Two scaffolds were implanted subcutaneously into each pocket, for a total of 4 
scaffolds per animal. Two samples were implanted for each group (n=2). The mice were 
sacrificed at 2 weeks post-surgery and the cell-scaffold constructs were harvested. The animal 
procedures were performed according to the guidelines approved by the University of Michigan 
Committee of Use and Care of Laboratory Animals. Specimens were process for histological 
analysis. Samples were processed for histological analysis. 
4.2.23 Histological Analysis  
Both in vitro and in vivo samples were washed with PBS, fixed in 10% formalin and 
embedded in paraffin blocks. 5 µm sections were prepared, subsequently deparaffinized, 
rehydrated with a graded series of ethanol, and stained with hematoxylin and eosin (H&E), 
Alizarin red S, and von Kossa. 
4.2.24 Statistical analysis 
Performed using SPSS Statistics Premium (Version 24, IBM, Inc.). Data are reported as 
mean ± standard deviation. Significance is determined as p < 0.05. 
4.3 Results 
4.3.1 Synthesis of poly(exomethylene lactide-co-lactic acid), Modification, and Characterization 
The polymer components EML, MDO, and HPLLA, were synthesized as previously 
discussed [Figure 4.1]. The components were shown extremely pure before polymerization  
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(NMR). The PELA polymer was synthesized and characterized using NMR, GPC, DSC, and 
TGA, [Figure 4.2]. Using these methods we were able to confirm that the novel PELA 
copolymer was successfully synthesized with a molecular weight of ~ 120 k Da (molecular 
weight determined via GPC) and with an incorporation of HEMA: EML outside the theoretical 
values based on the feed ratios, 10:1, 25:1, 50:1, and 100:1 (determined by 1H NMR) [Figure 
4.2C]. In our study, we found that the 10:1 was the closest to ratio found as our theoretical value, 
with 25:1 being second.  
 
 
Figure 4.1 Synthesis scheme and mode of modification of PELA polymer.  
A) Synthesis scheme of exomethylene lactide by brominating and debromination allylic 
carbon as described in 2.2.9 B) Synthesis scheme for HEMA-PLLA using a Tin catalyst 
(stannous octoate) in a bulk reaction C) Synthesis scheme of degradable PELA polymer using 
MDO to provide degradation of the carbon-carbon backbone D) Schematic depicting method 
of modification of both polymer before and after processing into tissue engineering scaffold. 
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Additionally, using TGA we were able to observe 3 distinct faces of the polymer 
degradation, with an initial mass loss at 200 °C that is attributed to the pendent groups breaking 
and leaving behind a COOH, OH, and carbon-carbon backbone [Figure 1D]. The second mass 
loss (highest ratio) is attributed to the PLLA portion being degraded, and lastly, the third mass 
loss can be attributed to the degradation of the carbon-carbon backbone. These assumptions were 
confirmed by observations of the individual components. The intensity of each mass loss (1st and 
3rd) varied depending on the ratio of HPLLA to EML. 
 
 
Figure 4.2 PELA polymer characterization.  
A). 500 MHz 1H NMR spectrum of PELA polymer in CDCl3 B) 500 MHz 13C NMR spectrum 
of PELA polymer in CDCl3 C) PELA polymer ratios considered and resulting polymer MW 
via GPC using a styrene standard D) Thermal decomposition of PELA, HEMAPLLA, and 
PEML polymers depicting loss of mass E) DSC spectrum depicting glass transition of PELA.   
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4.3.2 PELA polymer conjugation with amine-containing molecules 
Before fabrication into tissue engineering constructs, we investigated the novel PELA 
polymer to determine if the EML pendants are able to click with the model amine containing 
molecules (NH2-PEG-Methoxy, aminehexanol, and L-Cysteine) chosen to demonstrate that the 
EML pendants can conjugate when synthesized in a copolymer. We demonstrated the stability 
and function of the novel PELA copolymer by showing it can be successfully modified without 
the need for heat or a catalyst, yet still conjugate molecules in water. In this study, we dissolved 
the PELA copolymer in DCM and added an amine containing molecule in either DDH2O or in 
DCM (PEG-NH2). After collecting the PELA polymers, they were modified and qualitatively 
characterized using FTIR. The conjugation was considered a success with the appearance of 
amide stretch at ~1630-1690. 
4.3.3 Thin-film Fabrication and Modification Observation of Physical Properties  
Thin-films from mixtures of PELA (10:1, 25:1, 50:1, 75:1, and 100:1) and PLLA were 
fabricated and cut to 5 mm diameter pieces and observed using SEM to verify the presence of 
nanofibers [Figure 4.3]. We further characterized the films to show the effects before and after 
conjugation with PEG-NH2 5 kDa. The SEM images indicated that the biomimetic nanofiber 
morphology was present in all the PELA films before modification and after modification; 
before modification the samples that contained 25:1 and 10:1 showed excellent nanofiber 
morphology and physical structure that was comparable to PLLA thin films. However, before 
modification it was evident that the films with increasing EML concentration had structural 
problems that presented as cracks and pores on the film surface of the samples for certain ratios 
(50:1 to 100:1). The samples that contained 25:1 and 10:1 showed excellent nanofiber 
morphology and physical structure that was comparable to PLLA thin films. After modification 
 93 
the PELA films that demonstrated cracks and pores (50:1 to 100:1) showed increased porosity 
and cracks; the 100:1 began to fall apart making it difficult to handle and destroying most of the 
nanofiber morphology [Figure 4.3]. The films that demonstrated excellent morphology (25:1 & 
10:1) before modification demonstrated excellent morphology, mechanical properties, and 
nanofiber structure post-modification [Figure 4.3]. Therefore, through this study we were able to 
                                   
 
Figure 4.3 PELA/PLLA polymer thin-film fabrication and characterization through SEM 
before and after modification with amine-PEG5000.  
a-b) PLLA film before/ after modification demonstrating nanofibrous morphology c-d) 
PLLA/PELA25:1 film before/ after modification demonstrating nanofibrous morphology c-h) 
PLLA/PELA films before/ after modification demonstrating loss of nanofibrous morphology. 
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demonstrate that the PELA copolymer could be fashioned into a two dimensional thin-film and 
for the first time the EML portion of the copolymer could be modified in an aqueous 
environment in a click-chemistry fashion, in the absence of organic solvents, heat, catalyst, or pH 
changes.  
 
 
Figure 4.4 Scaffold fabrication and characterization through SEM before and after modification 
with amine-PEG5000. 
a-d) PLLA film before and after modification demonstrating nanofibrous and interconnected 
morphology e-h) PLLA/PELA25:1 film before and after modification demonstrating nanofibrous 
and interconnected morphology c-h) PLLA/PELA films before and after modification 
demonstrating loss of porous and interconnected morphology. 
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4.3.4 Scaffold Fabrication and Modification and Observation of Physical Properties  
Although two-dimensional structures can be a useful, the most useful tissue engineering 
constructs are three-dimensional due to mimicking the natural environment cells occupy. Due to 
the structural results observed after fabrication of the PELA thin-films, the scaffolds that we 
fabricated with the PELA polymers consisted of those with ratios of 10:1, 25:1, 50:1 and 
compared the physical and robustness of the scaffold to PLLA [Figure 4.4]. This is important as 
the scaffolds with higher EML where brittle and break apart by handling. Similarly, to the results 
seen in the films the scaffolds formed from PELA 10:1, 25:1 showed excellent morphology, 
nanofiber structure, and mechanical properties before and after modification with PEG-NH2 5k. 
The scaffolds fabricated from PELA 50:1 showed cracks and chips in the physical morphology 
before and after modification. Through this experiment we were able to demonstrate that we can 
fabricate a three-dimensional scaffold from PELA with similar physical and mechanical 
properties as those of PLLA scaffolds but can now be post modified in a facile method in the 
absence of toxic solvents, catalyst, or UV-light. Due to these structural and physical results all 
further experiments focused on the PELA 25:1 thin-film and scaffolds unless stated otherwise. 
4.3.5 PELA thin-Film and scaffold conjugation with amine-containing molecules and 
quantification of conjugation 
After fabrication into tissue engineering constructs, we investigated the EML pendants if 
they are able to click with amine containing molecules. We demonstrated the stability and 
function of the constructs to be successfully modified without the need for heat or a catalyst, yet 
still conjugate molecules in water. In this study, the constructs were modified as depicted in 
Figure 4.1 and characterized using FTIR [Figure 4.5A].  The conjugation was considered a 
success with the appearance of amide stretch at ~1630-1690. The films and scaffolds both 
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demonstrated that they could be conjugated due to the formation of the amide bond formation. 
The PELA Thin-films and scaffolds where successfully quantified for amine molecules attached 
unto the surface. Films contained ~10 mg of dopamine conjugated, and scaffolds had ~25 mg of 
5k-PEG-NH2 conjugated, approximately 10x as much PEG compared to PLLA scaffolds. This 
gives us an indication to the degree of modification possible through the use of these tissue 
engineered constructs. 
4.3.6 Thin-film and Scaffold Modification Visualization Through Confocal Imagery  
In order to qualitatively determine the degree of modification that the PELA thin-films 
and scaffolds undergo they were modified with FITC-PEG-NH2 both in DDH2O and in 
methanol. This was done to mimic a potential small molecule that is insoluble in an aqueous 
 
 
Figure 4.5 Characterization and quantification of “click-chemistry like” conjugation.  
Characterization on thin-films and scaffold after conjugation with amine containing 
molecules A) FTIR spectrum of conjugation of amine containing molecules with PELA 
polymer B) Quantification of attachment of dopamine and PEG-NH2 compared to PLLA 
scaffold, n = 5. 
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environment. Additionally, BSA-FITC (aq) was utilized to demonstrate that proteins through 
their surface amino acids of L-Lysine and L-Arginine which contain free NH2 can be conjugated 
to the films and scaffolds. The films and scaffolds were soaked and modified as previously 
described before they were observed via confocal microscopy. Through this experiment we are 
able to demonstrate that the PELA thin-films and scaffolds can be easily modified with either 
NH2-PEG-FITC and the BSA FITC, [Figure 4.6A]. The PELA scaffolds showed excellent 
conjugation of both dye containing molecules compared to the PLLA thin-films and scaffolds. 
 
 
Figure 4.6 Scaffold modification with NH2-PEG FITC & BSA-FITC, characterization, and 
contact Angle. 
 
A) Modification of thin-films and scaffolds with fluorescent molecule to visualize 
conjugation of amine containing molecules B) Confocal 3D rendering of scaffold modified 
with amine-PEG-FITC C) contact angle measurement of PLLA, PLLA/PELA, PLLA/PELA 
thin-film conjugated with PEG-amine to demonstrate increased surface hydrophilicity. 
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Where only the scaffolds demonstrated limited fluorescence, which can be attributed to surface 
interaction and entrapment of the fluorescence molecules on the nanofibrous and porous surface 
of PLLA. Through three-dimensional rendering we are able to observe that the conjugation 
occurred throughout the entirety of the scaffold [Figure 4.6B]. 
4.3.7 Characterization of surface wettability through contact angle 
The effects of modification were characterized by calculating the surface hydrophilicity 
of PELA thin-films before and after modification with NH2-PEG5000 and comparing them to 
PLLA thin-films, [Figure 4.6C]. Through this characterization we can see that both PLLA and 
PELA are hydrophobic with contact angles greater than 100 ° and 110, respectively. However, 
once modified the PELA films surface hydrophilicity changes considerably with values ranging 
from 80 - 85° at 5 mg of PEG conjugation and 45 – 50 ° at 25 mg of PEG conjugated 
4.3.8 Mass Loss Quantification of PLLA scaffolds and PELA scaffolds  
In order to evaluate the degradation rate of the PELA scaffolds, as well as determine how 
the conjugation of molecules on the surface increase the hydrophilicity and affect the 
degradation rate PELA scaffolds were fabricated and conjugated with increasing amounts of 
NH2-PEG 5k Da and the mass loss was recorded over time. Visually, the PELA group 
conjugated with NH2-PEG began to fall apart at day 10, with all scaffolds breaking apart into 
large and small pieces by day 30 [Figure 4.7]. In comparison, the PLLA group remained intact 
and only a small amount of scaffold was lost after 35 d. This was also observed by quantifying 
mass loss during this time: the PLLA scaffold lost only ~ 15 % of its initial mass, the PELA with 
no heparin and the PLLA scaffold with heparin lost ~ 18-25 %, and the PELA with 100 mg PEG  
 99 
conjugated lost ~ 99 % of the total mass. The nanoarchitecture observed at day 0 and at day 35 
showed that the nanofibers and overall morphology had changed considerably in the PELA with 
PEG group but did not change significantly in the other groups. Therefore, we can conclude that 
there is an increase of hydrophilicity in the microenvironment and that the increase accelerates 
the rate of degradation as more PEG-NH2 was conjugated. Through the use of this knowledge we 
can not only have a scaffold with biomimetic physical and mechanical properties that can be 
facile modified in a click-chemistry fashion but in addition we can utilize the EML pendants to 
tailor the degradation of the scaffold. 
 
 
Figure 4.7 Mass loss quantification of PLLA and PELA scaffolds conjugated with PEG-NH2. 
Quantification of mass remaining at predetermined time points of PELA polymer conjugated 
with varying amounts of PEGNH2 compared to PLLA and PLLA with PEGNH2. 
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4.3.9 Polymeric nanospheres fabricated and attachment on PELA Thin-Films and Scaffold  
Polymeric particles are another method of imparting biological cues to a tissue 
engineering scaffolds. Through the use of these particles, regulatory signals could be delivered to 
the localized environment in a controlled manner. In doing so the microenvironment can be 
enhanced for a prolonged duration. For this reason, polymeric particles have been utilized 
extensively in combination with scaffolds for tissue engineering to elicit cellular response205, 219. 
However facile methods to attach such particles in a manner in which the scaffold, the particle, 
or regulatory signal, which can include expensive and sensitive proteins or mRNAs, in the 
absence of chemicals, heat, acid/base would be a powerful tool in the tissue engineering tool kit. 
To show that PELA can be used to conjugate polymeric vesicles we synthesized 3 distinct 
polymers and fabricated them into vesicles. The three polymers were PLLA (~ 10 k Da), amine 
initiated PLGA (~ 10 k Da), and amine initiated PLGA with a PEG linker of 1 k Da (polymer 
~11 k Da), the polymers were characterized by NMR and GPC for end group functionalization 
(amine presence) and molecular weight determination . NH2-PLGA, NH2-PEG-PLGA, and 
PLGA was successfully fabricated into nanospheres and loaded with NH2PEG-Rhodamine B 
with a size ranging from 2-3 µm. The PELA and PLLA films were soaked for a day before 
conjugation with particles suspended in both water and methanol, washed to remove 
unconjugated spheres, and observed through SEM and confocal microscopy [Figure 4.8A]. 
Through these means we were able to determine that the PLLA films allowed minimal 
attachment of the amine containing particles based on the limited visualization of particles on the 
surface (linker and no linker) [Figure 4.8A]. However, there was a sizeable distinction between 
the number of particles on the PLLA and the PELA surface both in water and in methanol, as we 
were able to visualize a vast number of particles on the PELA surface [Figure 4.8A]. There was 
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no difference between the amine-PLGA (linker or no linker) number of particles on the surface, 
meaning that the linker utilized played no considerable role in the attachment. Of note is that the 
 
 
Figure 4.8 Thin Film and Scaffold Modification with Polymeric Microspheres for Sustained 
Drug Released. 
 
A) Amine-functionalized polymeric particles and non-amine functionalized polymeric 
particles conjugated on thin films fabricated from PELA or PLLA visualized by SEM and 
confocal microscopy B) PELA scaffold with amine-functionalized polymeric particles.  
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PLLA particles showed minimal attachment unto the surface of the PELA film [Figure 4.8]. 
Signifying that their presence is due to entrapment and not conjugation.  
In order to show that the PELA scaffolds can be utilized to attach polymeric vesicles and 
thereby be utilized for tissue engineering purposes, we conjugated the NH2-PLGA (no linker) 
particles unto a PELA scaffolds and characterized in the same manner as the films. As in the 
films, we saw a large number of particles conjugated unto the scaffold surface and through-out 
the scaffold. Additionally, there was no clustering or agglomeration of the particles [Figure 4.8 
B]. Through these experiments we are able to demonstrate for the first time to conjugate 
polymeric vesicles in a click-chemistry fashion in the absence of chemicals, heat, and solvents.  
4.3.10 Scaffold biocompatibility “in vitro” and “in vivo” through subcutaneous implantation  
Of concern was if the amine reactive EML pendants would negatively impact the 
scaffolds biocompatibility when cells are seeded by annealing them in place through conjugation 
of transmembrane proteins or molecules with free amines leading to physical deformation, 
diminished proliferation, or cell death. In order to demonstrate that the reactive EML pendants 
would not alter the cellular morphology we seeded iPS-MSCs unto the PELA and PLLA 
scaffolds and observed the cell morphology through SEM and confocal after staining the β-actin 
stained with phalloidin (red) and nuclei with DAPI (blue), [Figure 4.9 A-B]. Of note is that both 
the 50:1 and 25:1 PELA polymers were used in this experiment in order to increase the ratio of 
EML pendants available and demonstrate their biocompatibility. After seeding the cells for two 
days we were able to observe that similar to the PLLA scaffolds, the cells seeded unto the PELA 
scaffolds spread and formed large films consisting of cells. The scaffolds porosity assisted in the 
cells moving through the scaffold and there was no discernable difference between the PELA 
and the PLLA scaffold, [Figure 4.9A]. Using confocal imagery after staining the nucleus and β-
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actin we are able to confirm again, that the morphology of cell was not altered due to the 
interaction with the amine reactive PELA copolymer. Both the cells in PLLA and PELA showed 
mature development of β-actin, a protein that is known to be a part of the cytoskeleton and 
contributes to the cellular elongation seen in the SEM, [Figure 4.9B].  
Additionally, the cell survival was confirmed after 5 days post-seeding through an MTS 
proliferation assay. Using this assay, we are able to confirm that the PELA polymers and 
scaffolds have no discerning cytotoxicity and are as biocompatible as the PLLA scaffolds in 
vitro. To demonstrate the PELA scaffolds biocompatibility in vivo, we implanted PELA 
scaffolds soaked in FBS, or non-soaked, and subcutaneously implanted them into the back of a 
mouse. At the end of 2 weeks the scaffolds were compared to the results of PLLA scaffolds 
 
 
Figure 4.9 Cytocompatibility of PELA scaffolds compared to PLLA scaffolds. 
A) SEM characterization of 3 day and 5 day cell seeding on PELA and PLLA scaffolds to 
demonstrate biocompatibility B) 3 day proliferation of iPS-MSCs. β-actin stained with 
phalloidin (red) and nuclei with DAPI (blue). Images at 10x (top) and 20x (bottom) C) 5 day 
MTS proliferation assay D) schematic illustration of PBS and FBS soaked PLLA and PELA 
1:25 scaffolds E) Subcutaneously implantation of scaffolds in mice for 2 weeks characterization 
via H&E staining to demonstrate host cell infiltration. Scale bars at 20 µm. 
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implanted in the same manner and stained with H & E. After the 2 weeks, we were able to 
conclude that the PELA scaffolds are indeed biocompatible in vitro and can be used as tissue 
engineering constructs. Both the PELA and PLLA scaffolds that were not soaked in FBS had less 
cells migrated into the scaffold. However, the FBS soaked PELA scaffold showed improved 
cellular penetration in the scaffolds. When compared qualitatively we can conclude that the 
PELA scaffolds conjugated with proteins in FBS are more biocompatible than PLLA scaffolds in 
vivo. Taken together, with the previous results we can determine that the PELA polymer can be 
utilized to fabricate a biomimetic scaffold that be further optimized in a click-chemistry fashion 
as a tissue engineering construct. 
4.4 Discussion 
Polymer scaffolds are an invaluable tool in tissue regeneration, providing a three-
dimensional template similar to that of the native extracellular matrix (ECM) for cells to grow 
and proliferate into the desired tissue. Tissue regeneration is optimized in tissue quality and time 
to regeneration when scaffolds mimic the natural ECM. Of importance is the biomimetic 
physical architecture that has been previously developed by Ma and coworkers 49, 59, 161,  where a 
three-dimensional fibrous architecture that is porous and interconnect is developed through a 
sugar leaching method and TIPS. Scaffolds with these features have been utilized and shown to 
be conducive for an array of tissue engineering applications and therefore offer a base starting 
point when developing novel scaffolds and biomaterials. 
Recently, considerable effort has been spent to enhance the scaffold’s biomimetic nature 
beyond physical characteristics by imparting biological motifs or regulatory signals that can 
trigger biologic responses. This has been a chemical and engineering challenge requiring an 
experienced material scientist due to the complicated procedures, toxic chemicals, solvents, as 
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well as the cost and time required. Additionally, these procedures can have deleterious effects 
due to trace chemicals left after implantation and can disrupt either the biomimetic architecture 
or the mechanical properties of the scaffold. Therefore, novel methods to develop scaffolds with 
biomimetic architecture that can be functionalized with such biological signals easily, efficiently, 
and economically are the focus of this work. 
To achieve this, we have developed a novel copolymer derived from L-Lactide, 
poly(exomethylene-co-lactic acid) (PELA), that can be fabricated into films and scaffolds with 
the aforementioned biomimetic architecture that is conducive for tissue formation, contains 
excellent mechanical properties, and can be easily conjugated with amine containing molecules. 
The selectivity for amine containing molecules (nucleophiles) is quite broad, achieving 
conjugation with weak and strong nucleophiles such as tris(hydroxymethyl)aminomethanol 
(weak pKa ~ 7.77) to guanidine (strong pKa ~13.8) in aqueous environments231. To demonstrate 
the broad nature of the reaction we conjugated various molecules, amino acids (R & K) (pKa 8 – 
12), serinol (pKa 9.0), dopamine (~ pKa 8.9, tetraethylpentamine (pKa9.68), with a range of pKa’s 
and determined that we achieved conjugation of the amine containing molecule via an amide 
formation in aqueous environments 232-234. Additionally, this is further explored through the use 
of NH2-PEG5K, as it is conjugated unto the PELA constructs both in water and in anhydrous 
methanol [Figure 4.6]. The pKa in water is reported at approximately 10 where in anhydrous 
methanol the pKa is estimated to be 30 % of the value seen in an aqueous environment 235, 236.    
Therefore, we can postulate that the conjugation of the nucleophilic addition is not dependent on 
the pKa (strong nucleophile) but on the amine of the amine containing molecule being free to 
form an amide bond. 
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After fully characterizing the copolymer chemical structure and reactivity [Figure 4.2], 
we set out by demonstrating that indeed the polymer could be fabricated into fibrous architecture 
by the development of two-dimensional thin-films [Figure 4.3]. Two-dimensional structures are 
utilized in material science and tissue engineering as a simple platform to investigate physical 
and mechanical properties, hydrophilicity (contact angle), conjugation efficiency, and 
biocompatibility. Through the use of thermally induced phase separation (TIPS), we fabricated 
films of the PELA polymers. We demonstrated that the polymer with less than 25:1 (EML to 
HPLLA) ratio indeed produced the biomimetic fibrous architecture with excellent mechanical 
property [Figure 4.3c]. This copolymer was further shown to be able to be used in the 
development of three-dimensional scaffolds [Figure 4.4]. The scaffolds developed using this 
copolymer (PELA25:1) were made porous by the addition of a sugar porogen and thereby 
incorporating the favorable biomimetic morphology [Figure 4.4 e-f].   
In the presence of an amine-containing molecule, the thin-films and scaffolds were 
rapidly modified in a click-chemistry approach via amide-bond formation in the absence of 
catalyst, heat, or organic solvents and without producing toxic byproducts [Figure 4.3-4.4]. For 
the first time, demonstrating that the EML pendants can be conjugated in water and methanol230. 
This is as crucial as the PEML stability, and reactivity was never evaluated previously in an 
aqueous environment our studies demonstrated that indeed the PELA polymer could serve for 
tissue engineering construct that can be conjugated under these circumstances and post-
fabrication 230. Most importantly, we were able to demonstrate that the mechanical properties and 
physical morphology of the scaffolds were not altered after modification, as it can be seen in the 
PELA25:1 thin films [Figure 4.3d] and scaffolds [Figure 4.4g-h] conjugated with PEG-NH2 
demonstrated no change when visualized under SEM.  
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Importantly we demonstrated that the molecules were conjugated on the surface and not 
just fouled unto the surface [Figure 4.5A]. Additionally, the mass of molecules that can be 
conjugated unto the surface was determined through the use of dopamine (~10 mg) on the thin-
films and NH2-PEG5k (25 mg) on the scaffolds [Figure 4.5B] - demonstrating that the PELA 
polymer can be conjugated in a click-chemistry like fashion and can be loaded with a known 
maximum mass of regulatory signals for films and scaffolds. The conjugation efficiency was 
further visualized through confocal microscopy of NH2-PEG-FITC and BSA-FITC unto PELA 
thin-films and scaffolds and comparing it PLLA films and scaffolds [Figure 4.6A]. A clear 
difference in fluorescence was seen with the PELA constructs compared to the PLLA that only 
demonstrated fluorescence due to entrapment of the NH2-PEG-FITC and BSA-FITC.  
The tissue engineering constructs demonstrated increased wettability, tailorable 
degradation, as well as excellent biocompatibility in vitro and in vivo. These superior attributes 
make scaffolds developed from this novel copolymer a promising tool for tissue engineering by 
providing a construct that can be optimized with biomimetic characteristics. By determining the 
contact angle, we demonstrated that we could tailor the hydrophilicity of the surface [Figure 4.6 
C], thereby having effects on the rate of degradation and biocompatibility. Likewise, to achieve 
complete polymer degradation, specifically in the carbon-carbon backbone, a cyclic ketene acetal 
was used. MDO is a unique molecule that is polymerized via free radical polymerization and 
structure switches to produce an ester in the backbone [Figure 4.1]. Through the use of this 
polymer, we were able to show complete degradation of the scaffolds that had 100 mg of NH2-
PEG5k introduced after 35 days [Figure 4.7].  
An alternative method to enhance the microenvironment is through the temporal and 
spatial control release of regulatory signals. This can be achieved through the use of polymeric 
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vesicles which have been shown to achieve such control release of growth factors, therapeutic 
agents, and proteins amongst others 63, 66, 205, 237-240. However, incorporating such polymeric 
vesicles unto scaffolds has been problematic due to the use of solvents, heat, or chemical 
treatment that alter the particle surface, affecting the release kinetics, as well as affect the 
nanofibrous structure of the scaffold. Additionally, in many of these systems you can see 
aggregation of the particles and thereby providing uneven release of the regulatory signal 
through the scaffold. For this reason, using the PELA scaffold to conjugate such particles and 
demonstrating click-chemistry conjugation of the particles that are homogeneously disbursed is a 
significant finding [Figure 4.8]. The polymeric vesicles where shown to conjugate on the surface 
with high efficiency under physiological conditions and in methanol, thereby demonstrating 
broad use. 
Taken together, we were able to demonstrate that the PELA polymer can be utilized to 
fabricate a tissue engineering scaffold with biomimetic physical characteristics. The constructs 
can be modified easily with biological motifs or regulatory signals on the surface that could 
trigger a biological response or in polymeric particles that can release such signals in a controlled 
released with spatial orientation. The biocompatibility and translational relevance of the 
biomimetic properties imparted on the PELA scaffolds were evaluated in vitro and in vivo. 
Culminating in in vivo studies with PELA scaffolds conjugated with proteins from FBS media 
that enhanced the host cell-penetration and remodeling over PLLA scaffolds. Proving that the 
PELA polymer fabricated into tissue-engineered scaffolds could serve as a tissue engineering 
construct and provide enhanced biocompatibility in vivo over other scaffolds. 
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4.5 Conclusion 
Scaffolds are an invaluable tool in tissue and regenerative engineering with their clinical 
use expanding as biomimetic features are optimized. By building on previously described 
biomimetic physical characteristics we were able to develop scaffolds that can be easily 
enhanced in a click-chemistry fashion. In this work, we investigated a novel copolymer, PELA, 
with reactivity towards amines derived from L-Lactide, and fabricated it into scaffolds for tissue 
engineering for the first-time with biomimetic architecture. The scaffolds fabricated from this 
polymer contained biomimetic physical (nanofibrous, porous and interconnected) and 
mechanical properties. Most importantly, the scaffolds were shown to be facilely modified in an 
aqueous environment in a click-chemistry fashion in the absence of organic solvents, chemicals, 
UV-light, while retaining the biomimetic properties post-modification. Additionally, the 
scaffolds were shown to be biocompatible both in vitro and in vivo similarly to PLLA scaffolds. 
Taken together, we believe we have developed a novel scaffold platform that can be utilized for 
numerous tissue engineering applications and can be scaled for use by scientists outside of 
materials science due to the ease of modification. Future studies can broaden the use of the 
PELA polymer by looking at the reactivity of nucleophiles beyond amines, thereby broading the 
use of the polymer for biomedical application.
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Chapter 5. Conclusions & Future Works 
5.1 Thesis summary 
Through the work presented in this thesis, we were able to demonstrate that tissue 
engineering techniques and methods can be simplified and made available for broad general use 
by groups who would traditionally abstain from using such approaches. Tissue engineering is an 
interdisciplinary field that requires more insight than what material scientists can provide. As 
described through the tissue engineering triad [Figure 1.1], the best possible tissue engineering 
constructs rely on biomaterials, cells (endogenous or exogenous), and regulatory signals to 
induce a cellular response. Therefore, it is expected that this knowledge and expertise will be 
drawn from more than only a material scientist and include the expertise and understanding of 
life scientists as well as physicians. However, due to the complexity, expertise needed, and cost 
of the equipment required to synthesize biodegradable polymers and fabricate tissue engineering 
constructs, groups outside materials and polymer science traditionally abstain from utilizing such 
techniques. Therefore, it is imperative that the material scientist simplify and demystify 
polymerization methods and tissue engineering construct fabrication in a manner - easily, 
tailorable, and economically - which can be utilized by a broad range of disciplines. Through this 
work, we put forth methods to synthesize rapidly tailorable and biodegradable polymers and 
methods to fabricate scaffolds with biomimetic physical architecture with minimal footprint, 
efficiently and economically, and tailored for the desired applications. 
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Developing HMW polymers in a rapidly, facile, and economical fashion with limited 
footprint and without traditional equipment utilized in material science laboratories provided the 
foundation for work provided in this thesis. Through the use of a novel synthesis method, we 
were able to demonstrate how HMW polymers from lactones can be synthesized for tissue 
engineering scaffolding. Additionally, through this method, we can synthesize polymers that are 
well defined in MW and end-functionalized if need be. Most, importantly we were able to 
synthesize HMW polymers of the PSLA polymer, which has a tailorable degree of functionality 
in the backbone, thereby producing scaffolds that can be easily modified with regulatory signals. 
As mentioned, this synthesis method has a very low footprint, requiring no dedicated hood space, 
hotplates, or specialized glassware. We utilize culture tubes and freezers commonly available in 
life science laboratories with minimal space required (culture tube is 20 cm in length by 2.5 cm 
in diameter) and can produce batches of HMW polymer of up to 10 g in as fast as one hour. The 
amount of polymer produced by this one-pot synthesis reaction in our experience is ideal scale 
for most laboratories. 
The importance and use of the PSLA polymer in tissue engineering was demonstrated for 
the first time in the literature by the work in this thesis through the development of tubular 
scaffolds for in situ implantation in rat models. The highly functional polymer was modified with 
heparin to tailor the degradation rate, surface hydrophilicity, and biocompatibility. In 
collaboration with Professor Bo Yang, a cardiovascular surgeon and researcher, we successfully 
implanted the scaffolds into rat models and observed them for three-months. After the 
predetermined time, the reconstructed scaffolds were explanted and evaluated. The scaffolds 
exceeded our expectations, demonstrating excellent reconstruction of the inner layer with mature 
vascular tissue, and deposition of collagen and elastin. Additionally, the scaffolds demonstrated 
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no sign of aneurism, hyperplasia, or lethal thrombi formation. This work demonstrated the 
potential of the PSLA polymer with its tailorable functionality to serve as a biodegradable 
polymer for Tissue Engineering. 
Modifying scaffolds and biomaterials with regulatory signals can lead to positive 
outcomes with regards to tissue formation such as cellular response (proliferation, 
differentiation, and mature tissue formation), ECM formation, and enhancing biocompatibility. 
Therefore, incorporating these signals can be an essential tissue engineering approach to improve 
the desired outcome. However, the post-modification of scaffolds can be a daunting experience, 
even for a material scientist. Modification techniques and approaches are not always effective, 
conjugation chemistries such as EDC-chemistry, aminolysis, and plasma treatment can 
experience difficulties. These problems can involve conjugation efficiency, disruption of the 
scaffold’s properties (nanofibrous structure & mechanical properties), and the potential to 
denature and damage the molecules that are being conjugated. Advance conjugation techniques 
and methods such as click-chemistry tools have been shown to be ideal for preventing and 
diminishing the negative effects of traditional conjugation methods. However, these tools can be 
prohibitively costly and require an experienced materials chemist to conjugate the click-
chemistry tools to the molecules that are being joined together. Therefore, these approaches are 
not a solution as a means to simplify and broaden the use of tissue engineering techniques 
beyond traditional material laboratories. For this reason, the PELA polymer can solve these 
problems, as it is able to be modified and conjugated by amine-containing regulatory signals by 
click-chemistry. We consider this a significant outcome of this work – as groups wishing to 
study specific effects due to a regulatory signal can do so without the need of material scientists.  
 113 
Taken together, the development of both the synthesis methods to form HMW polymers 
such as PLLA and PSLA and the development of copolymers which are easily modified (PELA), 
combined with previously described scaffold fabrication methods make it possible to fabricate 
scaffolds that contain biomimetic physical architecture in a facile and rapid manner. Most 
importantly, we believe that through the work presented in this document, we have simplified 
processes in the tissue engineering field, opening the door for groups outside the materials 
discipline to utilize tissue engineering tools and have achieved the aim of the work. 
5.2 Proposed Future Work 
While the focus of this work was to demonstrate how we can simplify and thereby 
broaden the use of tissue engineering techniques as well as show how the biodegradable 
polymers we developed can be used in tissue engineering. There are still many areas to continue 
to explore and make an impact on this work. We specifically want to highlight three distinct 
areas which we are exploring 1) demonstrating living like polymerization properties of cold 
polymerization leading to ultra-high molecular weight (>1,000,000) 2) development of a fast 
degradable dense outer layer to match the degradation of the inner layer 3) Exploring the use of 
the PELA polymer as a biodegradable polymer to fabricate polymeric particles as cancer. The 
work and approach will be summarized in the following sections. 
5.2.1 Synthesis of Ultra high molecular weight PLLA through guanidine catalyst 
In the literature the TBD catalyzed reaction is referenced as a semi-living reaction 92. In 
the literature, the TBD catalyzed reaction is referenced as a semi-living reaction 92. However, 
this has not been fully explored as of now. In our work, we have seen that the catalyst remains 
active after one-month in the reaction vessel. We demonstrated its viability as we can induce 
polymer chain growth through the addition of additional monomer or decreasing the viscosity of 
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the reaction by lower the w/v % of the polymer concentration. We are pursuing these avenues as 
a means to increase the HMW currently achieved (350 k Da). The goal is to demonstrate living 
polymerization properties and achieve MWs of > 1000 k Da. We believe that this benchmark 
will extend the use of what we can currently utilize the synthesized polymer for 3-D printing or 
fabrication of degradable cups and straws. 
5.2.2 Tunable degradation of the outer layer dense-layer   
Currently, we are developing a replacement of the outer “dense-layer” that was deposited 
by electrospinning PCL. Although, the PCL fibers provided exceptional mechanical properties 
that ensured the scaffold could sustain the hemodynamic forces as well as the suturing process. 
The polymer degrades very slowly (2-3 years) and can be problematic by causing calcification in 
the reconstructed vessel192, 197. Therefore, the ideal polymer to fabricate the outer-dense layer 
would provide the mechanical strength to endure the suturing processes but can be tailored to 
degrade at defined times. We are attempting to solve the issue by two routes 1) Electrospinning 
PSLA fibers, which are strong and nonelastic to provide the mechanical strength 2) Development 
of fast-degrading elastic polymers from MTC (methyl trioxocane) and MDO. 
In this approach, through the fabrication of the PSLA polymer, we create fibers that 
mechanical strong (3x M Pa vs PLLA) but with very little elasticity. The fibers developed in this 
fashion have been demonstrated to contain the mechanical strength to endure suturing. We 
postulate that through these tailorable polymers, we can modulate the degradation of the outer 
layer and provide tailorable degradation rates similar to the inner layer. Additionally, through the 
use of MDO and MTC, we are synthesizing an elastic copolymer with increased hydrophilicity 
due to the ratio of MTC. We postulate that through the use of fibers fabricated from this 
MTC/MDO copolymer we will achieve tailorable degradation rate by modulating the feed ratio 
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and retain the favorable elastic properties we observe with PCL. Through these methods, we aim 
to enhance our current scaffold design and ensure that we provide a scaffold that can be 100 % 
tailored for the duration we designate. 
5.2.3 Fabrication of polymeric particles from PELA polymer  
Being able to functionalize the surface of a material can be beneficial in drug delivery to 
either shield the particle to prevent an immune response or to incorporate binding motifs. 
Therefore, a high density of chemical functionality on the material is beneficial as we can 
conjugate an increasing amount of binding or shielding motifs. However, traditional chemical 
functional groups can experience poor conjugation efficiency. Hence, a polymeric particle 
fabricated from PELA can prove to be beneficial to improve the conjugation efficiency between 
binding and shielding motifs. Using our polymerization method detailed in chapter 4, we can 
modulate the density of reactive EML groups on the surface of the polymeric particle. In this 
manner, we can modulate the density of motifs we wish to attach. Most importantly, the PELA 
polymer can be dissolved in DCM, and processes by well-established and facile methods outline 
by Ma and coworkers 36, 68, 205, 241. As proof of concept, the particles have been conjugated with a 
cell-adhesion peptide specific for SKBR-3 breast cancer cells and have been shown to have a 
high rate of particle uptake compared to particles without the binding motif. These particles also 
lead to higher cell death compared to our control groups when loaded with cancer therapeutic. 
Thereby demonstrating that this highly reactive polymer can be utilized for numerous 
applications in tissue engineering and regenerative medicine.
 116 
Chapter 6. Bibliography 
1. Breuer, C. K.;  Shin'oka, T.;  Tanel, R. E.;  Zund, G.;  Mooney, D. J.;  Ma, P. X.;  Miura, 
T.;  Colan, S.;  Langer, R.;  Mayer, J. E.; Vacanti, J. P., Tissue engineering lamb heart 
valve leaflets. Biotechnol Bioeng 1996, 50 (5), 562-7. 
2. Burdick, J. A.;  Mauck, R. L.; Wiley online library., Biomaterials for tissue engineering 
applications a review of the past and future trends. Springer: Wien ; New York, 2011; pp. 
1 online resource (x, 564 p.). http://dx.doi.org/10.1002/9783527646821. 
3. He, D.;  Dong, W.;  Tang, S.;  Wei, J.;  Liu, Z.;  Gu, X.;  Li, M.;  Guo, H.; Niu, Y., Tissue 
engineering scaffolds of mesoporous magnesium silicate and poly(epsilon-caprolactone)-
poly(ethylene glycol)-poly(epsilon-caprolactone) composite. Journal of materials 
science. Materials in medicine 2014, 25 (6), 1415-24. 
4. Smith, L. A.; Ma, P. X., Nano-fibrous scaffolds for tissue engineering. Colloids Surf B 
Biointerfaces 2004, 39 (3), 125-31. 
5. Song, Y.;  Feijen, J.;  Grijpma, D. W.; Poot, A. A., Tissue engineering of small-diameter 
vascular grafts: a literature review. Clin Hemorheol Microcirc 2011, 49 (1-4), 357-74. 
6. Wobma, H.; Vunjak-Novakovic, G., Tissue Engineering and Regenerative Medicine 
2015: A Year in Review. Tissue Eng Part B Rev 2016, 22 (2), 101-13. 
 117 
7. Kim, B. S.; Mooney, D. J., Development of biocompatible synthetic extracellular 
matrices for tissue engineering. Trends Biotechnol 1998, 16 (5), 224-30. 
8. Lutolf, M. P.; Hubbell, J. A., Synthetic biomaterials as instructive extracellular 
microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 2005, 23 (1), 
47-55. 
9. Ma, H.;  Hu, J.; Ma, P. X., Polymer scaffolds for small-diameter vascular tissue 
engineering. Adv Funct Mater 2010, 20 (17), 2833-2841. 
10. Agrawal, C. M.; Ray, R. B., Biodegradable polymeric scaffolds for musculoskeletal 
tissue engineering. J Biomed Mater Res 2001, 55 (2), 141-50. 
11. Holland, T. A.; Mikos, A. G., Biodegradable polymeric scaffolds. Improvements in bone 
tissue engineering through controlled drug delivery. Adv Biochem Eng Biotechnol 2006, 
102, 161-85. 
12. Kim, J.;  Yaszemski, M. J.; Lu, L., Three-dimensional porous biodegradable polymeric 
scaffolds fabricated with biodegradable hydrogel porogens. Tissue Eng Part C Methods 
2009, 15 (4), 583-94. 
13. Luderer, F.;  Begerow, I.;  Schmidt, W.;  Martin, H.;  Grabow, N.;  Bunger, C. M.;  
Schareck, W.;  Schmitz, K. P.; Sternberg, K., Enhanced visualization of biodegradable 
polymeric vascular scaffolds by incorporation of gold, silver and magnetite nanoparticles. 
J Biomater Appl 2013, 28 (2), 219-31. 
 118 
14. Nam, Y. S.; Park, T. G., Porous biodegradable polymeric scaffolds prepared by thermally 
induced phase separation. J Biomed Mater Res 1999, 47 (1), 8-17. 
15. Albertsson, A. C.; Ljungquist, O., Degradable Polyesters as Biomaterials. Acta Polym 
1988, 39 (1-2), 95-104. 
16. Ma, P. X., Scaffolds for tissue fabrication. Materials Today 2004, 7 (5), 30-40. 
17. Ma, P. X., Biomimetic materials for tissue engineering. Adv Drug Deliver Rev 2008, 60 
(2), 184-198. 
18. Liu, X.; Ma, P. X., Polymeric scaffolds for bone tissue engineering. Ann Biomed Eng 
2004, 32 (3), 477-86. 
19. Haddad, T.;  Noel, S.;  Liberelle, B.;  El Ayoubi, R.;  Ajji, A.; De Crescenzo, G., 
Fabrication and surface modification of poly lactic acid (PLA) scaffolds with epidermal 
growth factor for neural tissue engineering. Biomatter 2016, 6 (1), e1231276. 
20. Huang, Y. X.;  Ren, J.;  Chen, C.;  Ren, T. B.; Zhou, X. Y., Preparation and properties of 
poly(lactide-co-glycolide) (PLGA)/ nano-hydroxyapatite (NHA) scaffolds by thermally 
induced phase separation and rabbit MSCs culture on scaffolds. J Biomater Appl 2008, 
22 (5), 409-32. 
21. Sachlos, E.; Czernuszka, J. T., Making tissue engineering scaffolds work. Review: the 
application of solid freeform fabrication technology to the production of tissue 
engineering scaffolds. Eur Cell Mater 2003, 5, 29-39; discussion 39-40. 
 119 
22. Mauney, J. R.; Adam, R. M., Dynamic reciprocity in cell-scaffold interactions. Adv Drug 
Deliv Rev 2015, 82-83, 77-85. 
23. Murphy, C. M.;  O'Brien, F. J.;  Little, D. G.; Schindeler, A., Cell-scaffold interactions in 
the bone tissue engineering triad. Eur Cell Mater 2013, 26, 120-32. 
24. Spector, M., Novel cell-scaffold interactions encountered in tissue engineering: 
contractile behavior of musculoskeletal connective tissue cells. Tissue Eng 2002, 8 (3), 
351-7. 
25. Gentile, P.;  Chiono, V.;  Carmagnola, I.; Hatton, P. V., An overview of poly(lactic-co-
glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci 
2014, 15 (3), 3640-59. 
26. Li, X. W.;  Li, H.;  Zhao, Y. Y.;  Tang, X. Y.;  Ma, S. F.;  Gong, B.; Li, M. F., Facile 
synthesis of well-defined hydrophilic polyesters as degradable poly(ethylene glycol)-like 
biomaterials. Polymer Chemistry 2015, 6 (36), 6452-6456. 
27. Wei, G.; Ma, P. X., Nanostructured Biomaterials for Regeneration. Adv Funct Mater 
2008, 18 (22), 3566-3582. 
28. Cortizo, M. S.;  Molinuevo, M. S.; Cortizo, A. M., Biocompatibility and biodegradation 
of polyester and polyfumarate based-scaffolds for bone tissue engineering. J Tissue Eng 
Regen Med 2008, 2 (1), 33-42. 
 120 
29. Kim, J. A.;  Lim, J.;  Naren, R.;  Yun, H. S.; Park, E. K., Effect of the biodegradation rate 
controlled by pore structures in magnesium phosphate ceramic scaffolds on bone tissue 
regeneration in vivo. Acta Biomater 2016, 44, 155-67. 
30. Mkhabela, V.; Ray, S. S., Biodegradation and bioresorption of poly(varepsilon-
caprolactone) nanocomposite scaffolds. Int J Biol Macromol 2015, 79, 186-92. 
31. Tesfamariam, B., Bioresorbable vascular scaffolds: Biodegradation, drug delivery and 
vascular remodeling. Pharmacol Res 2016, 107, 163-171. 
32. Mo, X.; Weber, H.-J., Electrospinning P(LLA-CL) Nanofiber: A Tubular Scaffold 
Fabrication with Circumferential Alignment. Macromolecular Symposia 2004, 217 (1), 
413-416. 
33. Smith, L. A.;  Liu, X.; Ma, P. X., Tissue Engineering with Nano-Fibrous Scaffolds. Soft 
Matter 2008, 4 (11), 2144-2149. 
34. Feng, G.;  Zhang, Z.;  Dang, M.;  Zhang, X.;  Doleyres, Y.;  Song, Y.;  Chen, D.; Ma, P. 
X., Injectable nanofibrous spongy microspheres for NR4A1 plasmid DNA transfection to 
reverse fibrotic degeneration and support disc regeneration. Biomaterials 2017, 131, 86-
97. 
35. Kuang, R.;  Zhang, Z.;  Jin, X.;  Hu, J.;  Gupte, M. J.;  Ni, L.; Ma, P. X., Nanofibrous 
spongy microspheres enhance odontogenic differentiation of human dental pulp stem 
cells. Adv Healthc Mater 2015, 4 (13), 1993-2000. 
 121 
36. Liu, Z.;  Chen, X.;  Zhang, Z.;  Zhang, X.;  Saunders, L.;  Zhou, Y.; Ma, P. X., 
Nanofibrous Spongy Microspheres To Distinctly Release miRNA and Growth Factors To 
Enrich Regulatory T Cells and Rescue Periodontal Bone Loss. ACS nano 2018, 12 (10), 
9785-9799. 
37. Dahl, S. L.;  Kypson, A. P.;  Lawson, J. H.;  Blum, J. L.;  Strader, J. T.;  Li, Y.;  Manson, 
R. J.;  Tente, W. E.;  DiBernardo, L.;  Hensley, M. T.;  Carter, R.;  Williams, T. P.;  
Prichard, H. L.;  Dey, M. S.;  Begelman, K. G.; Niklason, L. E., Readily available tissue-
engineered vascular grafts. Sci Transl Med 2011, 3 (68), 68ra9. 
38. Hu, J. A.;  Sun, X. A.;  Ma, H. Y.;  Xie, C. Q.;  Chen, Y. E.; Ma, P. X., Porous 
nanofibrous PLLA scaffolds for vascular tissue engineering. Biomaterials 2010, 31 (31), 
7971-7977. 
39. Hu, J.; Ma, P. X., Nano-fibrous tissue engineering scaffolds capable of growth factor 
delivery. Pharm Res 2011, 28 (6), 1273-81. 
40. Woo, K. M.;  Chen, V. J.; Ma, P. X., Nano-fibrous scaffolding architecture selectively 
enhances protein adsorption contributing to cell attachment. J Biomed Mater Res A 2003, 
67 (2), 531-7. 
41. Bhatnagar, R.; Li, S., Biomimetic scaffolds for tissue engineering. Conf Proc IEEE Eng 
Med Biol Soc 2004, 2004, 5021-3. 
42. Holzwarth, J. M.; Ma, P. X., Biomimetic nanofibrous scaffolds for bone tissue 
engineering. Biomaterials 2011, 32 (36), 9622-9. 
 122 
43. Khalili, S.;  Nouri Khorasani, S.;  Razavi, M.;  Hashemi Beni, B.;  Heydari, F.; Tamayol, 
A., Nanofibrous scaffolds with biomimetic structure. J Biomed Mater Res A 2018, 106 
(2), 370-376. 
44. Owen, S. C.; Shoichet, M. S., Design of three-dimensional biomimetic scaffolds. J 
Biomed Mater Res A 2010, 94 (4), 1321-31. 
45. Park, J. Y.;  Park, S. H.;  Kim, M. G.;  Park, S. H.;  Yoo, T. H.; Kim, M. S., Biomimetic 
Scaffolds for Bone Tissue Engineering. Adv Exp Med Biol 2018, 1064, 109-121. 
46. Park, K. E.;  Jung, S. Y.;  Lee, S. J.;  Min, B. M.; Park, W. H., Biomimetic nanofibrous 
scaffolds: preparation and characterization of chitin/silk fibroin blend nanofibers. Int J 
Biol Macromol 2006, 38 (3-5), 165-73. 
47. Park, K. E.;  Kang, H. K.;  Lee, S. J.;  Min, B. M.; Park, W. H., Biomimetic nanofibrous 
scaffolds: preparation and characterization of PGA/chitin blend nanofibers. 
Biomacromolecules 2006, 7 (2), 635-43. 
48. Yuan, N.;  Rezzadeh, K. S.; Lee, J. C., Biomimetic Scaffolds for Osteogenesis. Receptors 
Clin Investig 2015, 2 (3). 
49. Hu, J.;  Sun, X.;  Ma, H.;  Xie, C.;  Chen, Y. E.; Ma, P. X., Porous nanofibrous PLLA 
scaffolds for vascular tissue engineering. Biomaterials 2010, 31 (31), 7971-7. 
50. Hu, J.;  Xie, C.;  Ma, H.;  Yang, B.;  Ma, P. X.; Chen, Y. E., Construction of vascular 
tissues with macro-porous nano-fibrous scaffolds and smooth muscle cells enriched from 
differentiated embryonic stem cells. PLoS One 2012, 7 (4), e35580. 
 123 
51. Yang, Y.;  Zhao, J.;  Zhao, Y.;  Wen, L.;  Yuan, X.; Fan, Y., Formation of porous PLGA 
scaffolds by a combining method of thermally induced phase separation and porogen 
leaching. Journal of Applied Polymer Science 2008, 109 (2), 1232-1241. 
52. Frank, A.;  Rath, S. K.; Venkatraman, S. S., Controlled release from bioerodible 
polymers: effect of drug type and polymer composition. J Control Release 2005, 102 (2), 
333-44. 
53. Fuoco, T.;  Finne-Wistrand, A.; Pappalardo, D., A Route to Aliphatic Poly(ester)s with 
Thiol Pendant Groups: From Monomer Design to Editable Porous Scaffolds. 
Biomacromolecules 2016, 17 (4), 1383-94. 
54. Hu, J.;  Wang, Y.;  Jiao, J.;  Liu, Z.;  Zhao, C.;  Zhou, Z.;  Zhang, Z.;  Forde, K.;  Wang, 
L.;  Wang, J.;  Baylink, D. J.;  Zhang, X. B.;  Gao, S.;  Yang, B.;  Chen, Y. E.; Ma, P. X., 
Patient-specific cardiovascular progenitor cells derived from integration-free induced 
pluripotent stem cells for vascular tissue regeneration. Biomaterials 2015, 73, 51-9. 
55. Liu, X.; Ma, P. X., Phase separation, pore structure, and properties of nanofibrous gelatin 
scaffolds. Biomaterials 2009, 30 (25), 4094-103. 
56. Soares, D. G.;  Zhang, Z.;  Mohamed, F.;  Eyster, T. W.;  de Souza Costa, C. A.; Ma, P. 
X., Simvastatin and nanofibrous poly(l-lactic acid) scaffolds to promote the odontogenic 
potential of dental pulp cells in an inflammatory environment. Acta Biomater 2018, 68, 
190-203. 
57. Wang, Z.;  Cui, Y.;  Wang, J.;  Yang, X.;  Wu, Y.;  Wang, K.;  Gao, X.;  Li, D.;  Li, Y.;  
Zheng, X. L.;  Zhu, Y.;  Kong, D.; Zhao, Q., The effect of thick fibers and large pores of 
 124 
electrospun poly(epsilon-caprolactone) vascular grafts on macrophage polarization and 
arterial regeneration. Biomaterials 2014, 35 (22), 5700-10. 
58. Chen, V. J.; Ma, P. X., Nano-fibrous poly(L-lactic acid) scaffolds with interconnected 
spherical macropores. Biomaterials 2004, 25 (11), 2065-73. 
59. Gupte, M. J.; Ma, P. X., Nanofibrous scaffolds for dental and craniofacial applications. J 
Dent Res 2012, 91 (3), 227-34. 
60. Kuang, R.;  Zhang, Z.;  Jin, X.;  Hu, J.;  Shi, S.;  Ni, L.; Ma, P. X., Nanofibrous spongy 
microspheres for the delivery of hypoxia-primed human dental pulp stem cells to 
regenerate vascularized dental pulp. Acta Biomater 2016, 33, 225-34. 
61. Ma, P. X.; Zhang, R., Synthetic nano-scale fibrous extracellular matrix. J Biomed Mater 
Res 1999, 46 (1), 60-72. 
62. Katsogiannis, K. A. G.;  Vladisavljević, G. T.; Georgiadou, S., Porous electrospun 
polycaprolactone (PCL) fibres by phase separation. European Polymer Journal 2015, 69, 
284-295. 
63. Kirby, G. T. S.;  White, L. J.;  Rahman, C. V.;  Cox, H. C.;  Qutachi, O.;  Rose, F. R. A. 
J.;  Hutmacher, D. W.;  Shakesheff, K. M.; Woodruff, M. A., PLGA-Based 
Microparticles for the Sustained Release of BMP-2. Polymers 2011, 3 (1), 571-586. 
64. Liu, X.;  Holzwarth, J. M.; Ma, P. X., Functionalized synthetic biodegradable polymer 
scaffolds for tissue engineering. Macromol Biosci 2012, 12 (7), 911-9. 
 125 
65. Liu, X.; Ma, P. X., The nanofibrous architecture of poly(L-lactic acid)-based functional 
copolymers. Biomaterials 2010, 31 (2), 259-69. 
66. Makadia, H. K.; Siegel, S. J., Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable 
Controlled Drug Delivery Carrier. Polymers 2011, 3 (3), 1377-1397. 
67. Mehta, R.;  Kumar, V.;  Bhunia, H.; Upadhyay, S. N., Synthesis of poly(lactic acid): A 
review. J Macromol Sci-Pol R 2005, C45 (4), 325-349. 
68. Smith, I. O.;  Liu, X. H.;  Smith, L. A.; Ma, P. X., Nanostructured polymer scaffolds for 
tissue engineering and regenerative medicine. Wires Nanomed Nanobi 2009, 1 (2), 226-
236. 
69. Gunatillake, P. A.; Adhikari, R., Biodegradable synthetic polymers for tissue 
engineering. Eur Cell Mater 2003, 5, 1-16; discussion 16. 
70. Brannigan, R. P.; Dove, A. P., Synthesis, properties and biomedical applications of 
hydrolytically degradable materials based on aliphatic polyesters and polycarbonates. 
Biomater Sci 2016, 5 (1), 9-21. 
71. Han, H.;  Zhu, J.;  Zhang, F. F.;  Li, F. X.;  Wang, X. L.;  Yu, J. Y.;  Qin, X. H.; Wu, D. 
Q., Hydrophilic and degradable polyesters based on l-aspartic acid with antibacterial 
properties for potential application in hernia repair. Biomater Sci 2019, 7 (12), 5404-
5413. 
72. Lecomte, P.; Jerome, C., Synthesis and Fabrication of Polyesters as Biomaterials. 
Polymeric Biomaterials: Structure and Function, Vol 1 2013, 1-36. 
 126 
73. Song, L.;  Ding, A. X.;  Zhang, K. X.;  Gong, B.;  Lu, Z. L.; He, L., Degradable 
polyesters via ring-opening polymerization of functional valerolactones for efficient gene 
delivery. Org Biomol Chem 2017, 15 (31), 6567-6574. 
74. Cheng, T.;  O'Rorke, R.;  Ortiz, R. F.;  Yan, T. Y.;  Hemmer, E.;  Vetrone, F.;  Marks, R. 
S.; Steele, T. W. J., Self-assembled photoadditives in polyester films allow stop and go 
chemical release. Acta Biomater 2017, 54, 186-200. 
75. Dhingra, S.;  Weisel, R. D.; Li, R. K., Synthesis of aliphatic polyester hydrogel for 
cardiac tissue engineering. Methods Mol Biol 2014, 1181, 51-9. 
76. Borgaonkar, P.;  Sharma, S.;  Chen, M.;  Bhowmick, S.; Schmidt, D. F., A flexible 
approach to the preparation of polymer scaffolds for tissue engineering. Macromol Biosci 
2007, 7 (2), 201-7. 
77. Gonzalez-Garcia, D. M.;  Marcos-Fernandez, A.;  Rodriguez-Lorenzo, L. M.;  Jimenez-
Gallegos, R.;  Vargas-Becerril, N.; Tellez-Jurado, L., Synthesis and in Vitro 
Cytocompatibility of Segmented Poly(Ester-Urethane)s and Poly(Ester-Urea-Urethane)s 
for Bone Tissue Engineering. Polymers (Basel) 2018, 10 (9). 
78. Idris, S. B.;  Arvidson, K.;  Plikk, P.;  Ibrahim, S.;  Finne-Wistrand, A.;  Albertsson, A. 
C.;  Bolstad, A. I.; Mustafa, K., Polyester copolymer scaffolds enhance expression of 
bone markers in osteoblast-like cells. J Biomed Mater Res A 2010, 94 (2), 631-9. 
79. Ye, H.;  Zhang, K.;  Kai, D.;  Li, Z.; Loh, X. J., Polyester elastomers for soft tissue 
engineering. Chem Soc Rev 2018, 47 (12), 4545-4580. 
 127 
80. Curia, S.;  Biundo, A.;  Fischer, I.;  Braunschmid, V.;  Gubitz, G. M.; Stanzione, J. F., 
3rd, Towards Sustainable High-Performance Thermoplastics: Synthesis, 
Characterization, and Enzymatic Hydrolysis of Bisguaiacol-Based Polyesters. 
ChemSusChem 2018, 11 (15), 2529-2539. 
81. Chang, S. H.;  Lee, H. J.;  Park, S.;  Kim, Y.; Jeong, B., Fast Degradable 
Polycaprolactone for Drug Delivery. Biomacromolecules 2018, 19 (6), 2302-2307. 
82. Laurent, C. P.;  Vaquette, C.;  Liu, X.;  Schmitt, J. F.; Rahouadj, R., Suitability of a 
PLCL fibrous scaffold for soft tissue engineering applications: A combined biological 
and mechanical characterisation. J Biomater Appl 2018, 32 (9), 1276-1288. 
83. Malikmammadov, E.;  Tanir, T. E.;  Kiziltay, A.;  Hasirci, V.; Hasirci, N., PCL and PCL-
based materials in biomedical applications. J Biomater Sci Polym Ed 2018, 29 (7-9), 863-
893. 
84. Jain, R. A., The manufacturing techniques of various drug loaded biodegradable 
poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000, 21 (23), 2475-90. 
85. Zund, G.;  Breuer, C. K.;  Shinoka, T.;  Ma, P. X.;  Langer, R.;  Mayer, J. E.; Vacanti, J. 
P., The in vitro construction of a tissue engineered bioprosthetic heart valve. Eur J 
Cardiothorac Surg 1997, 11 (3), 493-7. 
86. Khosravi, R.;  Best, C. A.;  Allen, R. A.;  Stowell, C. E.;  Onwuka, E.;  Zhuang, J. J.;  
Lee, Y. U.;  Yi, T.;  Bersi, M. R.;  Shinoka, T.;  Humphrey, J. D.;  Wang, Y.; Breuer, C. 
K., Long-Term Functional Efficacy of a Novel Electrospun Poly(Glycerol Sebacate)-
Based Arterial Graft in Mice. Ann Biomed Eng 2016, 44 (8), 2402-16. 
 128 
87. Lee, K. W.;  Stolz, D. B.; Wang, Y., Substantial expression of mature elastin in arterial 
constructs. Proc Natl Acad Sci U S A 2011, 108 (7), 2705-10. 
88. Yoo, Y.-C.;  Kim, H.-Y.;  Jin, F.-L.; Park, S.-J., Synthesis of poly(glycolide-
caprolactone) copolymers for application as bioabsorbable suture materials. 
Macromolecular Research 2013, 21 (6), 687-692. 
89. Blocks, Stars and Combs: Complex Macromolecular Architecture Polymers via Click 
Chemistry. In Click Chemistry for Biotechnology and Materials Science, pp 89-117. 
90. Prabaharan, M.;  Grailer, J. J.;  Pilla, S.;  Steeber, D. A.; Gong, S., Amphiphilic multi-
arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for 
tumor-targeted drug delivery. Biomaterials 2009, 30 (29), 5757-66. 
91. Kim, H.;  Olsson, J. V.;  Hedrick, J. L.; Waymouth, R. M., Facile Synthesis of 
Functionalized Lactones and Organocatalytic Ring-Opening Polymerization. ACS Macro 
Letters 2012, 1 (7), 845-847. 
92. Simon, L.; Goodman, J. M., The mechanism of TBD-catalyzed ring-opening 
polymerization of cyclic esters. J Org Chem 2007, 72 (25), 9656-62. 
93. Garkhal, K.;  Verma, S.;  Jonnalagadda, S.; Kumar, N., Fast degradable poly(L-lactide-
co-ε-caprolactone) microspheres for tissue engineering: Synthesis, characterization, and 
degradation behavior. Journal of Polymer Science Part A: Polymer Chemistry 2007, 45 
(13), 2755-2764. 
 129 
94. Zhang, X.;  MacDonald, D. A.;  Goosen, M. F.; McAuley, K. B., Mechanism of lactide 
polymerization in the presence of stannous octoate: the effect of hydroxy and carboxylic 
acid substances. Journal of Polymer Science Part A: Polymer Chemistry 1994, 32 (15), 
2965-2970. 
95. Park, T. G., Degradation of poly(lactic-co-glycolic acid) microspheres: effect of 
copolymer composition. Biomaterials 1995, 16 (15), 1123-30. 
96. Lu, L.;  Garcia, C. A.; Mikos, A. G., In vitro degradation of thin poly(DL-lactic-co-
glycolic acid) films. J Biomed Mater Res 1999, 46 (2), 236-244. 
97. Sugiura, T.;  Tara, S.;  Nakayama, H.;  Yi, T.;  Lee, Y. U.;  Shoji, T.;  Breuer, C. K.; 
Shinoka, T., Fast-degrading bioresorbable arterial vascular graft with high cellular 
infiltration inhibits calcification of the graft. J Vasc Surg 2017, 66 (1), 243-250. 
98. Yang, X.;  Wei, J.;  Lei, D.;  Liu, Y.; Wu, W., Appropriate density of PCL nano-fiber 
sheath promoted muscular remodeling of PGS/PCL grafts in arterial circulation. 
Biomaterials 2016, 88, 34-47. 
99. Lee, H.;  Yoon, H.; Kim, G., Highly oriented electrospun polycaprolactone 
micro/nanofibers prepared by a field-controllable electrode and rotating collector. 
Applied Physics A 2009, 97 (3), 559-565. 
100. Sprott, M. R.;  Gallego-Ferrer, G.;  Dalby, M. J.;  Salmeron-Sanchez, M.; Cantini, M., 
Functionalization of PLLA with Polymer Brushes to Trigger the Assembly of Fibronectin 
into Nanonetworks. Adv Healthc Mater 2019, 8 (3), e1801469. 
 130 
101. Roberts, M. J.;  Bentley, M. D.; Harris, J. M., Chemistry for peptide and protein 
PEGylation. Adv Drug Deliv Rev 2002, 54 (4), 459-76. 
102. Trappmann, B.;  Gautrot, J. E.;  Connelly, J. T.;  Strange, D. G.;  Li, Y.;  Oyen, M. L.;  
Cohen Stuart, M. A.;  Boehm, H.;  Li, B.;  Vogel, V.;  Spatz, J. P.;  Watt, F. M.; Huck, 
W. T., Extracellular-matrix tethering regulates stem-cell fate. Nat Mater 2012, 11 (7), 
642-9. 
103. Protein and Peptide Conjugation to Polymers and Surfaces Using Oxime Chemistry. In 
Click Chemistry for Biotechnology and Materials Science, pp 53-68. 
104. Hoyle, C. E.; Bowman, C. N., Thiol-ene click chemistry. Angew Chem Int Ed Engl 2010, 
49 (9), 1540-73. 
105. Bao, Y. S.;  Zhaorigetu, B.;  Agula, B.;  Baiyin, M.; Jia, M., Aminolysis of aryl ester 
using tertiary amine as amino donor via C-O and C-N bond activations. J Org Chem 
2014, 79 (2), 803-8. 
106. Ju, M.;  Gong, F.;  Cheng, S.; Gao, Y., - Fast and Convenient Synthesis of Amine-
Terminated Polylactide as a Macroinitiator for <svg style="vertical-align:-
0.18pt;width:15.525px;" id="M1" height="10.7" version="1.1" viewBox="0 0 15.525 
10.7" width="15.525" xmlns:xlink="http://www.w3.org/1999/xlink" 
xmlns="http://www.w3.org/2000/svg">. 2011, - 2011. 
107. Zhang, Z.;  Gupte, M. J.;  Jin, X.; Ma, P. X., Injectable Peptide Decorated Functional 
Nanofibrous Hollow Microspheres to Direct Stem Cell Differentiation and Tissue 
Regeneration. Adv Funct Mater 2015, 25 (3), 350-360. 
 131 
108. Diaz, D. D.;  Rajagopal, K.;  Strable, E.;  Schneider, J.; Finn, M. G., "Click" chemistry in 
a supramolecular environment: stabilization of organogels by copper(I)-catalyzed azide-
alkyne [3 + 2] cycloaddition. J Am Chem Soc 2006, 128 (18), 6056-7. 
109. Copper-Catalyzed ‘Click’ Chemistry for Surface Engineering. In Click Chemistry for 
Biotechnology and Materials Science, pp 291-307. 
110. Presolski, S. I.;  Hong, V. P.; Finn, M. G., Copper-Catalyzed Azide-Alkyne Click 
Chemistry for Bioconjugation. Curr Protoc Chem Biol 2011, 3 (4), 153-162. 
111. Himo, F.;  Lovell, T.;  Hilgraf, R.;  Rostovtsev, V. V.;  Noodleman, L.;  Sharpless, K. B.; 
Fokin, V. V., Copper(I)-catalyzed synthesis of azoles. DFT study predicts unprecedented 
reactivity and intermediates. J Am Chem Soc 2005, 127 (1), 210-6. 
112. Fluorogenic Copper(I)-Catalyzed Azide–Alkyne Cycloaddition Reactions and their 
Applications in Bioconjugation. In Click Chemistry for Biotechnology and Materials 
Science, pp 327-353. 
113. Kolb, H. C.;  Finn, M. G.; Sharpless, K. B., Click Chemistry: Diverse Chemical Function 
from a Few Good Reactions. Angew Chem Int Ed Engl 2001, 40 (11), 2004-2021. 
114. Copper-Free Click Chemistry. In Click Chemistry for Biotechnology and Materials 
Science, pp 29-51. 
115. Yi, G.;  Son, J.;  Yoo, J.;  Park, C.; Koo, H., Application of click chemistry in 
nanoparticle modification and its targeted delivery. Biomater Res 2018, 22, 13. 
 132 
116. Mudgal, M. M.;  Birudukota, N.; Doke, M. A., Applications of Click Chemistry in the 
Development of HIV Protease Inhibitors. Int J Med Chem 2018, 2018, 2946730. 
117. Kalelkar, P. P.;  Geng, Z.;  Finn, M. G.; Collard, D. M., Azide-Substituted Polylactide: A 
Biodegradable Substrate for Antimicrobial Materials via Click Chemistry Attachment of 
Quaternary Ammonium Groups. Biomacromolecules 2019, 20 (9), 3366-3374. 
118. Gotsbacher, M. P.; Codd, R., Azido-Desferrioxamine Siderophores as Functional Click-
Chemistry Probes Generated in Culture upon Adding a Diazo-Transfer Reagent. 
Chembiochem 2019. 
119. Deane, C., Bioorthogonal chemistry: Click on, click off. Nat Chem Biol 2017, 13 (10), 
1057. 
120. Koo, H.;  Choi, M.;  Kim, E.;  Hahn, S. K.;  Weissleder, R.; Yun, S. H., Bioorthogonal 
Click Chemistry-Based Synthetic Cell Glue. Small 2015, 11 (48), 6458-66. 
121. Pereira, R. F.;  Barrias, C. C.;  Bartolo, P. J.; Granja, P. L., Cell-instructive pectin 
hydrogels crosslinked via thiol-norbornene photo-click chemistry for skin tissue 
engineering. Acta Biomater 2018, 66, 282-293. 
122. Mohanty, N.;  Vass, I.; Demeter, S., Copper Toxicity Affects Photosystem II Electron 
Transport at the Secondary Quinone Acceptor, Q(B). Plant Physiol 1989, 90 (1), 175-9. 
123. Aston, N. S.;  Watt, N.;  Morton, I. E.;  Tanner, M. S.; Evans, G. S., Copper toxicity 
affects proliferation and viability of human hepatoma cells (HepG2 line). Hum Exp 
Toxicol 2000, 19 (6), 367-76. 
 133 
124. Arredondo, M.;  Cambiazo, V.;  Tapia, L.;  Gonzalez-Aguero, M.;  Nunez, M. T.;  Uauy, 
R.; Gonzalez, M., Copper overload affects copper and iron metabolism in Hep-G2 cells. 
Am J Physiol Gastrointest Liver Physiol 2004, 287 (1), G27-32. 
125. Rostovtsev, V. V.;  Green, L. G.;  Fokin, V. V.; Sharpless, K. B., A stepwise huisgen 
cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and 
terminal alkynes. Angew Chem Int Ed Engl 2002, 41 (14), 2596-9. 
126. Baskin, J. M.;  Prescher, J. A.;  Laughlin, S. T.;  Agard, N. J.;  Chang, P. V.;  Miller, I. 
A.;  Lo, A.;  Codelli, J. A.; Bertozzi, C. R., Copper-free click chemistry for dynamic in 
vivo imaging. Proc Natl Acad Sci U S A 2007, 104 (43), 16793-7. 
127. Kalia, J.; Raines, R. T., Hydrolytic stability of hydrazones and oximes. Angew Chem Int 
Ed Engl 2008, 47 (39), 7523-6. 
128. Kolmel, D. K.; Kool, E. T., Oximes and Hydrazones in Bioconjugation: Mechanism and 
Catalysis. Chem Rev 2017, 117 (15), 10358-10376. 
129. Marsili, L.;  Franceschi, G.;  Galliani, C.;  Sanfilippo, A.; Vigevani, A., New rifamycins. 
II. Synthesis and biological activity of oximes, hydrazones, and semicarbazones of 3-N-
(piperidin-4-one)rifamycin S. Farmaco Sci 1982, 37 (12), 781-6. 
130. Morales, S.;  Acena, J. L.;  Garcia Ruano, J. L.; Cid, M. B., Sustainable Synthesis of 
Oximes, Hydrazones, and Thiosemicarbazones under Mild Organocatalyzed Reaction 
Conditions. J Org Chem 2016, 81 (20), 10016-10022. 
 134 
131. Verma, K. K., Spot-test detection of aryl hydrazines, hydrazones, osazones, oximes and 
aromatic amines. Talanta 1979, 26 (3), 257-9. 
132. Matson, J. B.; Stupp, S. I., Drug release from hydrazone-containing peptide amphiphiles. 
Chem Commun (Camb) 2011, 47 (28), 7962-4. 
133. Xu, W.;  Ding, J.;  Xiao, C.;  Li, L.;  Zhuang, X.; Chen, X., Versatile preparation of 
intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin conjugate for 
malignancy therapeutic. Biomaterials 2015, 54, 72-86. 
134. Xu, W.;  Ding, J.;  Xiao, C.;  Li, L.;  Zhuang, X.; Chen, X., Corrigendum to "Versatile 
preparation of intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin 
conjugate for malignancy therapeutic" [Biomaterials 54 (2015) 72-86]. Biomaterials 
2018, 163, 88. 
135. Hardy, J. G.;  Lin, P.; Schmidt, C. E., Biodegradable hydrogels composed of oxime 
crosslinked poly(ethylene glycol), hyaluronic acid and collagen: a tunable platform for 
soft tissue engineering. J Biomater Sci Polym Ed 2015, 26 (3), 143-61. 
136. Baker, A. E. G.;  Bahlmann, L. C.;  Tam, R. Y.;  Liu, J. C.;  Ganesh, A. N.;  Mitrousis, 
N.;  Marcellus, R.;  Spears, M.;  Bartlett, J. M. S.;  Cescon, D. W.;  Bader, G. D.; 
Shoichet, M. S., Benchmarking to the Gold Standard: Hyaluronan-Oxime Hydrogels 
Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture. Adv Mater 
2019, 31 (36), e1901166. 
 135 
137. Di Tuoro, D.;  Portaccio, M.;  Lepore, M.;  Arduini, F.;  Moscone, D.;  Bencivenga, U.; 
Mita, D. G., An acetylcholinesterase biosensor for determination of low concentrations of 
Paraoxon and Dichlorvos. N Biotechnol 2011, 29 (1), 132-8. 
138. Lowe, A. B., Thiol-ene "click" reactions and recent applications in polymer and materials 
synthesis: a first update. Polymer Chemistry 2014, 5 (17), 4820-4870. 
139. Wendeln, C.;  Rinnen, S.;  Schulz, C.;  Arlinghaus, H. F.; Ravoo, B. J., Photochemical 
microcontact printing by thiol-ene and thiol-yne click chemistry. Langmuir 2010, 26 (20), 
15966-71. 
140. Saada, M. C.;  Ombouma, J.;  Montero, J. L.;  Supuran, C. T.; Winum, J. Y., Thiol-ene 
click chemistry for the synthesis of highly effective glycosyl sulfonamide carbonic 
anhydrase inhibitors. Chem Commun (Camb) 2013, 49 (50), 5699-701. 
141. Liu, Y.;  Hou, W.;  Sun, H.;  Cui, C.;  Zhang, L.;  Jiang, Y.;  Wu, Y.;  Wang, Y.;  Li, J.;  
Sumerlin, B. S.;  Liu, Q.; Tan, W., Thiol-ene click chemistry: a biocompatible way for 
orthogonal bioconjugation of colloidal nanoparticles. Chem Sci 2017, 8 (9), 6182-6187. 
142. Northrop, B. H.; Coffey, R. N., Thiol-ene click chemistry: computational and kinetic 
analysis of the influence of alkene functionality. J Am Chem Soc 2012, 134 (33), 13804-
17. 
143. Lv, Y.;  Lin, Z.; Svec, F., "Thiol-ene" click chemistry: a facile and versatile route for the 
functionalization of porous polymer monoliths. Analyst 2012, 137 (18), 4114-8. 
 136 
144. Xin, S.;  Wyman, O. M.; Alge, D. L., Assembly of PEG Microgels into Porous Cell-
Instructive 3D Scaffolds via Thiol-Ene Click Chemistry. Adv Healthc Mater 2018, 7 (11), 
e1800160. 
145. Ruizendaal, L.;  Pujari, S. P.;  Gevaerts, V.;  Paulusse, J. M.; Zuilhof, H., Biofunctional 
silicon nanoparticles by means of thiol-ene click chemistry. Chem Asian J 2011, 6 (10), 
2776-86. 
146. Yao, X.;  Zheng, H.;  Zhang, Y.;  Ma, X.;  Xiao, Y.; Wang, Y., Engineering Thiol-Ene 
Click Chemistry for the Fabrication of Novel Structurally Well-Defined Multifunctional 
Cyclodextrin Separation Materials for Enhanced Enantioseparation. Anal Chem 2016, 88 
(9), 4955-64. 
147. Luong, N. D.;  Sinh le, H.;  Johansson, L. S.;  Campell, J.; Seppala, J., Functional 
graphene by thiol-ene click chemistry. Chemistry 2015, 21 (8), 3183-6. 
148. Wang, J.;  Wang, X.;  Yan, G.;  Fu, S.; Tang, R., pH-sensitive nanogels with ortho ester 
linkages prepared via thiol-ene click chemistry for efficient intracellular drug release. J 
Colloid Interface Sci 2017, 508, 282-290. 
149. Matheny, M.;  McPheeters, M. L.;  Glasser, A.;  Mercaldo, N.;  Weaver, R. B.;  Jerome, 
R. N.;  Walden, R.;  McKoy, J. N.;  Pritchett, J.; Tsai, C., In Systematic Review of 
Cardiovascular Disease Risk Assessment Tools, Rockville (MD), 2011. 
150. Kaplan, G. A.; Keil, J. E., Socioeconomic factors and cardiovascular disease: a review of 
the literature. Circulation 1993, 88 (4 Pt 1), 1973-98. 
 137 
151. World Health, O. Global status report on non-communicable diseases 2010; 2011. 
152. Falk, E.;  Shah, P. K.; Fuster, V., Coronary plaque disruption. Circulation 1995, 92 (3), 
657-71. 
153. Stary, H. C.;  Chandler, A. B.;  Dinsmore, R. E.;  Fuster, V.;  Glagov, S.;  Insull, W., Jr.;  
Rosenfeld, M. E.;  Schwartz, C. J.;  Wagner, W. D.; Wissler, R. W., A definition of 
advanced types of atherosclerotic lesions and a histological classification of 
atherosclerosis. A report from the Committee on Vascular Lesions of the Council on 
Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995, 15 
(9), 1512-31. 
154. Stary, H. C.;  Chandler, A. B.;  Glagov, S.;  Guyton, J. R.;  Insull, W., Jr.;  Rosenfeld, M. 
E.;  Schaffer, S. A.;  Schwartz, C. J.;  Wagner, W. D.; Wissler, R. W., A definition of 
initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the 
Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart 
Association. Circulation 1994, 89 (5), 2462-78. 
155. Stary, H. C.;  Blankenhorn, D. H.;  Chandler, A. B.;  Glagov, S.;  Insull, W., Jr.;  
Richardson, M.;  Rosenfeld, M. E.;  Schaffer, S. A.;  Schwartz, C. J.;  Wagner, W. D.; et 
al., A definition of the intima of human arteries and of its atherosclerosis-prone regions. 
A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, 
American Heart Association. Arterioscler Thromb 1992, 12 (1), 120-34. 
156. Davies, M. J., The pathophysiology of acute coronary syndromes. Heart 2000, 83 (3), 
361-6. 
 138 
157. Davies, M. J., Pathophysiology of acute coronary syndromes. Indian Heart J 2000, 52 
(4), 473-9. 
158. Hashimoto, M.;  Greenberg, M. M.;  Kow, Y. W.;  Hwang, J. T.; Cunningham, R. P., The 
2-deoxyribonolactone lesion produced in DNA by neocarzinostatin and other damaging 
agents forms cross-links with the base-excision repair enzyme endonuclease III. J Am 
Chem Soc 2001, 123 (13), 3161-2. 
159. Wu, J.;  Wu, L.;  Xu, X.;  Xu, X.;  Yin, X.;  Chen, Y.; Hu, Y., Microspheres made by 
w/o/o emulsion method with reduced initial burst for long-term delivery of endostar, a 
novel recombinant human endostatin. Journal of Pharmaceutical Sciences 2009, 98 (6), 
2051-2058. 
160. Wu, W.;  Allen, R. A.; Wang, Y., Fast-degrading elastomer enables rapid remodeling of a 
cell-free synthetic graft into a neoartery. Nat Med 2012, 18 (7), 1148-53. 
161. Wang, Y.;  Hu, J.;  Jiao, J.;  Liu, Z.;  Zhou, Z.;  Zhao, C.;  Chang, L. J.;  Chen, Y. E.;  
Ma, P. X.; Yang, B., Engineering vascular tissue with functional smooth muscle cells 
derived from human iPS cells and nanofibrous scaffolds. Biomaterials 2014, 35 (32), 
8960-9. 
162. Shinoka, T.;  Shum-Tim, D.;  Ma, P. X.;  Tanel, R. E.;  Langer, R.;  Vacanti, J. P.; Mayer, 
J. E., Jr., Tissue-engineered heart valve leaflets: does cell origin affect outcome? 
Circulation 1997, 96 (9 Suppl), II-102-7. 
 139 
163. Shinoka, T.;  Ma, P. X.;  Shum-Tim, D.;  Breuer, C. K.;  Cusick, R. A.;  Zund, G.;  
Langer, R.;  Vacanti, J. P.; Mayer, J. E., Jr., Tissue-engineered heart valves. Autologous 
valve leaflet replacement study in a lamb model. Circulation 1996, 94 (9 Suppl), II164-8. 
164. Patterson, J. T.;  Gilliland, T.;  Maxfield, M. W.;  Church, S.;  Naito, Y.;  Shinoka, T.; 
Breuer, C. K., Tissue-engineered vascular grafts for use in the treatment of congenital 
heart disease: from the bench to the clinic and back again. Regenerative Medicine 2012, 7 
(3), 409-419. 
165. Nemeno-Guanzon, J. G.;  Lee, S.;  Berg, J. R.;  Jo, Y. H.;  Yeo, J. E.;  Nam, B. M.;  Koh, 
Y. G.; Lee, J. I., Trends in Tissue Engineering for Blood Vessels. Journal of Biomedicine 
and Biotechnology 2012. 
166. van Haaften, E. E.;  Bouten, C. V. C.; Kurniawan, N. A., Vascular Mechanobiology: 
Towards Control of In Situ Regeneration. Cells 2017, 6 (3). 
167. Li, S.;  Sengupta, D.; Chien, S., Vascular tissue engineering: from in vitro to in situ. 
Wires Syst Biol Med 2014, 6 (1), 61-76. 
168. Cleary, M. A.;  Geiger, E.;  Grady, C.;  Best, C.;  Naito, Y.; Breuer, C., Vascular tissue 
engineering: the next generation. Trends Mol Med 2012, 18 (7), 394-404. 
169. Kurobe, H.;  Maxfield, M. W.;  Breuer, C. K.; Shinoka, T., Concise review: tissue-
engineered vascular grafts for cardiac surgery: past, present, and future. Stem Cells 
Transl Med 2012, 1 (7), 566-71. 
 140 
170. Conklin, B. S.;  Richter, E. R.;  Kreutziger, K. L.;  Zhong, D. S.; Chen, C., Development 
and evaluation of a novel decellularized vascular xenograft. Med Eng Phys 2002, 24 (3), 
173-83. 
171. Kakisis, J. D.;  Liapis, C. D.;  Breuer, C.; Sumpio, B. E., Artificial blood vessel: The 
Holy Grail of peripheral vascular surgery. J Vasc Surg 2005, 41 (2), 349-354. 
172. Bos, G. W.;  Poot, A. A.;  Beugeling, T.;  van Aken, W. G.; Feijen, J., Small-diameter 
vascular graft prostheses: current status. Arch Physiol Biochem 1998, 106 (2), 100-15. 
173. Radomski, J. S.;  Jarrell, B. E.;  Pratt, K. J.; Williams, S. K., Effects of in vitro aging on 
human endothelial cell adherence to dacron vascular graft material. J Surg Res 1989, 47 
(2), 173-7. 
174. Hauptmann, S.;  Klosterhalfen, B.;  Mittermayer, C.;  Ruhlmann, K. U.;  Kaufmann, R.; 
Hocker, H., Evidence for macrophage-mediated defluorization of a Teflon vascular graft. 
J Mater Sci-Mater M 1996, 7 (6), 345-348. 
175. Weiss, W. M.;  Riles, T. S.;  Gouge, T. H.; Mizrachi, H. H., Angiosarcoma at the Site of a 
Dacron Vascular Prosthesis - a Case-Report and Literature-Review. J Vasc Surg 1991, 14 
(1), 87-91. 
176. de Valence, S.;  Tille, J. C.;  Giliberto, J. P.;  Mrowczynski, W.;  Gurny, R.;  Walpoth, B. 
H.; Moller, M., Advantages of bilayered vascular grafts for surgical applicability and 
tissue regeneration. Acta Biomater 2012, 8 (11), 3914-20. 
 141 
177. Soletti, L.;  Hong, Y.;  Guan, J.;  Stankus, J. J.;  El-Kurdi, M. S.;  Wagner, W. R.; Vorp, 
D. A., A bilayered elastomeric scaffold for tissue engineering of small diameter vascular 
grafts. Acta Biomater 2010, 6 (1), 110-22. 
178. Gui, L.;  Dash, B. C.;  Luo, J.;  Qin, L.;  Zhao, L.;  Yamamoto, K.;  Hashimoto, T.;  Wu, 
H.;  Dardik, A.;  Tellides, G.;  Niklason, L. E.; Qyang, Y., Implantable tissue-engineered 
blood vessels from human induced pluripotent stem cells. Biomaterials 2016, 102, 120-9. 
179. Wissing, T. B.;  Bonito, V.;  Bouten, C. V. C.; Smits, A., Biomaterial-driven in situ 
cardiovascular tissue engineering-a multi-disciplinary perspective. NPJ Regen Med 2017, 
2, 18. 
180. Wang, F.;  Mohammed, A.;  Li, C.;  Ge, P.;  Wang, L.; King, M. W., Degradable/non-
degradable polymer composites for in-situ tissue engineering small diameter vascular 
prosthesis application. Biomed Mater Eng 2014, 24 (6), 2127-33. 
181. Henry, J. J. D.;  Yu, J.;  Wang, A.;  Lee, R.;  Fang, J.; Li, S., Engineering the mechanical 
and biological properties of nanofibrous vascular grafts for in situ vascular tissue 
engineering. Biofabrication 2017, 9 (3), 035007. 
182. Liu, J.;  Qin, Y.;  Wu, Y.;  Sun, Z.;  Li, B.;  Jing, H.;  Zhang, C.;  Li, C.;  Leng, X.;  
Wang, Z.; Kong, D., The surrounding tissue contributes to smooth muscle cells' 
regeneration and vascularization of small diameter vascular grafts. Biomater Sci 2018. 
183. Dong, X.;  Yuan, X.;  Wang, L.;  Liu, J.;  Midgley, A. C.;  Wang, Z.;  Wang, K.;  Liu, J.;  
Zhu, M.; Kong, D., Construction of a bilayered vascular graft with smooth internal 
 142 
surface for improved hemocompatibility and endothelial cell monolayer formation. 
Biomaterials 2018, 181, 1-14. 
184. Wang, W.;  Hu, J.;  He, C.;  Nie, W.;  Feng, W.;  Qiu, K.;  Zhou, X.;  Gao, Y.; Wang, G., 
Heparinized PLLA/PLCL nanofibrous scaffold for potential engineering of small-
diameter blood vessel: tunable elasticity and anticoagulation property. J Biomed Mater 
Res A 2015, 103 (5), 1784-97. 
185. Lee, S. J.;  Kim, M. E.;  Nah, H.;  Seok, J. M.;  Jeong, M. H.;  Park, K.;  Kwon, I. K.;  
Lee, J. S.; Park, S. A., Vascular endothelial growth factor immobilized on mussel-
inspired three-dimensional bilayered scaffold for artificial vascular graft application: In 
vitro and in vivo evaluations. J Colloid Interface Sci 2019, 537, 333-344. 
186. Shinoka, T.;  Breuer, C. K.;  Tanel, R. E.;  Zund, G.;  Miura, T.;  Ma, P. X.;  Langer, R.;  
Vacanti, J. P.; Mayer, J. E., Jr., Tissue engineering heart valves: valve leaflet replacement 
study in a lamb model. Ann Thorac Surg 1995, 60 (6 Suppl), S513-6. 
187. Ravi, S.; Chaikof, E. L., Biomaterials for vascular tissue engineering. Regen Med 2010, 5 
(1), 107-20. 
188. Sell, S. A.;  McClure, M. J.;  Garg, K.;  Wolfe, P. S.; Bowlin, G. L., Electrospinning of 
collagen/biopolymers for regenerative medicine and cardiovascular tissue engineering. 
Adv Drug Deliv Rev 2009, 61 (12), 1007-19. 
189. Shinoka, T.;  Shum-Tim, D.;  Ma, P. X.;  Tanel, R. E.;  Isogai, N.;  Langer, R.;  Vacanti, 
J. P.; Mayer, J. E., Jr., Creation of viable pulmonary artery autografts through tissue 
engineering. J Thorac Cardiovasc Surg 1998, 115 (3), 536-45; discussion 545-6. 
 143 
190. Vaz, C. M.;  van Tuijl, S.;  Bouten, C. V.; Baaijens, F. P., Design of scaffolds for blood 
vessel tissue engineering using a multi-layering electrospinning technique. Acta Biomater 
2005, 1 (5), 575-82. 
191. Ye, L.;  Wu, X.;  Mu, Q.;  Chen, B.;  Duan, Y.;  Geng, X.;  Gu, Y.;  Zhang, A.;  Zhang, 
J.; Feng, Z. G., Heparin-Conjugated PCL Scaffolds Fabricated by Electrospinning and 
Loaded with Fibroblast Growth Factor 2. J Biomater Sci Polym Ed 2011, 22 (1-3), 389-
406. 
192. de Valence, S.;  Tille, J. C.;  Mugnai, D.;  Mrowczynski, W.;  Gurny, R.;  Moller, M.; 
Walpoth, B. H., Long term performance of polycaprolactone vascular grafts in a rat 
abdominal aorta replacement model. Biomaterials 2012, 33 (1), 38-47. 
193. Ercolani, E.;  Del Gaudio, C.; Bianco, A., Vascular tissue engineering of small-diameter 
blood vessels: reviewing the electrospinning approach. J Tissue Eng Regen Med 2015, 9 
(8), 861-88. 
194. Xie, C.;  Hu, J.;  Ma, H.;  Zhang, J.;  Chang, L. J.;  Chen, Y. E.; Ma, P. X., Three-
dimensional growth of iPS cell-derived smooth muscle cells on nanofibrous scaffolds. 
Biomaterials 2011, 32 (19), 4369-75. 
195. Huang, C.;  Wang, S.;  Qiu, L.;  Ke, Q.;  Zhai, W.; Mo, X., Heparin loading and pre-
endothelialization in enhancing the patency rate of electrospun small-diameter vascular 
grafts in a canine model. ACS Appl Mater Interfaces 2013, 5 (6), 2220-6. 
196. Nieponice, A.;  Soletti, L.;  Guan, J.;  Hong, Y.;  Gharaibeh, B.;  Maul, T. M.;  Huard, J.;  
Wagner, W. R.; Vorp, D. A., In vivo assessment of a tissue-engineered vascular graft 
 144 
combining a biodegradable elastomeric scaffold and muscle-derived stem cells in a rat 
model. Tissue Eng Part A 2010, 16 (4), 1215-23. 
197. Li, W.;  Chen, J.;  Xu, P.;  Zhu, M.;  Wu, Y.;  Wang, Z.;  Zhao, T.;  Cheng, Q.;  Wang, 
K.;  Fan, G.;  Zhu, Y.; Kong, D., Long-term evaluation of vascular grafts with 
circumferentially aligned microfibers in a rat abdominal aorta replacement model. J 
Biomed Mater Res B Appl Biomater 2018, 106 (7), 2596-2604. 
198. Higutchi, C.;  Sarraf, Y. S.;  Nardino, E. P.;  Pereira, W. M. G.;  Daboin, B. E. G.;  
Carvalho, L. E. W.; Correa, J. A., Vascular Reconstruction Technique Using a Tubular 
Graft for Leiomyosarcoma of the Inferior Vena Cava: A Case Report. EJVES Short Rep 
2017, 36, 5-8. 
199. Kricheldorf, H. R.;  Kreiser-Saunders, I.; Stricker, A., Polylactones 48. SnOct(2)-initiated 
polymerizations of lactide: A mechanistic study. Macromolecules 2000, 33 (3), 702-709. 
200. Fiore, G. L.;  Jing, F.;  Young, J. V. G.;  Cramer, C. J.; Hillmyer, M. A., High Tg 
aliphatic polyesters by the polymerization of spirolactide derivatives. Polymer Chemistry 
2010, 1 (6), 870-877. 
201. Corneillie, S.; Smet, M., PLA architectures: the role of branching. Polymer Chemistry 
2015, 6 (6), 850-867. 
202. Jing, F.; Hillmyer, M. A., A bifunctional monomer derived from lactide for toughening 
polylactide. J Am Chem Soc 2008, 130 (42), 13826-7. 
 145 
203. Smith, L. A.; Ma, P. X., Computer-designed nano-fibrous scaffolds. Methods Mol Biol 
2012, 868, 125-34. 
204. Wei, G.;  Jin, Q.;  Giannobile, W. V.; Ma, P. X., The enhancement of osteogenesis by 
nano-fibrous scaffolds incorporating rhBMP-7 nanospheres. Biomaterials 2007, 28 (12), 
2087-96. 
205. Jin, Q.;  Wei, G.;  Lin, Z.;  Sugai, J. V.;  Lynch, S. E.;  Ma, P. X.; Giannobile, W. V., 
Nanofibrous scaffolds incorporating PDGF-BB microspheres induce chemokine 
expression and tissue neogenesis in vivo. PLoS One 2008, 3 (3), e1729. 
206. Lohmeijer, B. G. G.;  Pratt, R. C.;  Leibfarth, F.;  Logan, J. W.;  Long, D. A.;  Dove, A. 
P.;  Nederberg, F.;  Choi, J.;  Wade, C.;  Waymouth, R. M.; Hedrick, J. L., Guanidine and 
amidine organocatalysts for ring-opening polymerization of cyclic esters. 
Macromolecules 2006, 39 (25), 8574-8583. 
207. Wang, J.;  Ma, H.;  Jin, X.;  Hu, J.;  Liu, X.;  Ni, L.; Ma, P. X., The effect of scaffold 
architecture on odontogenic differentiation of human dental pulp stem cells. Biomaterials 
2011, 32 (31), 7822-30. 
208. Qiang, N.;  Tang, S.;  Shi, X. J.;  Li, H.;  Ma, Y. H.;  Tao, H. X.; Lin, Q., Synthesis of 
functional polyester for fabrication of nano-fibrous scaffolds and its effect on PC12 cells. 
J Biomater Sci Polym Ed 2016, 27 (3), 191-201. 
209. Sun, H.;  Feng, K.;  Hu, J.;  Soker, S.;  Atala, A.; Ma, P. X., Osteogenic differentiation of 
human amniotic fluid-derived stem cells induced by bone morphogenetic protein-7 and 
enhanced by nanofibrous scaffolds. Biomaterials 2010, 31 (6), 1133-9. 
 146 
210. Roh, J. D.;  Sawh-Martinez, R.;  Brennan, M. P.;  Jay, S. M.;  Devine, L.;  Rao, D. A.;  
Yi, T.;  Mirensky, T. L.;  Nalbandian, A.;  Udelsman, B.;  Hibino, N.;  Shinoka, T.;  
Saltzman, W. M.;  Snyder, E.;  Kyriakides, T. R.;  Pober, J. S.; Breuer, C. K., Tissue-
engineered vascular grafts transform into mature blood vessels via an inflammation-
mediated process of vascular remodeling. Proc Natl Acad Sci U S A 2010, 107 (10), 
4669-74. 
211. Yu, X.;  Yang, Y.; Xu, H., Lightweight Materials from Biopolymers and Biofibers. 
American Chemical Society: 2014; Vol. 1175, p 0. 
212. van Luyn, M. J.;  Plantinga, J. A.;  Brouwer, L. A.;  Khouw, I. M.;  de Leij, L. F.; van 
Wachem, P. B., Repetitive subcutaneous implantation of different types of 
(biodegradable) biomaterials alters the foreign body reaction. Biomaterials 2001, 22 (11), 
1385-91. 
213. Soletti, L.;  Nieponice, A.;  Guan, J.;  Stankus, J. J.;  Wagner, W. R.; Vorp, D. A., A 
seeding device for tissue engineered tubular structures. Biomaterials 2006, 27 (28), 4863-
70. 
214. Anderson, J. M.;  Rodriguez, A.; Chang, D. T., Foreign body reaction to biomaterials. 
Semin Immunol 2008, 20 (2), 86-100. 
215. Trindade, R.;  Albrektsson, T.;  Tengvall, P.; Wennerberg, A., Foreign Body Reaction to 
Biomaterials: On Mechanisms for Buildup and Breakdown of Osseointegration. Clin 
Implant Dent Relat Res 2016, 18 (1), 192-203. 
 147 
216. Song, L.;  Zhou, Q.;  Duan, P.;  Guo, P.;  Li, D.;  Xu, Y.;  Li, S.;  Luo, F.; Zhang, Z., 
Successful development of small diameter tissue-engineering vascular vessels by our 
novel integrally designed pulsatile perfusion-based bioreactor. PLoS One 2012, 7 (8), 
e42569. 
217. Tara, S.;  Kurobe, H.;  Rocco, K. A.;  Maxfield, M. W.;  Best, C. A.;  Yi, T.;  Naito, Y.;  
Breuer, C. K.; Shinoka, T., Well-organized neointima of large-pore poly(L-lactic acid) 
vascular graft coated with poly(L-lactic-co-epsilon-caprolactone) prevents calcific 
deposition compared to small-pore electrospun poly(L-lactic acid) graft in a mouse aortic 
implantation model. Atherosclerosis 2014, 237 (2), 684-91. 
218. Hinderer, S.;  Brauchle, E.; Schenke-Layland, K., Generation and Assessment of 
Functional Biomaterial Scaffolds for Applications in Cardiovascular Tissue Engineering 
and Regenerative Medicine. Adv Healthc Mater 2015, 4 (16), 2326-41. 
219. Wei, G.;  Jin, Q.;  Giannobile, W. V.; Ma, P. X., Nano-fibrous scaffold for controlled 
delivery of recombinant human PDGF-BB. J Control Release 2006, 112 (1), 103-10. 
220. Liu, X.;  Jin, X.; Ma, P. X., Nanofibrous hollow microspheres self-assembled from star-
shaped polymers as injectable cell carriers for knee repair. Nat Mater 2011, 10 (5), 398-
406. 
221. Pan, Z.; Ding, J., Poly(lactide-co-glycolide) porous scaffolds for tissue engineering and 
regenerative medicine. Interface Focus 2012, 2 (3), 366-77. 
222. Liu, Q.;  Wang, J.;  Chen, Y.;  Zhang, Z.;  Saunders, L.;  Schipani, E.;  Chen, Q.; Ma, P. 
X., Suppressing mesenchymal stem cell hypertrophy and endochondral ossification in 3D 
 148 
cartilage regeneration with nanofibrous poly(l-lactic acid) scaffold and matrilin-3. Acta 
Biomater 2018, 76, 29-38. 
223. Das, S.; Bellare, J. R., Dental Pulp Stem Cells in Customized 3D Nanofibrous Scaffolds 
for Regeneration of Peripheral Nervous System. Methods Mol Biol 2018. 
224. Wang, J.;  Liu, X.;  Jin, X.;  Ma, H.;  Hu, J.;  Ni, L.; Ma, P. X., The odontogenic 
differentiation of human dental pulp stem cells on nanofibrous poly(L-lactic acid) 
scaffolds in vitro and in vivo. Acta Biomater 2010, 6 (10), 3856-63. 
225. Wang, C. C.;  Lin, L. H.;  Chen, C. W.; Lo, Y. C., Surface Modification of Poly(lactic 
acid) Fabrics with Plasma Pretreatment and Chitosan/Siloxane Polyesters Coating for 
Color Strength Improvement. Polymers (Basel) 2017, 9 (8). 
226. Britner, J.; Ritter, H., Self-Activation of Poly(methylenelactide) through Neighboring-
Group Effects: A Sophisticated Type of Reactive Polymer. Macromolecules 2015, 48 
(11), 3516-3522. 
227. Bailey, W. J.;  Ni, Z.; Wu, S.-R., Synthesis of poly-ϵ-caprolactone via a free radical 
mechanism. Free radical ring-opening polymerization of 2-methylene-1,3-dioxepane. 
Journal of Polymer Science: Polymer Chemistry Edition 1982, 20 (11), 3021-3030. 
228. Bailey, W. J.; Zhou, L. L., A New Elimination with Phase-Transfer Catalysis for Cyclic 
Ketene Acetals. Tetrahedron Lett 1991, 32 (12), 1539-1540. 
 149 
229. Liu, M.;  Xie, C.;  Pan, H.;  Pan, J.; Lu, W., Separation of polyethylene glycols and their 
fluorescein-labeled compounds depending on the hydrophobic interaction by high-
performance liquid chromatography. J Chromatogr A 2006, 1129 (1), 61-6. 
230. Ju, M.;  Gong, F.;  Cheng, S.; Gao, Y., Fast and Convenient Synthesis of Amine-
Terminated Polylactide as a Macroinitiator for -Benzyloxycarbonyl-L-Lysine-N-
Carboxyanhydrides. International Journal of Polymer Science 2011, 2011, 7. 
231. Eckert, F.; Klamt, A., Accurate prediction of basicity in aqueous solution with COSMO-
RS. J Comput Chem 2006, 27 (1), 11-9. 
232. Bryantsev, V. S.;  Diallo, M. S.; Goddard, W. A., 3rd, pKa calculations of aliphatic 
amines, diamines, and aminoamides via density functional theory with a Poisson-
Boltzmann continuum solvent model. J Phys Chem A 2007, 111 (20), 4422-30. 
233. Fitch, C. A.;  Platzer, G.;  Okon, M.;  Garcia-Moreno, B. E.; McIntosh, L. P., Arginine: 
Its pKa value revisited. Protein Sci 2015, 24 (5), 752-61. 
234. Corona-Avendano, S.;  Alarcon-Angeles, G.;  Rosquete-Pina, G. A.;  Rojas-Hernandez, 
A.;  Gutierrez, A.;  Ramirez-Silva, M. T.;  Romero-Romo, M.; Palomar-Pardave, M., 
New insights on the nature of the chemical species involved during the process of 
dopamine deprotonation in aqueous solution: theoretical and experimental study. J Phys 
Chem B 2007, 111 (7), 1640-7. 
235. Rossini, E.;  Bochevarov, A. D.; Knapp, E. W., Empirical Conversion of pK a Values 
between Different Solvents and Interpretation of the Parameters: Application to Water, 
Acetonitrile, Dimethyl Sulfoxide, and Methanol. ACS Omega 2018, 3 (2), 1653-1662. 
 150 
236. Mahato, R. I., Biomaterials for delivery and targeting of proteins and nucleic acids. CRC 
Press: Boca Raton :, 2005; Vol. Boca Raton :. 
237. Kim, K. K.; Pack, D. W., Microspheres for Drug Delivery. In BioMEMS and Biomedical 
Nanotechnology: Volume I Biological and Biomedical Nanotechnology, Ferrari, M.;  Lee, 
A. P.; Lee, L. J., Eds. Springer US: Boston, MA, 2006; pp 19-50. 
238. Muzykantov, V. R., Targeted Drug Delivery to Endothelial Adhesion Molecules. 2013; 
Vol. 2013, p 27. 
239. Reischl, D.; Zimmer, A., Drug delivery of siRNA therapeutics: potentials and limits of 
nanosystems. Nanomedicine 2009, 5 (1), 8-20. 
240. Rives, C. B., Tissue engineering scaffolds for protein and DNA delivery: A platform for 
islet transplantation. ProQuest: 2008. 
241. Liu, X.;  Won, Y.; Ma, P. X., Porogen-induced surface modification of nano-fibrous 
poly(L-lactic acid) scaffolds for tissue engineering. Biomaterials 2006, 27 (21), 3980-7. 
 
